<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission - Graves, PM - 2018 | Cochrane Library</title> <meta content="Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission - Graves, PM - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008152.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission - Graves, PM - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008152.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008152.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Primaquine or other 8‐aminoquinolines for reducing &lt;i&gt;Plasmodium falciparum&lt;/i&gt; transmission" name="citation_title"/> <meta content="Patricia M Graves" name="citation_author"/> <meta content="James Cook University" name="citation_author_institution"/> <meta content="pgraves.work@gmail.com" name="citation_author_email"/> <meta content="Leslie Choi" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Hellen Gelband" name="citation_author"/> <meta content="Global Health Consulting" name="citation_author_institution"/> <meta content="Paul Garner" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD008152.pub5" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/02/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008152.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008152.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008152.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antimalarials [*administration &amp; dosage]; Artemisinins [administration &amp; dosage, therapeutic use]; Chloroquine [administration &amp; dosage, therapeutic use]; Drug Combinations; Glucosephosphate Dehydrogenase Deficiency [*diagnosis]; Malaria, Falciparum [parasitology, *prevention &amp; control, transmission]; Mefloquine [administration &amp; dosage, therapeutic use]; Non-Randomized Controlled Trials as Topic; Plasmodium falciparum [drug effects]; Primaquine [*administration &amp; dosage, analogs &amp; derivatives]; Pyrimethamine [administration &amp; dosage]; Quinine [therapeutic use]; Randomized Controlled Trials as Topic; Sulfadoxine [administration &amp; dosage]; Time Factors" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008152.pub5&amp;doi=10.1002/14651858.CD008152.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Qh5938oe";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008152\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008152\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD008152.pub5",title:"Primaquine or other 8\\u2010aminoquinolines for reducing   \u003ci\u003ePlasmodium falciparum\u003c/i\u003e transmission",firstPublishedDate:"Feb 2, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008152.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008152.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008152.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008152.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008152.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008152.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008152.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008152.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008152.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008152.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2273 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008152.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-sec-0156"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-sec-0023"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-sec-0024"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-sec-0029"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-sec-0030"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-sec-0068"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-sec-0143"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/appendices#CD008152-sec-0161"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/table_n/CD008152StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/table_n/CD008152StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Primaquine or other 8‐aminoquinolines for reducing <i>Plasmodium falciparum</i> transmission </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/information#CD008152-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Patricia M Graves</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/information#CD008152-cr-0003">Leslie Choi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/information#CD008152-cr-0004">Hellen Gelband</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008152.pub5/information#CD008152-cr-0005">Paul Garner</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/information/en#CD008152-sec-0167">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 February 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008152.pub5">https://doi.org/10.1002/14651858.CD008152.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008152-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008152-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008152-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008152-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008152-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008152-abs-0001" lang="en"> <section id="CD008152-sec-0001"> <h3 class="title" id="CD008152-sec-0001">Background</h3> <p>The 8‐aminoquinoline (8AQ) drugs act on <i>Plasmodium falciparum</i> gametocytes, which transmit malaria from infected people to mosquitoes. In 2012, the World Health Organization (WHO) recommended a single dose of 0.25 mg/kg primaquine (PQ) be added to malaria treatment schedules in low‐transmission areas or those with artemisinin resistance. This replaced the previous recommendation of 0.75 mg/kg, aiming to reduce haemolysis risk in people with glucose‐6‐phosphate dehydrogenase deficiency, common in people living in malarious areas. Whether this approach, and at this dose, is effective in reducing transmission is not clear. </p> </section> <section id="CD008152-sec-0002"> <h3 class="title" id="CD008152-sec-0002">Objectives</h3> <p>To assess the effects of single dose or short‐course PQ (or an alternative 8AQ) alongside treatment for people with <i>P. falciparum</i> malaria. </p> </section> <section id="CD008152-sec-0003"> <h3 class="title" id="CD008152-sec-0003">Search methods</h3> <p>We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; and the WHO International Clinical Trials Registry Platform (ICRTP) portal using ‘malaria*', ‘falciparum', ‘primaquine', ‘8‐aminoquinoline', and eight 8AQ drug names as search terms. We checked reference lists of included trials, and contacted researchers and organizations. Date of last search: 21 July 2017. </p> </section> <section id="CD008152-sec-0004"> <h3 class="title" id="CD008152-sec-0004">Selection criteria</h3> <p>Randomized controlled trials (RCTs) or quasi‐RCTs in children or adults, adding PQ (or alternative 8AQ) as a single dose or short course alongside treatment for <i>P. falciparum</i> malaria. </p> </section> <section id="CD008152-sec-0005"> <h3 class="title" id="CD008152-sec-0005">Data collection and analysis</h3> <p>Two authors screened abstracts, applied inclusion criteria, and extracted data. We sought evidence on transmission (community incidence), infectiousness (people infectious and mosquitoes infected), and potential infectiousness (gametocyte measures assessed by microscopy or polymerase chain reaction [PCR]). We grouped trials into artemisinin and non‐artemisinin treatments, and stratified by PQ dose (low, 0.2 to 0.25 mg/kg; moderate, 0.4 to 0.5 mg/kg; high, 0.75 mg/kg). We used GRADE, and absolute effects of infectiousness using trial control groups. </p> </section> <section id="CD008152-sec-0006"> <h3 class="title" id="CD008152-sec-0006">Main results</h3> <p>We included 24 RCTs and one quasi‐RCT, comprising 43 arms. Fourteen trials evaluated artemisinin treatments (23 arms), nine trials evaluated non‐artemisinin treatments (13 arms), and two trials included both artemisinin and non‐artemisinin arms (three and two arms, respectively). Two trial arms used bulaquine. Seven PQ arms used low dose (six with artemisinin), 11 arms used moderate dose (seven with artemisinin), and the remaining arms used high dose. Fifteen trials tested for G6PD status: 11 excluded participants with G6PD deficiency, one included only those with G6PD deficiency, and three included all, irrespective of status. The remaining 10 trials either did not test or did not report on testing. </p> <p>No cluster trials evaluating community effects on malaria transmission met the inclusion criteria. </p> <p><b>With artemisinin treatment</b> </p> <p><i>Low dose PQ</i> </p> <p>Infectiousness (participants infectious to mosquitoes) was reduced (day 3 or 4: RR 0.12, 95% CI 0.02 to 0.88, 3 trials, 105 participants; day 8: RR 0.34, 95% CI 0.07 to 1.58, 4 trials, 243 participants; <i>low certainty evidence</i> ). This translates to a reduction in percentage of people infectious on day 3 or 4 from 14% to 2%, and, for day 8, from 4% to 1%; the waning infectiousness in the control group by day 8 making the absolute effect smaller by day 8. For gametocytes detected by PCR, there was little or no effect of PQ at day 3 or 4 (RR 1.02, 95% CI 0.87 to 1.21; 3 trials, 414 participants; <i>moderate certainty evidence</i> ); with reduction at day 8 (RR 0.52, 95% CI 0.41 to 0.65; 4 trials, 532 participants; <i>high certainty evidence).</i> Severe haemolysis was infrequent, with or without PQ, in these groups with few G6PD‐deficient individuals (RR 0.98, 95% CI 0.69 to 1.39; 4 trials, 752 participants, <i>moderate certainty evidence)</i>. </p> <p><i>Moderate dose PQ</i> </p> <p>Infectiousness was reduced (day 3 or 4: RR 0.13, 95% CI 0.02 to 0.94; 3 trials, 109 participants; day 8 RR 0.33, 95% CI 0.07 to 1.57; 4 trials, 246 participants; <i>low certainty evidence</i>). Illustrative risk estimates for moderate dose were the same as low dose. The pattern and level of certainty of evidence with gametocytes detected by PCR was the same as low dose, and severe haemolysis was infrequent in both groups. </p> <p><i>High dose PQ</i> </p> <p>Infectiousness was reduced (day 4: RR 0.2, 95% CI 0.02 to 1.68, 1 trial, 101 participants; day 8: RR 0.18, 95% CI 0.02 to 1.41, 2 trials, 181 participants, <i>low certainty evidence</i>). The effects on gametocyte prevalence showed a similar pattern to moderate and low dose PQ. Trials did not systematically report evidence of haemolysis. </p> <p><b>With non‐artemisinin treatment</b> </p> <p>Trials with non‐artemisinin treatment have been conducted only for moderate and high dose PQ. With high dose, infectiousness appeared markedly reduced on day 5 (RR 0.09, 95% CI 0.01 to 0.62; 30 participants, <i>very low certainty evidence</i>), with similar reductions at day 8. For both moderate dose (two trials with 221 people) and high dose (two trials with 30 people), reduction in gametocytes (detected by microscopy) showed similar patterns as for artemisinin treatments, with little or no effect at day 4 or 5, and larger effects by day 8. No trials with non‐artemisinin partner drugs systematically sought evidence of severe haemolysis. </p> <p>Two trials comparing bulaquine with PQ suggest bulaquine may have larger effects on gametocytes by microscopy on day 8 (RR 0.41, 95% CI 0.26 to 0.66; 2 trials, 112 participants). </p> </section> <section id="CD008152-sec-0007"> <h3 class="title" id="CD008152-sec-0007">Authors' conclusions</h3> <p>A single low dose of PQ (0.25 mg/kg) added to artemisinin‐based combination therapy for malaria reduces infectiousness of people to mosquitoes at day 3‐4 and day 8, and appears as effective as higher doses. The absolute effect is greater at day 3 or 4, and smaller at day 8, in part because of the lower infectiousness in the control group. There was no evidence of increased haemolysis at 0.25 mg/kg, but few G6PD‐deficient individuals were included in the trials. The effect on infectiousness precedes the effect of PQ on gametocyte prevalence. We do not know whether single dose PQ could reduce malaria transmission at community level. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008152-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008152-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008152-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008152-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008152-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008152-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008152-abs-0003" lang="en"> <h3>A single dose of primaquine added to malaria treatment to prevent malaria transmission</h3> <p><b>What is the aim of this review?</b> </p> <p>To assess the effects of adding a single dose of primaquine (PQ) to treatment for falciparum malaria to reduce disease transmission. This Cochrane Review update includes 25 controlled trials. The date of latest search was 21 July 2017. </p> <p><b>Key messages</b> </p> <p>A single low dose of PQ, at 0.25 mg/kg, which the World Health Organization (WHO) recommends adding to artemisinin‐based combination therapy for malaria, reduces infectiousness (transmission from people to mosquitoes). In the trials, the percentage of people who infected mosquitoes three to four days after treatment was reduced from 14% to 2%, with a smaller effect at day 8, from 4% to 1%, with no evidence of harm. </p> <p><b>What was studied in the review</b> </p> <p>PQ kills gametocytes (malaria transmission stages) of the falciparum malaria parasite. Gametocytes infect mosquitoes during a bite, thus perpetuating transmission. There is concern that PQ may cause red blood cells to burst (haemolysis) in people with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency, a genetically‐determined condition common in many malaria‐endemic settings, which can lead to anaemia. Recognizing concerns about the risk of haemolysis, the WHO reduced the recommended PQ dose from 0.75 mg/kg to 0.25 mg/kg in 2012. </p> <p>Ideally, this approach would be tested by randomly assigning villages to standard malaria treatment, or standard treatment plus a low dose of PQ, then measuring the effect on malaria over time but this would be difficult and expensive. So, indirect indicators are used to shed light on effectiveness, including feeding studies, in which mosquitoes are allowed to feed on people (or their blood), comparing those who were assigned PQ with those who were not. Alternatively, researchers may simply monitor the presence (prevalence), number (density), and duration (time of persistence) of gametocytes in the blood of people after different treatments, assuming that gametocytes are viable irrespective of exposure to PQ. </p> <p><i><b>What the research says</b> </i> </p> <p>The 25 included trials span several decades and include a variety of treatments and PQ doses. Related to safety assessment, some trials tested participants for G6PD activity. Other trials reported results based on their G6PD status, others did not test (or did not say whether they did), and others tested and excluded people with G6PD deficiency. </p> <p>There were no ideal community‐level studies that would answer the question directly.</p> <p>Five feeding trials with multiple arms included three low‐dose, three medium‐dose, and two high‐dose comparisons, showing a markedly reduced proportion of people infectious who received PQ in trials with any events. Two trials using older malaria treatments and high dose PQ had similar results. </p> <p>The other trials focused on indirect measures of potential infectiousness of humans to mosquitoes. In these trials, PQ shortened the period of potential infectiousness, with a lower prevalence and density of gametocytes up to day 8 after treatment. The effect was similar at all PQ dose levels. </p> <p>Few serious haemolytic events occurred in these trials, but PQ did affect non‐serious haemoglobin measures, even at low doses. </p> <p><b>What are the main results of the review?</b> </p> <p>A single low dose of PQ added to an artemisinin regimen for malaria reduces infectiousness to mosquitoes and is relatively safe for most people. </p> <p>PQ at WHO‐recommended dose reduces infectiousness to mosquitoes on day 3‐4 and day 8 with no evidence of harm. It is unclear whether this reduction would materially reduce malaria transmission in communities. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008152-sec-0156" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008152-sec-0156"></div> <h3 class="title" id="CD008152-sec-0157">Implications for practice</h3> <section id="CD008152-sec-0157"> <p>Current policy recommendations are that 0.25 mg/kg PQ should be added as a single dose to primary treatment for <i>P. falciparum</i> malaria in areas of low transmission to reduce infectiousness of treated individuals to mosquitoes, under the assumption that this will contribute to reducing malaria prevalence. </p> <p>This Cochrane Review of all reliable data supports the idea of reducing infectiousness of people to mosquitoes, but provides very little evidence on the question of whether this reduction is of any material value in reducing community prevalence. It is consistent with the recommendation that PQ not be used in high endemicity areas, where the dilutional effects of a large part of the population carrying asymptomatic infections would likely outweigh a potential benefit. In a low endemicity area, what might be important is whether most people with parasitaemia are likely to be treated. If PQ is used systematically, monitoring malaria prevalence in a well‐designed programme might provide useful information on its effectiveness. </p> <p>If PQ is to be used, then it should be implemented as early as possible during treatment as the effects on infectivity appear to be maximal early in the treatment course. </p> <p>Risk of harm at the currently recommended dose of 0.25 mg/kg was low in the study participants, relatively few of whom were G6PD‐deficient. However, the emphasis in the included trials, hence in this systematic review, is on the efficacy of PQ, and evidence from these sources is insufficient to comment definitively on safety in all affected populations. </p> </section> <h3 class="title" id="CD008152-sec-0158">Implications for research</h3> <section id="CD008152-sec-0158"> <p>The totality of the evidence from the trials included in this review does not provide a clear answer about whether, or under what circumstances, low‐dose PQ could materially reduce the community malaria burden. We do not envision direct evidence being generated that will fill this high‐level gap; to do so would require many large cluster‐randomized trials at different endemicity levels, conducted over many years. A realistic approach would combine evidence from randomized trials and possibly some observational data in robust mathematical models to predict the impact of PQ on malaria transmission at the community level across the range of endemicity levels. This Cochrane Review is the first step toward determining whether the existing information is sufficient to inform modelling studies and, if not, what specific questions must be addressed in further field or laboratory research to generate evidence that can be used for sound future recommendations. </p> <p>A next step could be the collaborative evaluation of current evidence by recent randomized trialists, mathematical modelers who are working on this question, and others involved with malaria control policy. It would be important to examine key parameter estimates (and the relevant variability in those parameter estimates) in relation to the question of whether low‐dose PQ should be implemented in combination with antimalarial treatment of acute episodes of malaria illness and, if yes, when and under what circumstances. A consensus could be reached about whether results from additional trials would provide missing information. This determination would guide decisions on the need for further trials and if needed, precisely what endpoints should be sought. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008152-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008152-sec-0023"></div> <div class="table" id="CD008152-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Single dose primaquine at 0.2 to 0.25 mg/kg compared to no primaquine, with artemisinin partner, for reducing P. falciparum transmission</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low‐dose primaquine (PQ) given with artemisinin combination treatment</b> </p> <p><b>Participants or population:</b> adults and children with malaria being treated with artemisinin combination treatment </p> <p><b>Settings:</b> Mali, Burkina Faso, The Gambia, Tanzania, Senegal </p> <p><b>Intervention:</b> single dose PQ dose 0.2 to 0.25 mg/kg </p> <p><b>Comparison:</b> no PQ </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no PQ, with artemisinin partner</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single dose PQ at 0.2 to 0.25 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 3‐4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.12<br/> (0.02 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 100<br/> (0 to 13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose PQ may reduce infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>243<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.34<br/> (0.07 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 100<br/> (0 to 6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose PQ may reduce infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 3 to 4 by PCR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>414<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.02<br/> (0.87 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 per 100<br/> (45 to 63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>2</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose PQ probably has little or no effect on gametocytes detected by PCR at day 3 to 4 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 8 by PCR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>532<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.52<br/> (0.41 to 0.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 per 100<br/> (19 to 31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose PQ reduces gametocytes detected by PCR at day 8</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with severe haemolysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>752<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.98<br/> (0.69 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 per 100<br/> (9 to 18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>2</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose PQ probably has little or no effect on severe haemolysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>PCR</b> : polymerase chain reaction; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 2 for imprecision: the CIs are wide; in addition, there is a large effect combined with a low number of events, which creates further uncertainty around the point estimate.<br/> <sup>2</sup>Downgraded by 1 for imprecision: the CIs are wide. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008152-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Single dose primaquine at 0.4 to 0.5 mg/kg compared to no primaquine, with artemisinin partner, for reducing P. falciparum transmission</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Moderate‐dose primaquine (PQ) given with artemisinin combination treatment</b> </p> <p><b>Participants or population:</b> adults and children with malaria being treated with artemisinin combination treatment </p> <p><b>Settings:</b> Mali, Burkina Faso, The Gambia, Uganda </p> <p><b>Intervention:</b> single dose PQ 0.4 to 0.5 mg/kg </p> <p><b>Comparison:</b> no PQ </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no PQ, with artemisinin partner,</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single dose PQ at 0.4 to 0.5 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 3‐4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.13<br/> (0.02 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 100<br/> (0 to 13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ may reduce infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>246<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.33<br/> (0.07 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 100</p> <p>(0 to 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ may reduce infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 3‐4, by PCR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>418<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.09<br/> (0.93 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 100</p> <p>(48 to 67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE<sup>2</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ probably has little or no effect on gametocytes detected by PCR on day 3 to 4 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 8, by PCR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>758<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.37<br/> (0.29 to 0.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 100</p> <p>(13 to 21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ reduces gametocytes detected by PCR on day 8</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with severe haemolysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.54<br/> (0.38 to 6.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> <p>(1 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>3</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ may increase severe haemolysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 2 for imprecision: the CIs are wide; in addition, there is a large effect combined with a low number of events, which creates further uncertainty around the point estimate.<br/> <sup>2</sup>Downgraded by 1 for imprecision: the CIs are wide.<br/> <sup>3</sup>Downgraded by 2 for imprecision: the CIs are very wide. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008152-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Single dose primaquine at 0.75 mg/kg compared to no primaquine, with artemisinin partner, for reducing P. falciparum transmission</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High‐dose primaquine (PQ) given with artemisinin combination treatment</b> </p> <p><b>Participants or population:</b> adults and children with malaria being treated with artemisinin combination treatment </p> <p><b>Settings:</b> Cambodia, Mali, Burkina Faso, The Gambia, Tanzania, Sudan, Uganda </p> <p><b>Intervention:</b> single dose PQ 0.75 mg/kg </p> <p><b>Comparison:</b> no PQ </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no PQ, with artemisinin partner</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single dose PQ at 0.75mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 3‐4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.20</p> <p>(0.02 to 1.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 100</p> <p>(0 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,2</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if high dose PQ may reduce infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>181<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.18<br/> (0.02 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 100</p> <p>(0 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dose PQ may reduce infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 3‐4, by PCR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.92<br/> (0.75 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 100</p> <p>(29 to 43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>3,4</sup> </p> <p>Due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dose PQ may have little or no effect on gametocytes detected by PCR</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 8, by PCR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>793<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.31<br/> (0.23 to 0.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> <p>(8 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dose PQ reduces gametocytes detected by PCR</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with severe haemolysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No estimate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if high dose PQ impacts on haemolysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>PCR</b> : polymerase chain reaction; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 2 for imprecision: the CIs are wide; in addition, there is a large effect combined with a low number of events, which creates further uncertainty around the point estimate. In addition, in this one trial baseline.<br/> <sup>2</sup>Baseline values for this outcome were unbalanced, but the downgrading by 2 for imprecision takes this in to account, as it could be a chance finding.<br/> <sup>3</sup>Downgraded by 1 for indirectness: all the data for the results come from one trial.<br/> <sup>4</sup>Downgraded by 1 for imprecision: the CIs are wide. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008152-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Single dose primaquine at 0.4 to 0.5 mg/kg compared to no primaquine, with non‐artemisinin partner, for reducing P. falciparum transmission</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Moderate‐dose primaquine (PQ) given with non‐artemisinin treatment</b> </p> <p><b>Participants or population:</b> adults and children with malaria being treated with non‐artemisinin treatment </p> <p><b>Settings:</b> Pakistan </p> <p><b>Intervention:</b> single dose PQ 0.4 to 0.5 mg/kg </p> <p><b>Comparison:</b> no PQ </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no PQ, with non‐artemisinin partner</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single dose PQ at 0.4 to 0.5 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 4‐5, by microscopy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>221<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/> (0.62 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 per 100</p> <p>(30 to 54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> <p>Due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ probably reduces gametocytes detected by microscopy</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 8, by microscopy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.60<br/> (0.49 to 0.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 per 100</p> <p>(40 to 61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> <p>Due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ probably reduces gametocytes detected by microscopy</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 for indirectness: all the results are from one setting. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008152-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Single dose primaquine at 0.75 mg/kg compared to no primaquine, with non‐artemisinin partner, for reducing P. falciparum transmission</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Medium‐dose primaquine (PQ) given with non‐artemisinin treatment</b> </p> <p><b>Participants or population:</b> adults and children with malaria being treated with non‐artemisinin treatment </p> <p><b>Settings:</b> China, Colombia, India, Indonesia </p> <p><b>Intervention:</b> single dose PQ 0.75 mg/kg </p> <p><b>Comparison:</b> no PQ </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no PQ, with non‐artemisinin partner</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single dose PQ at 0.75 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 5</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.09<br/> (0.01 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 100</p> <p>(1 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1,2</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether high dose PQ reduces infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.07<br/> (0.01 to 0.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 100</p> <p>(1 to 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1,2</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether high dose PQ reduces infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 5, by microscopy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.85<br/> (0.48 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 per 100</p> <p>(24 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW<sup>3,4</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dose PQ may reduce gametocytes detected by microscopy</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 8, by microscopy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>186<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.39<br/> (0.25 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 100</p> <p>(12 to 29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE<sup>5</sup> </p> <p>Due to risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dose PQ probably reduces gametocytes detected by microscopy</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 for risk of bias: unclear risk of bias in several domains from both studies.<br/> <sup>2</sup>Downgraded by 2 for imprecision: the CIs are wide; in addition, there is a large effect combined with a low number of events, which creates further uncertainty around the point estimate.<br/> <sup>3</sup>Downgraded by 1 for risk of bias: <a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a> had serious risk for selection bias and <a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a> had unclear risk of bias in several domains.<br/> <sup>4</sup>Downgraded by 1 for imprecision: the CIs are wide.<br/> <sup>5</sup>Downgraded by 1 for risk of bias: <a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a> had serious risk for selection bias and <a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a> had unclear risk of bias in several domains. <a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a> had serious risk of bias for several domains. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008152-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008152-sec-0024"></div> <section id="CD008152-sec-0025"> <h3 class="title" id="CD008152-sec-0025">Description of the condition</h3> <p>Malaria is a febrile illness due to infection with the <i>Plasmodium</i> parasite, and is transmitted between humans via mosquitoes (<a href="./references#CD008152-bbs2-0123" title="PhillipsMA , BurrowsJN , ManyandoC , vanHuijsduijnenRH , VanVoorhisWC , WellsTNC . Malaria. Nature Reviews. Disease Primers2017;3:17050. [DOI: 10.1038/mdp.2017.50] ">Phillips 2017</a>). Of the five <i>Plasmodium</i> species known to cause illness in humans, <i>Plasmodium falciparum</i> is the most common, especially in sub‐Saharan Africa, and causes the majority of severe illnesses and deaths (<a href="./references#CD008152-bbs2-0142" title="World Health Organization. World Malaria Report 2016. www.who.int/malaria/publications/world‐malaria‐report‐2016/report/en/ (accessed 16 January 2018). ">WHO 2016</a>). The clinical illness develops due to the presence of asexual stage parasites (merozoites and schizonts) in the person's bloodstream, but transmission to mosquitoes is via sexual stage parasites (gametocytes), which develop from other blood stages at some point after infection (<a href="./references#CD008152-bbs2-0123" title="PhillipsMA , BurrowsJN , ManyandoC , vanHuijsduijnenRH , VanVoorhisWC , WellsTNC . Malaria. Nature Reviews. Disease Primers2017;3:17050. [DOI: 10.1038/mdp.2017.50] ">Phillips 2017</a>). </p> <p>Artemisinin‐based combination therapies (ACTs) are currently recommended worldwide as the primary treatment for infection with <i>P. falciparum</i> (<a href="./references#CD008152-bbs2-0136" title="World Health Organization. Guidelines for the Treatment of Malaria. 2nd Edition. Geneva: World Health Organization, 2010. ">WHO 2010</a>). The artemisinin derivatives treat the clinical illness by rapidly reducing the number of circulating schizonts and merozoites, which also reduces the potential for these stages to develop into gametocytes for onward transmission. The artemisinin derivatives have been shown to kill early developing gametocytes, but they have no direct effects on mature gametocytes (<a href="./references#CD008152-bbs2-0125" title="PriceR , NostenF , LuxemburgerC , ter KuileFO , PaiphunL , ChongsuphajaisiddhiT , et al. The effects of artemisinin derivatives on malaria transmissibility. Lancet1996;347(9016):1654‐8. ">Price 1996</a>; <a href="./references#CD008152-bbs2-0098" title="ChotivanichK , SattabongkotJ , UdomsangpetchU , LooareesuwanS , DayNP , ColemanRE , et al. Transmission‐blocking activities of quinine, primaquine, and artesunate. Antimicrobial Agents and Chemotherapy2006;50(6):1927‐30. ">Chotivanich 2006</a>; <a href="./references#CD008152-bbs2-0119" title="OkellLC , DrakeleyCJ , GhaniAC , BousemaT , SutherlandCJ . Reduction of transmission from malaria patients by artemisinin therapies: a pooled analysis of six randomized trials. Malaria Journal2008;7:125. ">Okell 2008a</a>; <a href="./references#CD008152-bbs2-0120" title="OkellLC , DrakeleyCJ , BousemaT , WhittyCJ , GhaniAC . Modelling the impact of artemisinin combination therapy and long‐acting treatments on malaria transmission intensity. PLoS Medicine2008;5(11):e226. ">Okell 2008b</a>). The partner drugs in ACTs (mefloquine, amodiaquine, piperaquine, lumefantrine, and sulfadoxine‐pyrimethamine) are schizonticides with variable effects on gametocytes, and none adequately targets mature gametocytes (<a href="./references#CD008152-bbs2-0100" title="DrakeleyC , SutherlandC , BousemaJT , SauerweinRW , TargettGA . The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. Trends in Parasitology2006;22(9):424‐30. ">Drakeley 2006</a>; <a href="./references#CD008152-bbs2-0089" title="BarnesKI , LittleF , MabuzaA , MngomezuluN , GovereJ , DurrheimD , et al. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine‐pyrimethamine resistance in falciparum malaria. Journal of Infectious Diseases2008;197(11):1605‐13. ">Barnes 2008</a>). In untreated infection, gametocytes can remain present for months as successive new generations are produced, and even following treatment they may persist for several weeks (<a href="./references#CD008152-bbs2-0127" title="SmalleyME , SindenRE . Plasmodium falciparum gametocytes: their longevity and infectivity. Parasitology1977;74(1):1‐8. ">Smalley 1977</a>; <a href="./references#CD008152-bbs2-0101" title="EichnerM , DiebnerHH , MolineauxL , CollinsWE , JefferyGM , DietzK . Genesis, sequestration and survival of Plasmodium falciparum gametocytes: parameter estimates from fitting a model to malaria therapy data. Transactions of the Royal Society of Tropical Medicine and Hygiene2001;95(5):497‐501. ">Eichner 2001</a>; <a href="./references#CD008152-bbs2-0092" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ">Bousema 2010</a>). </p> <p>The mean circulation time of a mature <i>P. falciparum</i> gametocyte in humans has been estimated by microscopy or polymerase chain reaction (PCR) to be between 3.4 and 6.5 days (<a href="http://archie.cochrane.org/sections/documents/view?version=z1406051707558069402211993610778%26format=REVMAN#REF-Smalley-1977" target="_blank">Smalley 1977</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1406051707558069402211993610778%26format=REVMAN#REF-Eichner-2001" target="_blank">Eichner 2001</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1406051707558069402211993610778%26format=REVMAN#REF-Bousema-2010" target="_blank">Bousema 2010</a>). The infectivity of a person depends on the density of gametocytes in the bloodstream (<a href="./references#CD008152-bbs2-0097" title="CarterR , GravesPM . Gametocytes. In: WernsdorferWH , MacGregorIA editor(s). Malaria: Principles and Practice of Malariology. Edinburgh: Churchill Livingstone, 1988. ">Carter 1988</a>; <a href="./references#CD008152-bbs2-0094" title="BousemaT , DinglasanRR , MorlaisI , GouagnaLC , vanWarmerdamT , Awono‐AmbenePH , et al. Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS One2012;7(8):e42821. ">Bousema 2012</a>). The percentage of bites on people that result in mosquito infection ranges between 0.3% and 46%, although most estimates are in the range of 1% to 10% (<a href="./references#CD008152-bbs2-0106" title="GravesPM , BurkotTR , CarterR , CattaniJA , LagogM , ParkerJ , et al. Measurement of malarial infectivity of human populations to mosquitoes in the Madang area, Papua New Guinea. Parasitology1988;96(Pt 2):251‐63. ">Graves 1988</a>; <a href="./references#CD008152-bbs2-0114" title="KilleenGF , RossA , SmithT . Infectiousness of malaria‐endemic human populations to vectors. American Journal of Tropical Medicine and Hygiene2006;75(2 Suppl):38‐45. ">Killeen 2006</a>; <a href="./references#CD008152-bbs2-0099" title="ChurcherTS , BousemaT , WalkerM , DrakeleyC , SchneiderP , OuédraogoAL , et al. Predicting mosquito infection from Plasmodium falciparum gametocye density and estimating the reservoir of infection. eLife2013;2:e00626. ">Churcher 2013</a>). </p> <p>After uptake of a <i>P. falciparum‐</i>infected blood‐meal by the mosquito, the haploid gametocytes mature into male and female gametes. When fertilized, diploid oocysts develop on the mosquito's stomach wall and subsequently mature into sporozoites that migrate to the salivary glands, ready to be released when biting the next host. The median number of oocysts formed in wild‐caught infected mosquitoes is two to three (<a href="http://archie.cochrane.org/sections/documents/view?version=z1406051707558069402211993610778%26format=REVMAN#REF-Rosenberg-2008" target="_blank">Rosenberg 2008</a>). Each oocyst develops thousands of sporozoites, but only about 20% are thought to reach the mosquito salivary glands and fewer than 25 sporozoites on average are ejected during mosquito blood‐feeding (<a href="http://archie.cochrane.org/sections/documents/view?version=z1406051707558069402211993610778%26format=REVMAN#REF-Rosenberg-1990" target="_blank">Rosenberg 1990</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1406051707558069402211993610778%26format=REVMAN#REF-Rosenberg-2008" target="_blank">Rosenberg 2008</a>). </p> </section> <section id="CD008152-sec-0026"> <h3 class="title" id="CD008152-sec-0026">Description of the intervention</h3> <p>Primaquine (PQ) is the only drug in common use that is known to kill mature <i>P. falciparum</i> gametocytes (<a href="./references#CD008152-bbs2-0031" title="BurgessRW , BrayRS . The effect of a single dose of primaquine upon the gametocytes, gametogony and sporogony of Laverania (= Plasmodium) falciparum. WHO/MAL/271. 24 August 1960. http://apps.who.int/iris/bitstream/10665/64747/1/WHO_Mal_271.pdf?ua=1 (accessed 15 January 2018). BurgessRW , BrayRS . The effect of a single dose of primaquine upon the gametocytes, gametogony and sporogony of Laverania falciparum . Bulletin of the World Health Organization1961;24:451‐6. ">Burgess 1961</a>; <a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a>; <a href="./references#CD008152-bbs2-0098" title="ChotivanichK , SattabongkotJ , UdomsangpetchU , LooareesuwanS , DayNP , ColemanRE , et al. Transmission‐blocking activities of quinine, primaquine, and artesunate. Antimicrobial Agents and Chemotherapy2006;50(6):1927‐30. ">Chotivanich 2006</a>), and with the recent emphasis on malaria elimination, there has been a renewed interest and emerging literature on PQ's potential value in reducing malaria transmission (<a href="./references#CD008152-bbs2-0102" title="EziefulaA , GoslingR , HwangJ , HsiangM , BousemaT , vonSeidleinL , et al. Rationale for short course primaquine in Africa to interrupt malaria transmission. Malaria Journal2012;11:360. ">Eziefula 2012</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1406051707558069402211993610778%26format=REVMAN#REF-White-2012" target="_blank">White 2012</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1406051707558069402211993610778%26format=REVMAN#REF-WHO-2012b" target="_blank">WHO 2012b</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1406051707558069402211993610778%26format=REVMAN#REF-White-2013" target="_blank">White 2013</a>). PQ is an 8‐aminoquinoline (8AQ) whose pharmacokinetic mode of action is not well understood, but it is known to be rapidly metabolized, with a half‐life of six hours (<a href="./references#CD008152-bbs2-0131" title="WhiteNJ . Antimalarial pharmacokinetics and treatment regimens. British Journal of Clinical Pharmacology1992;34(1):1‐10. ">White 1992</a>). PQ does not directly affect <i>P. falciparum</i> asexual stages which cause the clinical illness (<a href="./references#CD008152-bbs2-0086" title="ArnoldJ , AlvingAS , HockwaldRS , ClaymanCB , DernRJ , BeutlerE , et al. The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P‐F‐6 strain). Journal of Laboratory and Clinical Medicine1955;46(3):391‐7. ">Arnold 1955</a>; <a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a>), and does not appear to affect the early or maturing gametocytes (<a href="./references#CD008152-bbs2-0091" title="BhasinVK , TragerW . Chapter XI: Gametocytocidal effects in vitro of primaquine and related compounds on Plasmodium falciparum. In: WernsdorferWH , TriggPI editor(s). Primaquine: Pharmacokinetics, Metabolism, Toxicity and Activity. Geneva: UNDP/World Bank/WHO, 1984. ">Bhasin 1984</a>; <a href="./references#CD008152-bbs2-0132" title="WhiteNJ . The role of antimalarial drugs in eliminating malaria. Malaria Journal2008;7(Suppl 1):S8. ">White 2008</a>). Consequently, a combination of PQ and an artemisinin derivative (as part of ACT) would target all gametocyte stages and have the greatest potential for reducing onward transmission to mosquitoes (<a href="./references#CD008152-bbs2-0138" title="Global Malaria Programme, World Health Organization. Single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Updated WHO Policy Recommendation. Geneva: World Health Organization, 2012. ">WHO 2012b</a>; <a href="./references#CD008152-bbs2-0134" title="WhiteNJ . Primaquine to prevent transmission of falciparum malaria. Lancet. Infectious Diseases2013;13(2):175‐81. ">White 2013</a>). </p> <p>One of the constraints to widespread use of PQ is that the drug is known to be a haemolytic trigger in people with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency. The deficiency is X‐linked and expressed in a wide variety of variants and levels of G6PD deficit (<a href="./references#CD008152-bbs2-0111" title="HowesRE , BattleKE , SatyagrahaAW , BairdJK , HaySI . G6PD deficiency: global distribution, genetic variants and primaquine therapy. Advances in Parasitology2013;81:133‐201. [DOI: 10.1016/B978‐0‐12‐407826‐0.00004‐7] ">Howes 2013</a>). PQ can occasionally cause serious haemolytic anaemia, haemoglobinaemia, and renal failure. The effect depends on the degree of enzyme deficiency, the dose of PQ, and the pattern of the exposure. These occasional, but clearly serious, adverse effects have led to a reputation of being "unsafe" (<a href="./references#CD008152-bbs2-0087" title="AshleyEA , RechtJ , WhiteNJ . Primaquine: the risks and the benefits. Malaria Journal2014;13:418. [DOI: 10.1186/1475‐2875‐13‐418] ">Ashley 2014</a>). Although the haemolysis appears less likely at lower dose, there have been few studies in G6PD‐deficient people at low doses of PQ (<a href="./references#CD008152-bbs2-0121" title="OlalekanU , GravesPM , SaundersR , GelbandH , RichardsonM , GarnerP . Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies. Malaria Journal2017;16:346. [DOI: 10.1186/s12936‐017‐1989‐3] ">Olalekan 2017</a>). </p> <p>The WHO 2010 <i>Guidelines for the Treatment of Malaria</i> recommended adding a single dose of PQ at 0.75 mg/kg to treatment for uncomplicated <i>P. falciparum</i> malaria in people who are not G6PD‐deficient with the goal of reducing transmission at the community level (<a href="./references#CD008152-bbs2-0136" title="World Health Organization. Guidelines for the Treatment of Malaria. 2nd Edition. Geneva: World Health Organization, 2010. ">WHO 2010</a>). However, since testing for G6PD deficiency was rarely done and due to the concerns about the safety of this single dose, the WHO convened a special expert review group in 2012 to reconsider this recommendation (<a href="./references#CD008152-bbs2-0137" title="World Health Organization. WHO Evidence Review Group: The safety and effectiveness of single dose primaquine as a P. falciparium gametoctyocide. Meeting Report. Geneva: World Health Organization, 2012. ">WHO 2012a</a>). The expert group concluded that: </p> <p> <ul id="CD008152-list-0001"> <li> <p>G6PD testing should be done more widely;</p> </li> <li> <p>countries already implementing single‐dose PQ should reduce the dose to 0.25 mg/kg in G6PD‐deficient patients; and </p> </li> <li> <p>countries not currently implementing single‐dose PQ but which are targeting malaria elimination, or are threatened by artemisinin resistance, should add 0.25 mg/kg PQ to treatment for uncomplicated <i>P. falciparum</i> malaria (<a href="./references#CD008152-bbs2-0133" title="WhiteNJ , QiaoLG , QiG , LuzzattoL . Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malaria Journal2012;11:418. ">White 2012</a>). </p> </li> </ul> </p> <p>These conclusions were then incorporated into a revised WHO recommendation in treatment guidelines (<a href="./references#CD008152-bbs2-0138" title="Global Malaria Programme, World Health Organization. Single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Updated WHO Policy Recommendation. Geneva: World Health Organization, 2012. ">WHO 2012b</a>) for 0.25 mg/kg PQ in the above circumstances, with the goal of reducing transmissibility of treated <i>P. falciparum</i> infections (except in pregnant women, infants under six months of age, and women breastfeeding infants under six months of age). A slightly revised policy was then included in an updated policy brief (<a href="./references#CD008152-bbs2-0139" title="World Health Organization. Policy brief on single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. WHO/HTM/GMP/2015.1. January 2015. www.who.int/malaria/publications/atoz/policy‐brief‐single‐dose‐primaquine‐pf/en/ (accessed 16 January 2018). ">WHO 2015a</a>), and in the third edition of the WHO <i>Guidelines for the Treatment of Malaria</i> (<a href="./references#CD008152-bbs2-0140" title="World Health Organization. Guidelines for the Treatment of Malaria. 3rd Edition. Geneva: World Health Organization, 2015. ">WHO 2015b</a>), which expanded the area of recommendation to all "low transmission areas"; this was a strong recommendation with low certainty evidence and it was stated that G6PD deficiency testing was not required. </p> </section> <section id="CD008152-sec-0027"> <h3 class="title" id="CD008152-sec-0027">How the intervention might work</h3> <p>A single dose of PQ could contribute to reducing malaria transmission through its effects on mature gametocytes, and it is reasonable to assume that reducing the density and duration of gametocytes in the blood of infected people (gametocytaemia) will reduce the duration of potential infectiousness to mosquitoes at the level of the individual (see <a href="#CD008152-fig-0001">Figure 1</a>). However, any subsequent effects on the number of mosquitoes infected from infected people (infectiousness) or the number of new malaria infections in the community (transmission) cannot be assumed and requires estimation of these effects using reliable methods and some direct evidence. </p> <div class="figure" id="CD008152-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Review logic framework: the potential points in the Plasmodium parasite life cycle that could be impacted by PQ and the outcomes used to measure impact. Abbreviations: AUC: area under the curve. EIR: entomological inoculation rate; PQ: primaquine." data-id="CD008152-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Review logic framework: the potential points in the <i>Plasmodium</i> parasite life cycle that could be impacted by PQ and the outcomes used to measure impact. Abbreviations: AUC: area under the curve. EIR: entomological inoculation rate; PQ: primaquine. </p> </div> </div> </div> <p>Infectiousness to mosquitoes can be measured directly by allowing mosquitoes to feed on infected individuals (or their blood) who have been treated with and without PQ (<a href="./references#CD008152-bbs2-0114" title="KilleenGF , RossA , SmithT . Infectiousness of malaria‐endemic human populations to vectors. American Journal of Tropical Medicine and Hygiene2006;75(2 Suppl):38‐45. ">Killeen 2006</a>; <a href="./references#CD008152-bbs2-0094" title="BousemaT , DinglasanRR , MorlaisI , GouagnaLC , vanWarmerdamT , Awono‐AmbenePH , et al. Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS One2012;7(8):e42821. ">Bousema 2012</a>; <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>; <a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>; <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>), or estimated indirectly by measuring the infection rates of wild‐caught mosquitoes (<a href="./references#CD008152-bbs2-0107" title="GravesPM , BurkotTR , SaulAJ , HayesRJ , CarterR . Estimation of anopheline survival rate, vectorial capacity and mosquito infection probability from malaria infection rates in villages near Madang, Papua New Guinea. Journal of Applied Ecology1990;27:134‐47. ">Graves 1990</a>; <a href="./references#CD008152-bbs2-0116" title="LinesJD , WilkesTJ , LyimoEO . Human malaria infectiousness measured by age‐specific sporozoite rates in Anopheles gambiae in Tanzania. Parasitology1991;102(2):167‐77. ">Lines 1991</a>). </p> <p>Community‐level transmission can be measured through large cluster‐randomized trials, or less reliably through controlled before‐and‐after studies. Within any community there are people who are carriers of <i>P. falciparum</i> gametocytes but who do not seek treatment (<a href="./references#CD008152-bbs2-0093" title="BousemaT , DrakeleyC . Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and eradication. Clinical Microbiology Reviews2011;24(2):377‐410. ">Bousema 2011</a>). This is most apparent in areas of high endemicity, where much of the adult population has acquired immunity, so low‐level parasitaemias do not produce symptoms. This reservoir of gametocytes in untreated adults will continue to facilitate community level transmission and may dilute any possible effect of PQ in moderate to high level transmission settings. Indeed, these dilutional effects may even be important in low transmission settings (<a href="./references#CD008152-bbs2-0122" title="OuédragoAL , BousemaT , SchneiderP , deVlasSJ , Ilboudo‐SanogoE , Cuzin‐OuattaraN , et al. Substantial contribution of submicroscopical Plasmodium falciparum gametocute carriage to the infectious reservoir in an area of seasonal transmission. PLoS One2009;4(12):e8410. ">Ouédraogo 2009</a>; <a href="./references#CD008152-bbs2-0095" title="BousemaT , OkellL , FelgerI , DrakeleyC . Asymptomatic malaria infections: detectability, transmissibility and public health relevance. Nature Reviews MIcrobiology2014;12(12):833‐40. [DOI: 10.1038/nrmicro3364] ">Bousema 2014</a>; <a href="./references#CD008152-bbs2-0128" title="StoneW , GoncalvesBP , BousemaT , DrakeleyC . Assessing the infectious reservoir of falciparum malaria, past and future. Trends in Parasitology2015;31(7):287‐296. ">Stone 2015</a>). </p> <p>Recently, with the move toward a target of elimination, some policy makers are considering mass treatment strategies to reduce transmission or contain outbreaks once transmission is reduced to low levels (<a href="./references#CD008152-bbs2-0130" title="vonSeidleinL , GreenwoodBM . Mass administrations of antimalarial drugs. Trends in Parasitology2003;19(10):452‐60. ">von Seidlein 2003</a>; <a href="./references#CD008152-bbs2-0129" title="SturrockHJW , HsiangMS , CohenJM , SmithDL , GreenhouseB , BousemaT , et al. Targeting asymptomatic malaria infections: active surveillance in control and elimination. PLoS Medicine2013;10(6):e1001467. ">Sturrock 2013</a>). In this situation, it seems more likely that a higher proportion of the population with gametocytes will be detected or treated, or both, and that this could be effective in reducing or interrupting transmission. This policy is being considered in countries with lower intensity transmission, or on islands or at the northern and southern fringes of malaria distribution, or both (<a href="./references#CD008152-bbs2-0105" title="Roll Back MalariaPartnership . Global Malaria Action Plan. Geneva: RBM/WHO, 2008. ">GMAP 2008</a>; <a href="./references#CD008152-bbs2-0118" title="MendisK , RietveldA , WarsameM , BosmanA , GreenwoodB , WernsdorferW . From malaria control to eradication: the WHO perspective. Tropical Medicine &amp; International Health2009;14(7):802‐9. ">Mendis 2009</a>). Effective antimalarial drugs are likely to play a large role in this new strategy. One question in this effort is whether there is a role for PQ given in addition to curative antimalarial drugs, including ACTs, to further reduce the infection transmissibility (<a href="./references#CD008152-bbs2-0132" title="WhiteNJ . The role of antimalarial drugs in eliminating malaria. Malaria Journal2008;7(Suppl 1):S8. ">White 2008</a>). Recent modelling has questioned the value of the additional impact of PQ to mass drug administration (MDA) (<a href="./references#CD008152-bbs2-0112" title="JohnstonGL , GethingPW , HaySI , SmithDL , FidockDA . Modeling within‐host effects of drugs on Plasmodium falciparum transmission and prospects for malaria elimination. PLoS Computational Biology2014;10(1):e1003434. ">Johnston 2014</a>; <a href="./references#CD008152-bbs2-0141" title="World Health Organization MPAC. Background document for Session 3 of the Malaria Policy Advisory Committee Meeting MPAC meeting, Sept 2015: Consensus modelling evidence to support the design of mass drug administration programs. www.who.int/malaria/mpac/mpac‐sept2015‐consensus‐modelling‐mda.pdf (accessed 16 January 2018). ">WHO 2015c</a>). </p> <p>The transmission blocking potential of PQ has also been suggested as a strategy to reduce the spread of artemisinin‐resistant parasites in Southeast Asia (<a href="./references#CD008152-bbs2-0096" title="BremanJG . Resistance to artemisinin‐based combination therapy. Lancet. Infectious Diseases2012;12(11):820‐2. ">Breman 2012</a>). While it is certainly important to urgently expand access to treatment for persons with such parasites, PQ does not act on asexual stages, which would still produce gametocytes as usual in resistant infections. Thus it is not clear how this would work, and it may actually be counterproductive (<a href="./references#CD008152-bbs2-0109" title="HastingIM . Gametocytocidal activity in antimalarial drugs speeds the spread of drug resistance. Tropical Medicine &amp; International Health2006;11(8):1206‐17. ">Hastings 2006</a>). </p> </section> <section id="CD008152-sec-0028"> <h3 class="title" id="CD008152-sec-0028">Why it is important to do this review</h3> <p>PQ could play a role in <i>P. falciparum</i> malaria control, particularly malaria elimination and possibly eradication. Defining the strategies in which PQ will be most effective depends on getting the details right on dose, timing, and the situations in which it is used. It has become clear that ACTs have differing effects on gametocyte carriage following treatment, even without PQ (<a href="./references#CD008152-bbs2-0143" title="WWARN . Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and metaanalysis of individual patient data. BMC Medicine2016;14:79. ">WWARN 2016</a>). Therefore the effectiveness may vary considerably, but adverse effects — particularly the haemolytic effects of PQ — occur independently of effectiveness. That is, even if used in situations when it is largely ineffective, the rate of adverse reactions will be constant. Since it is the haemolytic effects that are often foremost in the minds of government health staff, building a case for the use of the drug depends on convincing evidence of its value in malaria control, including in implementation of WHO recommendations. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008152-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008152-sec-0029"></div> <p>1. To summarize any reliable direct research evidence that community programmes of single low dose PQ reduce malaria transmission. </p> <p>2. For currently recommended artemisinin combination treatments for <i>P. falciparum</i> infections, to summarize reliable research evidence on the effect of adding a single dose of PG/8AQ on infectiousness of infected people to mosquitoes, gametocytaemia and any evidence of haemolysis, stratified by: </p> <p> <ul id="CD008152-list-0002"> <li> <p>the current standard recommended dose of 0.25 mg/kg;</p> </li> <li> <p>previously recommended doses (up to 0.75 mg/kg).</p> </li> </ul> </p> <p>3. To repeat the analysis of effects of single dose PQ, stratified by dose, for non‐artemisinin based combination treatments for <i>P. falciparum</i> infections. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008152-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008152-sec-0030"></div> <section id="CD008152-sec-0031"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008152-sec-0032"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs) or quasi‐RCTs including individual‐ or cluster‐RCTs. Cluster‐RCTs must have had at least two clusters per arm. </p> </section> <section id="CD008152-sec-0033"> <h4 class="title">Types of participants</h4> <p>Adults or children with <i>P. falciparum</i> infection or a mixed infection of <i>P. falciparum</i> and other <i>Plasmodium</i> species. For individual RCTs, eligible studies must have diagnosed patients by blood slide, rapid diagnostic test, or other valid molecular method; for cluster‐RCTs, diagnosis could have been by clinical judgment if that was standard in the trial area at the time of the trial. </p> </section> <section id="CD008152-sec-0034"> <h4 class="title">Types of interventions</h4> <section id="CD008152-sec-0035"> <h5 class="title">Intervention</h5> <p>A single dose or short course (up to seven days) of PQ (at doses of 0.2 mg/kg per day or above) or other 8AQ added to malaria treatment(s). </p> </section> <section id="CD008152-sec-0036"> <h5 class="title">Control</h5> <p>Identical treatment for malaria not including PQ/8AQ (or substituting placebo for PQ/8AQ); or using a different 8AQ with same malaria treatment, or using different dose of PQ/8AQ with same malaria treatment(s). </p> </section> </section> <section id="CD008152-sec-0037"> <h4 class="title">Types of outcome measures</h4> <section id="CD008152-sec-0038"> <h5 class="title">Transmission</h5> <p>Any measure of community burden or incidence of malaria (entomological inoculation rate (EIR) measured in mosquitoes, incidence of new malaria infections, or prevalence of malaria infection). </p> </section> <section id="CD008152-sec-0039"> <h5 class="title">Infectiousness</h5> <p> <ul id="CD008152-list-0003"> <li> <p>Number of participants infectious (leading to infection with oocysts or sporozoites in at least one mosquito fed on them or their blood) at day 3‐5 and day 8. </p> </li> <li> <p>Proportion of mosquitoes infected by direct or membrane feeding on blood of participants at day 3‐5 and day 8. </p> </li> </ul> </p> </section> <section id="CD008152-sec-0040"> <h5 class="title">Potential infectiousness</h5> <p> <ul id="CD008152-list-0004"> <li> <p>Number of participants with gametocytes detected by PCR on day 3‐4 and day 8.</p> </li> <li> <p>Number of participants with gametocyte detected by microscopy on day 3‐4 and day 8.</p> </li> </ul> </p> <p>Other measures of gametocytes including gametocyte clearance time (time to disappearance of gametocytes from the blood) and area under the curve of gametocyte density over time where reported. </p> </section> <section id="CD008152-sec-0041"> <h5 class="title">Adverse effects</h5> <p> <ul id="CD008152-list-0005"> <li> <p>Serious adverse events leading to hospital admission or death.</p> </li> <li> <p>Participants with severe haemolysis as defined by the trial authors. It was defined as drop of ≥ 25% (<a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>), ≥ 2 g (<a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>), or ≥ 2 g of haemoglobin (<a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>) over the course of follow‐up. </p> </li> </ul> </p> <p>We also describe maximum or average absolute or percent change in haemoglobin or packed cell volume (PCV) when this is reported. </p> <p><a href="#CD008152-fig-0001">Figure 1</a> provides an outline of transmission of malaria to help clarify the outcomes. </p> </section> </section> </section> <section id="CD008152-sec-0042"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant trials, regardless of language or publication status (published, unpublished, in press, and in progress). </p> <section id="CD008152-sec-0043"> <h4 class="title">Electronic searches</h4> <section id="CD008152-sec-0044"> <h5 class="title">Databases</h5> <p>We searched the following databases up to 21 July 2017 using the search terms and strategy described in <a href="./appendices#CD008152-sec-0162">Appendix 1</a>: the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (Issue 1, 2017); MEDLINE (PubMed; 1966 to 21 July 2017); Embase (OVID; 1980 to 21 July 2017); and LILACS (BIREME, 1982 to 21 July 2017). Also, we checked ClinicalTrials.gov (<a href="https://clinicaltrials.gov/ct2/home" target="_blank">https://clinicaltrials.gov/ct2/home</a>) and the WHO International Clinical Trials Registry Platform (ICTRP); <a href="http://www.who.int/ictrp/en/" target="_blank">http://www.who.int/ictrp/en/</a>; both accessed 21 July 2017) using ‘malaria*', ‘falciparum', ‘primaquine', ‘8‐aminoquinoline', and eight other individual 8AQ names as search terms.  </p> </section> <section id="CD008152-sec-0045"> <h5 class="title">Conference proceedings</h5> <p>We searched the following conference proceedings for relevant abstracts: the MIM Pan‐African Malaria Conferences and the American Society of Tropical Medicine and Hygiene (ASTMH) to December 2009. </p> </section> </section> <section id="CD008152-sec-0046"> <h4 class="title">Searching other resources</h4> <section id="CD008152-sec-0047"> <h5 class="title">Researchers and organizations</h5> <p>We contacted researchers who were authors of some of the included and in‐progress trials, other trial authors, and other experts in the field of malaria chemotherapy. </p> </section> <section id="CD008152-sec-0048"> <h5 class="title">Reference lists</h5> <p>We checked the reference lists of all studies identified by the above methods.</p> </section> </section> </section> <section id="CD008152-sec-0049"> <h3 class="title" id="CD008152-sec-0049">Data collection and analysis</h3> <section id="CD008152-sec-0050"> <h4 class="title">Selection of studies</h4> <p>Two review authors (PMG and HG) independently screened all citations and abstracts identified by the search strategy, including ongoing studies, for potentially eligible studies. We independently assessed full reports of potentially eligible studies for inclusion in the review. Notably, we did not contact any trial authors for clarification regarding inclusion (although we later contacted several about trial details) because it was clear whether trials were or were not eligible for inclusion. We used translations of eight papers published in Chinese to assess eligibility. We resolved differences of opinion by discussion with PG. We listed all studies excluded after full‐text assessment, and their reasons for exclusion, in the ‘<a href="./references#CD008152-sec-0179" title="">Characteristics of excluded studies</a>' table. We have illustrated the study selection process in a PRISMA diagram. </p> </section> <section id="CD008152-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (PMG and HG) independently extracted the following information for each trial using a data extraction form. </p> <section id="CD008152-sec-0052"> <h5 class="title">Trial characteristics</h5> <p> <ul id="CD008152-list-0006"> <li> <p>Design (RCT or quasi‐RCT, type of randomization).</p> </li> <li> <p>Dates and duration of trial.</p> </li> </ul> </p> </section> <section id="CD008152-sec-0053"> <h5 class="title">Participant characteristics</h5> <p> <ul id="CD008152-list-0007"> <li> <p>Number of participants.</p> </li> <li> <p>Age and sex of participants.</p> </li> <li> <p>Proportion with G6PD deficiency.</p> </li> <li> <p>Proportion with gametocytes at onset of trial.</p> </li> <li> <p>Inclusion criteria.</p> </li> <li> <p>Exclusion criteria.</p> </li> </ul> </p> </section> <section id="CD008152-sec-0054"> <h5 class="title">Intervention characteristics</h5> <p> <ul id="CD008152-list-0008"> <li> <p>Type of drug, dose, and schedule.</p> </li> </ul> </p> </section> <section id="CD008152-sec-0055"> <h5 class="title">Presented outcomes</h5> <p> <ul id="CD008152-list-0009"> <li> <p>Description of outcomes presented in the papers.</p> </li> </ul> </p> </section> <section id="CD008152-sec-0056"> <h5 class="title">Other</h5> <p> <ul id="CD008152-list-0010"> <li> <p>Location of trial, setting, and source of funding.</p> </li> <li> <p>Local endemicity of malaria.</p> </li> </ul> </p> </section> <section id="CD008152-sec-0057"> <h5 class="title">Outcomes data</h5> <p>For each trial, two review authors (PMG and HG) extracted data on the trial outcomes eligible for inclusion in this review for the PQ and non‐PQ groups. We extracted the number of participants randomized and the numbers analysed in each treatment group for each outcome. For dichotomous data outcomes (proportion of participants infectious to mosquitoes, proportion of participants with gametocytes, proportion of mosquitoes infected), we extracted the number of participants experiencing the event of interest and the total number of participants or mosquitoes in each treatment arm of each trial. We noted details on the method of determining parasite presence and density, for example light microscopy (if so, the method of staining and number of fields examined), PCR, or other methods. </p> <p>For G6PD deficiency, we noted the sex of the carrier (if stated) and the method used to determine G6PD deficiency, either phenotypically (by enzyme function) or genotypically (PCR). We adopted the definition of ‘deficient' used in the trials that assessed this outcome. We extracted adverse event data for each individual type of event wherever possible. Where adverse events were reported separately for more than one dose (for short‐course regimens), we attempted to record the average number of people reporting each adverse event for each dose. If trials reported the occurrence of adverse events at more than one time point following a single dose, but did not record the total number of people reporting each event, we attempted to record the events occurring in the first time period. </p> <p>In cases of disagreement, we double checked the data and we reached consensus through discussion between all review authors. </p> </section> </section> <section id="CD008152-sec-0058"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (PMG and HG) independently assessed the risk of bias of the included trials as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008152-bbs2-0110" title="HigginsJPT , AltmanDH , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). For each included trial, we assigned a judgement of low, unclear, or high risk of bias for the following components: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective outcome reporting, and other biases. </p> <p>For sequence generation and allocation concealment, we described the methods used, if given. For blinding, we described who was blinded and the blinding method. For incomplete outcome data, we reported the percentage and proportion of loss to follow‐up (the number of participants for whom outcomes are not measured of the number randomized), if given. For selective outcome reporting, we stated any discrepancies between the methods and the results in terms of the outcomes measured and the outcomes reported; we also stated if we knew that an outcome was measured but was not reported in the publication. For other biases we described any other trial features that could have affected the trial's results (for example, whether a trial was stopped early or if no sample size calculation was included). We resolved any disagreements through discussion. </p> <p>We reported the results of the risk of bias assessment in a ‘Risk of bias' table and displayed them in a ‘Risk of bias' summary and ‘Risk of bias' graph (<a href="#CD008152-fig-0002">Figure 2</a>; <a href="#CD008152-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD008152-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="‘Risk of bias' summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD008152-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>‘Risk of bias' summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> </div> <div class="figure" id="CD008152-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="‘Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD008152-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>‘Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> </div> </section> <section id="CD008152-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed the data using Review Manager 5 (RevMan 5) (<a href="./references#CD008152-bbs2-0126" title="Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre. The Cochrane Collaboration, 2014. ">RevMan 2014</a>). For dichotomous data, we estimated the risk ratio (RR) and used the Mantel‐Haenszel method with fixed‐effect, or with random‐effects if there was heterogeneity. For continuous data, we estimated the mean difference (MD). All results are presented with 95% confidence intervals (CIs). We reported results only for days after the first day of PQ treatment, which, in some trials, was later than the beginning of primary treatment. </p> <p>When one trial contained more than one comparison with the same placebo group and there was an analysis total or subtotal, we divided the placebo group participants between the comparisons to avoid double‐counting participants and falsely overestimating the precision. </p> </section> <section id="CD008152-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <p>All the included trials were individually randomized and analysed accordingly.</p> </section> <section id="CD008152-sec-0061"> <h4 class="title">Dealing with missing data</h4> <p>Where data were missing from the trials or details were unclear, we attempted to contact the trial authors. We used complete case analysis (that is, excluding dropouts rather than ‘intention to treat' analysis) for trials with missing data. </p> </section> <section id="CD008152-sec-0062"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between the trials by examining the forest plots to check for overlapping CIs, using the Chi<sup>2</sup> test for heterogeneity with a 10% level of significance and the I<sup>2</sup> statistic with a value of 50% to represent moderate levels of heterogeneity. </p> </section> <section id="CD008152-sec-0063"> <h4 class="title">Assessment of reporting biases</h4> <p>There were insufficient trials (less than 10) within each comparison to assess the likelihood of small trial effects, such as publication bias, by examining a funnel plot for asymmetry (<a href="./references#CD008152-bbs2-0110" title="HigginsJPT , AltmanDH , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD008152-sec-0064"> <h4 class="title">Data synthesis</h4> <p>We prespecified subgroups for analysis by artemisinin or non‐artemisinin based malaria treatment regimens and described which antimalarial drug was used for each comparison in a footnote. We prespecified strata by PQ dose category: low (0.2 to 0.25 mg/kg), medium (0.4 to 0.5 mg/kg), and high (0.75 mg/kg dose); and grouped the 8AQ drugs as PQ and other. Throughout this review, to enable standardization between trials, we designated the first day of any treatment drug as day 1 rather than day 0 as reported in some trials. </p> <p>Where not stated as mg/kg, we reported the PQ dose as the adult dose with the equivalent dose reported as mg/kg; most trials stated that the dose was adjusted for children and if not stated, we made this assumption. </p> <p>When there was no statistically significant heterogeneity between trials, we applied the fixed‐effect meta‐analysis model. When we observed statistically significant heterogeneity within groups that could not be explained by subgroup or sensitivity analyses, we used a random‐effects meta‐analysis model. When we determined substantial heterogeneity from the assessments of heterogeneity (I² statistic value &gt; 50%), we did not undertake meta‐analysis but instead presented a Forest plot with the pooled effect suppressed. </p> <section id="CD008152-sec-0065"> <h5 class="title">Certainty of the evidence</h5> <p>We assessed the certainty of the evidence using the GRADE approach (<a href="./references#CD008152-bbs2-0108" title="GuyattGH , OxmanAD , SchünemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380‐2. [DOI: 10.1016/j.jclinepi.2010.09.011] ">Guyatt 2011</a>). We rated each primary outcome as described by <a href="./references#CD008152-bbs2-0088" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. [DOI: 10.1016/j.jclinepi.2010.07.015] ">Balshem 2011</a> as follows. </p> <p> <ul id="CD008152-list-0011"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>RCTs start as high certainty evidence but can be downgraded if there are valid reasons within the following five categories: risk of bias, imprecision, inconsistency, indirectness, and publication bias. Studies can also be upgraded if there is a large effect; a dose response effect; and if all plausible residual confounding would reduce a demonstrated effect or would suggest a spurious effect if no effect was observed (<a href="./references#CD008152-bbs2-0088" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. [DOI: 10.1016/j.jclinepi.2010.07.015] ">Balshem 2011</a>). We summarized our findings in a ‘Summary of findings’ table. </p> </section> </section> <section id="CD008152-sec-0066"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In our protocol, we stated we would investigate heterogeneity in relation to drug resistance pattern, the parasite density before treatment, and the local endemicity of malaria. However, we identified too few trials for inclusion to perform these analyses. </p> </section> <section id="CD008152-sec-0067"> <h4 class="title">Sensitivity analysis</h4> <p>There were insufficient trials to conduct a sensitivity analysis to investigate the robustness of the results to the quality (risk of bias) components. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008152-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008152-sec-0068"></div> <section id="CD008152-sec-0069"> <h3 class="title">Description of studies</h3> <section id="CD008152-sec-0070"> <h4 class="title">Results of the search</h4> <p>In the last published version of this review, <a href="./references#CD008152-bbs2-0146" title="GravesPM , GelbandH , GarnerP . Primaquine or other 8‐aminoquinoline for reducing Plasmodium falciparum transmission. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD008152.pub4] ">Graves 2015</a>, we included a total of 18 trials. There was one instance of duplicate reports of the same trial in different languages (<a href="./references#CD008152-bbs2-0003" title="ChenPQ , LiGQ , GuoXB . The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin [Chinese]. Zhonghua Yi Xue Za Zhi1994;74(4):209‐10, 253‐4. ChenPQ , LiGQ , GuoXB , HeKR , FuYX , FuLC , et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal1994;107(9):709‐11. ">Chen 1994</a>). Trials frequently included arms with distinct comparisons of different malaria treatment partner drugs, doses, or schedules; thus the 18 previously included trials had 30 arms. </p> <p>For this update, a literature search update to 21 July 2017 identified 53 new records. Four new publications (Eziefula 2013; Eziefula 2014; Pett 2014; Chang 2016) were additional reports from a previously included trial (<a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>). Of the remainder, 10 records were selected for full text review and we excluded 39 records. </p> <p>Ten new publications described seven new trials published since the last revision (<a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>; <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>; <a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>; <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>; <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>). The Goncalves study is regarded as two trials because the two phases had different inclusion criteria (<a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>). </p> <p>The seven new trials included a total of 16 separate comparison arms. Therefore, this update now includes 25 trials which had 46 total arms (<a href="#CD008152-tbl-0006">Table 1</a>). There were 14 trials with artemisinin‐only arms (seven with one arm, two with two arms, three with three arms, one with four arms, and one with five arms). There were nine trials with non‐artemisinin only arms (six with one arm and three with two arms). Two trials had both artemisinin and non‐artemisinin arms. Three artemisinin arms in two trials were excluded because they used doses lower than 0.2 mg/kg (<a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>; <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>), leaving 43 included arms in the 25 trials. </p> <div class="table" id="CD008152-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Trial locations, partner drugs, gametocyte status at onset, G6PD status, and PQ dose and treatment schedule</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Place</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>G6PD status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parasite species</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Partner or alternative drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion with gametocytes at onset (control group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion with gametocytes at onset (experimental group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Day(s)* PQ given</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target PQ dose per day</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>Artemisinin‐based partner</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="31" valign="top"> <p>AS or ACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colombia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+MQ</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.8% Mic</p> <p>(N = 23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.3% Mic</p> <p>(N = 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Mali</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Only non‐deficient included<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>DHAP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>100% Mic</p> <p>(N = 15)</p> <p>Table 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic (N = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0625 mg/kg**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic (N = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.125 mg/kg**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic (N = 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic (N = 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0005" title="El‐SayedB , El‐ZakiSE , BabikerH , GadallaN , AgeepT , MansourF , et al. A randomized open‐label trial of artesunate‐sulfadoxine‐pyrimethamine with or without primaquine for elimination of sub‐microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One2007;2(12):e1311. ">El‐Sayed 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sudan</p> <p>(east)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+SP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5% PCR</p> <p>(N = 52)</p> <p>Table 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5% PCR</p> <p>(N = 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Uganda</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Only non‐deficient included<sup>2</sup> </p> <p>(PCR testing of those included after FST)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>AL</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>23.1% Mic</p> <p>(N = 117)</p> <p>79.8% PCR</p> <p>(N = 114)</p> <p>Table 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.3% MIc</p> <p>(N = 115)</p> <p>86.7% PCR</p> <p>(N = 113)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 mg/kg**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.4% Mic</p> <p>(N = 113)</p> <p>78.7% PCR</p> <p>(N = 108)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.4% Mic</p> <p>(N = 116)</p> <p>82.0% PCR</p> <p>(N = 111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Burkina Faso</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only non‐deficient included<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AL</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17.7% Mic</p> <p>(N = 62)</p> <p>Table 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32% Mic (N = 75)</p> <p>92.9% PCR (N = 70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.5% Mic</p> <p>(N = 73)</p> <p>85.5% PCR (N = 62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Burkina Faso</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only non‐deficient included<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AL</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69.4% Mic</p> <p>(N = 49)</p> <p>Table 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.3% Mic (N = 47)</p> <p>93.7% PCR (N = 48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3% Mic (N = 46)</p> <p>100.0% PCR (N = 46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cambodia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Screened and severely deficient excluded<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf or Pf+Pv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10% Mic</p> <p>44% PCR</p> <p>(N = 51)</p> <p>Table 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8% Mic</p> <p>49% PCR</p> <p>(N = 50)</p> <p>Table 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Screened and all included<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AL</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 patient had gametocytes at recruitment but treatment group not given</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% Mic</p> <p>(N = 220)</p> <p>both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>The Gambia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Only non‐deficient included<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>DHAP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>47.7% PCR</p> <p>(N = 153)</p> <p>Table 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.4% PCR (N = 148)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.6% PCR</p> <p>(N = 152)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.4% PCR</p> <p>(N = 146)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only non‐deficient included<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS</p> <p>days 1 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.1% Mic</p> <p>(N = 23)</p> <p>Table 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.0% Mic</p> <p>(N = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>days 1 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> <p>(North east)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Screened and all included<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+SP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.4% Mic (N = 63)</p> <p>88.2% PCR</p> <p>(N = 51)</p> <p>Table 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9% Mic</p> <p>(N = 53)</p> <p>90.6% PCR</p> <p>(N = 53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Myanmar</p> <p>(3 states)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Not screened</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Pf or mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+AQ</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.1% Mic</p> <p>(N = 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.6% Mic</p> <p>(N = 71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AL</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.5% Mic</p> <p>(N = 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.1% Mic</p> <p>(N = 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+MQ</p> <p>fixed dose</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.3% Mic</p> <p>(N = 83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.9%% Mic</p> <p>(N = 86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS</p> <p>days 1 to 3 + MQ day 1 loose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.5% Mic</p> <p>(N = 82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6% Mic</p> <p>(N = 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>e</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.6% Mic</p> <p>(N = 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5% Mic</p> <p>(N = 83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0022" title="SutantoI , SuprijantoS , KosasihA , DahlanMS , SyafruddinD , KusriastutiR , et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin‐piperaquine in South Sumatra, Western Indonesia: an open‐label, randomized, controlled trial. Clinical Infectious Diseases2013;56(5):685–93. ">Sutanto 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indonesia</p> <p>(south Sumatra)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only non‐deficient included<sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4% Mic</p> <p>(N = 178)</p> <p>Figure 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.0% Mic</p> <p>(on day 3)</p> <p>(N = 171)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Senegal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Screened and all included<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AL</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6.7% Mic</p> <p>(N = 135)</p> <p>Table 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>7.9% Mic</p> <p>(N = 139)</p> <p>Table 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>0.25 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAP</p> <p>days 1 to 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+AQ</p> <p>days 1 to 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0024" title="VásquezAM , SanínF , AlvarezLG , TobónA , RíosA , BlairS . Therapeutic efficacy of a regimen of artesunate‐mefloquine‐primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development [Estudio piloto de la eficacia y de los efectos sobre los gametocitos del esquema artesunato‐mefloquina‐primaquina para la malaria por Plasmodium falciparum]. Biomedica2009;29(2):307‐19. ">Vásquez 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colombia (Antioquia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+MQ</p> <p>days 1 to 3</p> <p>(MQ only on day 2 for children &lt; 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16% Mic</p> <p>(N = 25)</p> <p>Figure 1 estimated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.0% Mic</p> <p>(N = 25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gabon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS i.m.</p> <p>days 1 to 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>(N = 106)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>(N = 108)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>days 1 to 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.5 mg</p> <p>(˜0.38 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>Non‐artemisinin partner</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>CQ or</p> <p>(CQ+SP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India (Mumbai)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not screened</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CQ</p> <p>days 1 to 3 or</p> <p>CQ</p> <p>days 1 to 3 + SP day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(within 3 days)</p> <p>(N = 45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0012" title="KhooKK . The treatment of malaria in glucose‐6‐phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology1981;75(6):591‐5. ">Khoo 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malaysia (Sabah)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only deficient included<sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf, Pv or mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CQ</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> <p>(˜0.42 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0013" title="KolaczinskiK , LeslieT , AliI , DurraniN , LeeS , BarendsM , et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One2012;7(1):e28957. ">Kolaczinski 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pakistan</p> <p>(3 Afghan refugee camps)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CQ days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.6% Mic</p> <p>(N = 239)</p> <p>Table 2 (combined CQ, CQ+AS, SP, SP+AS groups)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.7% Mic</p> <p>(N = 76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> <p>mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008152-bbs2-0014" title="LedermanER , MaguireJD , SumawinataIW , ChandK , ElyazarI , EstianaL , et al. Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia. Malaria Journal2006;5:108. ">Lederman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Indonesia (Central Java)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only non‐deficient included<sup>9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CQ</p> <p>days 1 to 3 + SP day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8.2% Mic</p> <p>(N = 61)</p> <p>Figure 3 est (combined CQ, CQ+SP groups)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25% Mic</p> <p>(N = 28)</p> <p>Figure 3 est</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.3%</p> <p>(N = 28)</p> <p>Figure 3 est</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0013" title="KolaczinskiK , LeslieT , AliI , DurraniN , LeeS , BarendsM , et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One2012;7(1):e28957. ">Kolaczinski 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pakistan (2 Afghan refugee camps)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SP day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above under Kolaczinski 2012 a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.1% Mic</p> <p>(N = 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AQ+SP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colombia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AQ</p> <p>days 1 to 3 + SP day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15% Mic</p> <p>(N = 20)</p> <p>Table 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30% Mic</p> <p>(N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>MQ or (MQ+SP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MQ day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg (˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0003" title="ChenPQ , LiGQ , GuoXB . The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin [Chinese]. Zhonghua Yi Xue Za Zhi1994;74(4):209‐10, 253‐4. ChenPQ , LiGQ , GuoXB , HeKR , FuYX , FuLC , et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal1994;107(9):709‐11. ">Chen 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China (Hainan province)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MQ</p> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 9)</p> <p>MQ group only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0020" title="SinghasivanonV , ChongsuphajaisiddhiT , SabchareonA , AttanathP , WebsterHK , EdsteinMD , et al. Pharmacokinetic study of mefloquine in Thai children aged 5‐12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. European Journal of Drug Metabolism and Pharmacokinetics1994;19(1):27‐32. ">Singhasivanon 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand (Bangkok)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MQ+SP fixed day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>(N = 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>(N = 7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>QN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India (Mumbai)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not screened</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QN i.v.</p> <p>days 1 to 2 and orally days 1 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.6% Mic</p> <p>(N = 44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(within 3 days)</p> <p>(N = 45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only non‐deficient included<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>QN</p> <p>days 1 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>23.3% Mic</p> <p>(N = 60)</p> <p>QN, QN+TC groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.6% Mic</p> <p>(N = 59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>days 1 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 mg base/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.4% Mic</p> <p>(N = 67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>days 1 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 mg base/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>Comparison of different 8AQ</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PQ versus Bulaquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0007" title="GogtayNJ , KamtekarKD , DalviSS , ChogleAR , AigalU , KshirsagarN . Preliminary report of the evaluation of the gametocytocidal action of bulaquine, in adult patients with acute, Plasmodium falciparum malaria. Annals of Tropical Medicine and Parasitology2004;98(5):525‐8. ">Gogtay 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> <p>(Mumbai)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only non‐deficient included<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QN + doxycycline days 1 to 7</p> <p>+ BQ day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No control group without 8‐AQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0008" title="GogtayNJ , KamtekarKD , DalviSS , MehtaSS , ChogleAR , AigalU , et al. A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide‐responsive uncomplicated falciparum malaria [ISCRTN50134587]. BMC Infectious Diseases2006;6:16. ">Gogtay 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only non‐deficient</p> <p>included<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QN + doxycycline days 1 to 7</p> <p>+ BQ day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No control group without 8‐AQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*first day of any treatment = day 1</p> <p>**arm excluded as dose &lt; 0.2 mg/kg</p> <p><sup>1</sup>G6PD colorimetric method, R&amp;D diagnostics, Papagos, Greece.<br/> <sup>2</sup>G6PD by fluorescence spot test.<br/> <sup>3</sup>G6PD by Binax Now Alere rapid test.<br/> <sup>4</sup>G6PD by fluorescent spot test (R&amp;D diagnostics, Greece) and quantitative enzyme activity testing (Trinity Biotech, Ireland).<br/> <sup>5</sup>G6PD (phenotypic) by CareStart ™ Access Bio test; (genotypic) by PCR and RFLP digestion for the two most common Afrcian G6PD polymorphisms.<br/> <sup>6</sup>G6PD by detection of single nucleotide polymorphisms (G202A, A376G) by PCR and ELISA.<br/> <sup>7</sup>G6PD by qualitative test.<br/> <sup>8</sup>G6PD by Brewer's methaemoglobin reduction test.<br/> <sup>9</sup>G6PD by semi‐quantitative G6PD assay.<br/> <sup>10</sup>G6PD method not reported. </p> <p>Abbreviations: G6PD = glucose‐6‐phosphate dehydrogenase; FST = fluorescent spot test; PQ = primaquine; CQ = chloroquine; SP = sulfadoxine‐pyrimethamine; MQ = mefloquine; QN = quinine; AS = artesunate; ACT = artemisinin‐based combination therapy; 8AQ: 8‐aminoquinoline; AQ = amodiaquine; AL = artemether‐lumefantrine; DHAP = dihydroxyartemisinin‐piperaquine; BQ = bulaquine; i.v. = intravenous injection; i.m. = intramuscular injection; Mic = microscopy; Pf = <i>P. falciparum</i> ; Pv = <i>P. vivax</i>. </p> </div> </div> <p>We updated <a href="#CD008152-fig-0004">Figure 4</a>, which shows the flow diagram of included studies, accordingly. We still could not locate three articles that were cited in the ‘<a href="./references#CD008152-bbs1-0003" title="">Studies awaiting classification</a>' section in the previous and this version. </p> <div class="figure" id="CD008152-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD008152-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD008152-sec-0071"> <h4 class="title">Included studies</h4> <p>The 25 included trials comprised 24 individually randomized RCTs and one quasi‐RCT which used alternate allocation (<a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a>). Two trials compared PQ and bulaquine (BQ), while 23 trials compared PQ versus no PQ. One trial of PQ, <a href="./references#CD008152-bbs2-0012" title="KhooKK . The treatment of malaria in glucose‐6‐phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology1981;75(6):591‐5. ">Khoo 1981</a>, did not distinguish between participants given a short or long course of PQ and therefore no outcomes are included in this review. Two trials did not include any gametocyte outcomes (<a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a>; <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>). </p> <section id="CD008152-sec-0072"> <h5 class="title">Trials reporting community transmission</h5> <p>No cluster trials examining malaria transmission intensity in communities met the inclusion criteria. </p> </section> <section id="CD008152-sec-0073"> <h5 class="title">Trials reporting infectiousness</h5> <p>Five trials reported on infectiousness of participants to mosquitoes by direct or membrane feeding of people given ACTs compared to ACT+PQ (<a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>; <a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>; <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>). These trials were conducted in Burkina Faso (partner drug AL), Mali (DHAP), The Gambia (DHAP), and Cambodia (DHAP), respectively. In addition, <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a> planned to test infectivity in Tanzania with AL as partner drug, but no infectiousness or gametocyte outcomes were reported. </p> <p>For direct measures of infectiousness with non‐ACT partner drugs, two small trials in China evaluated the infectiousness to mosquitoes of people treated with mefloquine (MQ) compared to MQ+PQ (<a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a>; <a href="./references#CD008152-bbs2-0003" title="ChenPQ , LiGQ , GuoXB . The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin [Chinese]. Zhonghua Yi Xue Za Zhi1994;74(4):209‐10, 253‐4. ChenPQ , LiGQ , GuoXB , HeKR , FuYX , FuLC , et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal1994;107(9):709‐11. ">Chen 1994</a>). </p> </section> <section id="CD008152-sec-0074"> <h5 class="title">Trials reporting potential infectiousness</h5> <p>Twenty‐two trials examined the impact of PQ or 8AQ on various measures of potential infectiousness, such as gametocyte prevalence or density over time in participants after treatment, gametocyte clearance time, or gametocyte circulation time. Three trials with artemisinin partners assessed gametocyte prevalence by PCR only (<a href="./references#CD008152-bbs2-0005" title="El‐SayedB , El‐ZakiSE , BabikerH , GadallaN , AgeepT , MansourF , et al. A randomized open‐label trial of artesunate‐sulfadoxine‐pyrimethamine with or without primaquine for elimination of sub‐microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One2007;2(12):e1311. ">El‐Sayed 2007</a>; <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>). Five trials reported both microscopy and PCR gametocyte detection (<a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a>; <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>; <a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>; <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>), and the others with either artemisinin or non‐artemsisinin partners reported gametocyte prevalence by microscopy only. </p> <p>Five trials with artemisinin partners reported area under curve (AUC) or log(10)AUC as a summary combined measure of gametocyte prevalence and density over time, using PCR estimates of density (<a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a>; <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>; <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>; <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>). </p> </section> <section id="CD008152-sec-0075"> <h5 class="title">Trials reporting adverse effects</h5> <p>Eleven trials reported adverse effects quantitatively, with 44 different types of effects reported. Nine trials included anaemia outcomes (<a href="./references#CD008152-bbs2-0005" title="El‐SayedB , El‐ZakiSE , BabikerH , GadallaN , AgeepT , MansourF , et al. A randomized open‐label trial of artesunate‐sulfadoxine‐pyrimethamine with or without primaquine for elimination of sub‐microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One2007;2(12):e1311. ">El‐Sayed 2007</a>; <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a>; <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>; <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>; <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>; <a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>; <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>; <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>), and two reported only non haemolytic effects (<a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a>; <a href="./references#CD008152-bbs2-0022" title="SutantoI , SuprijantoS , KosasihA , DahlanMS , SyafruddinD , KusriastutiR , et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin‐piperaquine in South Sumatra, Western Indonesia: an open‐label, randomized, controlled trial. Clinical Infectious Diseases2013;56(5):685–93. ">Sutanto 2013</a>) (<a href="./references#CD008152-fig-0013" title="">Analysis 1.9</a> to <a href="./references#CD008152-fig-0022" title="">Analysis 1.18</a>, and <a href="./references#CD008152-fig-0034" title="">Analysis 3.6</a>). </p> </section> <section id="CD008152-sec-0076"> <h5 class="title">Participants</h5> <section id="CD008152-sec-0077"> <h6 class="title">Place of recruitment</h6> <p>Participants were usually people attending health clinics for treatment, but <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> actively recruited participants from the community for a second phase of the trial when insufficient infective participants were found in phase 1. </p> </section> <section id="CD008152-sec-0078"> <h6 class="title">Age</h6> <p>Four trials did not state the participants' ages (<a href="./references#CD008152-bbs2-0012" title="KhooKK . The treatment of malaria in glucose‐6‐phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology1981;75(6):591‐5. ">Khoo 1981</a>; <a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a>; <a href="./references#CD008152-bbs2-0003" title="ChenPQ , LiGQ , GuoXB . The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin [Chinese]. Zhonghua Yi Xue Za Zhi1994;74(4):209‐10, 253‐4. ChenPQ , LiGQ , GuoXB , HeKR , FuYX , FuLC , et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal1994;107(9):709‐11. ">Chen 1994</a>; <a href="./references#CD008152-bbs2-0005" title="El‐SayedB , El‐ZakiSE , BabikerH , GadallaN , AgeepT , MansourF , et al. A randomized open‐label trial of artesunate‐sulfadoxine‐pyrimethamine with or without primaquine for elimination of sub‐microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One2007;2(12):e1311. ">El‐Sayed 2007</a>), and five trials included children only: <a href="./references#CD008152-bbs2-0020" title="SinghasivanonV , ChongsuphajaisiddhiT , SabchareonA , AttanathP , WebsterHK , EdsteinMD , et al. Pharmacokinetic study of mefloquine in Thai children aged 5‐12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. European Journal of Drug Metabolism and Pharmacokinetics1994;19(1):27‐32. ">Singhasivanon 1994</a> (five to 12 years); <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a> (three to 15 years); <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a> (one to 10 years); <a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> and <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> (two to 15 years). Nine trials used a wide age range of children and adults: <a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a> (six to 60 years); <a href="./references#CD008152-bbs2-0024" title="VásquezAM , SanínF , AlvarezLG , TobónA , RíosA , BlairS . Therapeutic efficacy of a regimen of artesunate‐mefloquine‐primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development [Estudio piloto de la eficacia y de los efectos sobre los gametocitos del esquema artesunato‐mefloquina‐primaquina para la malaria por Plasmodium falciparum]. Biomedica2009;29(2):307‐19. ">Vásquez 2009</a> (≥ one year); <a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a> (&gt; six months); <a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a> (one to 75 years); <a href="./references#CD008152-bbs2-0013" title="KolaczinskiK , LeslieT , AliI , DurraniN , LeeS , BarendsM , et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One2012;7(1):e28957. ">Kolaczinski 2012</a> (three to 70 years); <a href="./references#CD008152-bbs2-0022" title="SutantoI , SuprijantoS , KosasihA , DahlanMS , SyafruddinD , KusriastutiR , et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin‐piperaquine in South Sumatra, Western Indonesia: an open‐label, randomized, controlled trial. Clinical Infectious Diseases2013;56(5):685–93. ">Sutanto 2013</a> (≥ five years); <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a> (≥ one year); <a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a> (&gt; one year) and <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> (five to 50 years). The remaining seven trials included teenagers and adults only: <a href="./references#CD008152-bbs2-0007" title="GogtayNJ , KamtekarKD , DalviSS , ChogleAR , AigalU , KshirsagarN . Preliminary report of the evaluation of the gametocytocidal action of bulaquine, in adult patients with acute, Plasmodium falciparum malaria. Annals of Tropical Medicine and Parasitology2004;98(5):525‐8. ">Gogtay 2004</a> (&gt; 18 years); <a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a> (&gt; 16 years); <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a> (18 to 65 years); <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a> (18 to 74 years); <a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a> (15 to 62 years); <a href="./references#CD008152-bbs2-0008" title="GogtayNJ , KamtekarKD , DalviSS , MehtaSS , ChogleAR , AigalU , et al. A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide‐responsive uncomplicated falciparum malaria [ISCRTN50134587]. BMC Infectious Diseases2006;6:16. ">Gogtay 2006</a> (&gt; 16 years); and <a href="./references#CD008152-bbs2-0014" title="LedermanER , MaguireJD , SumawinataIW , ChandK , ElyazarI , EstianaL , et al. Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia. Malaria Journal2006;5:108. ">Lederman 2006</a> (≥ 15 years). See the ‘<a href="./references#CD008152-sec-0178" title="">Characteristics of included studies</a>' section. </p> </section> <section id="CD008152-sec-0079"> <h6 class="title">G6PD deficiency</h6> <p>For G6PD deficiency, two trials did not screen participants (<a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a>; <a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a>), three trials screened and included all participants (<a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a>; <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>; <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>), one trial included only G6PD‐deficient participants (<a href="./references#CD008152-bbs2-0012" title="KhooKK . The treatment of malaria in glucose‐6‐phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology1981;75(6):591‐5. ">Khoo 1981</a>), 11 trials included only non‐severely deficient participants (<a href="./references#CD008152-bbs2-0007" title="GogtayNJ , KamtekarKD , DalviSS , ChogleAR , AigalU , KshirsagarN . Preliminary report of the evaluation of the gametocytocidal action of bulaquine, in adult patients with acute, Plasmodium falciparum malaria. Annals of Tropical Medicine and Parasitology2004;98(5):525‐8. ">Gogtay 2004</a>; <a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a>; <a href="./references#CD008152-bbs2-0008" title="GogtayNJ , KamtekarKD , DalviSS , MehtaSS , ChogleAR , AigalU , et al. A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide‐responsive uncomplicated falciparum malaria [ISCRTN50134587]. BMC Infectious Diseases2006;6:16. ">Gogtay 2006</a>; <a href="./references#CD008152-bbs2-0014" title="LedermanER , MaguireJD , SumawinataIW , ChandK , ElyazarI , EstianaL , et al. Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia. Malaria Journal2006;5:108. ">Lederman 2006</a>; <a href="./references#CD008152-bbs2-0022" title="SutantoI , SuprijantoS , KosasihA , DahlanMS , SyafruddinD , KusriastutiR , et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin‐piperaquine in South Sumatra, Western Indonesia: an open‐label, randomized, controlled trial. Clinical Infectious Diseases2013;56(5):685–93. ">Sutanto 2013</a>; <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>; <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>; <a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>; <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>), and the remaining eight studies made no comment (<a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a>; <a href="./references#CD008152-bbs2-0003" title="ChenPQ , LiGQ , GuoXB . The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin [Chinese]. Zhonghua Yi Xue Za Zhi1994;74(4):209‐10, 253‐4. ChenPQ , LiGQ , GuoXB , HeKR , FuYX , FuLC , et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal1994;107(9):709‐11. ">Chen 1994</a>; <a href="./references#CD008152-bbs2-0020" title="SinghasivanonV , ChongsuphajaisiddhiT , SabchareonA , AttanathP , WebsterHK , EdsteinMD , et al. Pharmacokinetic study of mefloquine in Thai children aged 5‐12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. European Journal of Drug Metabolism and Pharmacokinetics1994;19(1):27‐32. ">Singhasivanon 1994</a>; <a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a>; <a href="./references#CD008152-bbs2-0005" title="El‐SayedB , El‐ZakiSE , BabikerH , GadallaN , AgeepT , MansourF , et al. A randomized open‐label trial of artesunate‐sulfadoxine‐pyrimethamine with or without primaquine for elimination of sub‐microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One2007;2(12):e1311. ">El‐Sayed 2007</a>; <a href="./references#CD008152-bbs2-0024" title="VásquezAM , SanínF , AlvarezLG , TobónA , RíosA , BlairS . Therapeutic efficacy of a regimen of artesunate‐mefloquine‐primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development [Estudio piloto de la eficacia y de los efectos sobre los gametocitos del esquema artesunato‐mefloquina‐primaquina para la malaria por Plasmodium falciparum]. Biomedica2009;29(2):307‐19. ">Vásquez 2009</a>; <a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a>; <a href="./references#CD008152-bbs2-0013" title="KolaczinskiK , LeslieT , AliI , DurraniN , LeeS , BarendsM , et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One2012;7(1):e28957. ">Kolaczinski 2012</a>); see <a href="#CD008152-tbl-0006">Table 1</a>. </p> </section> <section id="CD008152-sec-0080"> <h6 class="title">Baseline infectiousness</h6> <p>In <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>, baseline infectiousness (proportion of persons infectious) prior to treatment in both groups combined was 58/73 (79%), with no obvious imbalance between the treatment groups. In Goncalves phase 1, no baseline infectiousness was measured (<a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>); in phase 2, 79 of the 149 participants were tested for infectiousness at baseline, and 30/79 (38%) were infectious (all groups combined) (<a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>). In <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>, baseline infectiousness of participants reported on day 0 appeared unbalanced: DHAP 6/51 (12%); DHAP+PQ 1/51 (2%). This is assumed to reflect selection bias or a failure of randomization. </p> </section> </section> <section id="CD008152-sec-0081"> <h5 class="title">Interventions</h5> <section id="CD008152-sec-0082"> <h6 class="title">Background drug</h6> <p>Sixteen trials (31 treatment arms) evaluated PQ given alongside artemisinin‐based treatments: artesunate (AS) (two trials, two arms), AS+SP (two trials, two arms), AS+MQ (three trials, four arms), AS+AQ (two trials, two arms), artemether‐lumefantrine (AL) (five trials, ten arms) and dihydroxyartemisinin‐piperaquine (DHAP) (six trials, 11 arms). Two trials included two and one arms, respectively, with doses too low (&lt; 0.2 mg/kg) to be included here (<a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>; <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>). One trial, <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>, included arms with AL, DHAP and ASAQ, but they were combined in the paper and here for analysis. </p> <p>Eleven trials (15 treatment arms) evaluated PQ or BQ, given alongside non‐artemisinin‐based treatments. Nine trials (13 treatment arms) evaluated PQ given alongside the following: chloroquine alone (CQ) (three trials, four arms), CQ alone or CQ+SP (one trial, one arm), SP (one trial, one arm), mefloquine (MQ) (two trials, two arms), MQ+SP (one trial, one arm), quinine (QN) (two trials, three arms), and amodiaquine (AQ)+SP (one trial, one arm). Two trials (two treatment arms) evaluated BQ given alongside the following: QN (one trial, one arm) and QN plus doxycycline (one trial, one arm). </p> </section> <section id="CD008152-sec-0083"> <h6 class="title">Dose</h6> <p>Sixteen trials included the previous standard dose of 0.75 mg/kg PQ per day (adult dose 45 mg/day); see <a href="#CD008152-tbl-0006">Table 1</a>. The trials using different doses were as follows. </p> <p> <ul id="CD008152-list-0012"> <li> <p><a href="./references#CD008152-bbs2-0012" title="KhooKK . The treatment of malaria in glucose‐6‐phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology1981;75(6):591‐5. ">Khoo 1981</a>: adult dose of 25 mg or approximately 0.42 mg/kg/day. </p> </li> <li> <p><a href="./references#CD008152-bbs2-0013" title="KolaczinskiK , LeslieT , AliI , DurraniN , LeeS , BarendsM , et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One2012;7(1):e28957. ">Kolaczinski 2012</a>: (two arms) 0.5 mg/kg or adult dose 30 mg/day. </p> </li> <li> <p><a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a>: the trial with QN had two arms, one with 0.25 mg/kg and the other 0.5 mg/kg per day (adult dose 15 mg or 30 mg per day, respectively); the comparison with AS used 0.5 mg/kg per day (adult dose 30 mg per day). </p> </li> <li> <p><a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a>: adult dose of 22.5 mg or approximately 0.38 mg/kg per day. </p> </li> <li> <p><a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>: 0.1 (not included in this review), 0.4 and 0.75 mg/kg. </p> </li> <li> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>: 0.125 (not included in this review) and 0.5 mg/kg in phase 1 and 0.0625 (not included in this review) and 0.25 mg/kg in phase 2. </p> </li> <li> <p><a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>: 0.2 and 0.4 mg/kg. </p> </li> <li> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>: 0.2 and 0.4 mg/kg. </p> </li> <li> <p><a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>: 0.2, 0.4 and 0.75 mg/kg. </p> </li> <li> <p><a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>: 0.25 mg/kg. </p> </li> <li> <p><a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>: 0.25 mg/kg. </p> </li> </ul> </p> <p>This review reports the results for clinically important doses only: 0.2 to 0.25 mg/kg, 0.4 to 0.5 mg/kg, and 0.75 mg/kg. </p> </section> <section id="CD008152-sec-0084"> <h6 class="title">Schedule</h6> <p>We regarded the first day of any treatment as day 1. Most trials used a single dose of PQ given on the following days. </p> <p> <ul id="CD008152-list-0013"> <li> <p>Day 1: <a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a>; <a href="./references#CD008152-bbs2-0003" title="ChenPQ , LiGQ , GuoXB . The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin [Chinese]. Zhonghua Yi Xue Za Zhi1994;74(4):209‐10, 253‐4. ChenPQ , LiGQ , GuoXB , HeKR , FuYX , FuLC , et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal1994;107(9):709‐11. ">Chen 1994</a>; <a href="./references#CD008152-bbs2-0020" title="SinghasivanonV , ChongsuphajaisiddhiT , SabchareonA , AttanathP , WebsterHK , EdsteinMD , et al. Pharmacokinetic study of mefloquine in Thai children aged 5‐12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. European Journal of Drug Metabolism and Pharmacokinetics1994;19(1):27‐32. ">Singhasivanon 1994</a>; <a href="./references#CD008152-bbs2-0014" title="LedermanER , MaguireJD , SumawinataIW , ChandK , ElyazarI , EstianaL , et al. Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia. Malaria Journal2006;5:108. ">Lederman 2006</a> (one of two comparisons); <a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a> (five arms); <a href="./references#CD008152-bbs2-0013" title="KolaczinskiK , LeslieT , AliI , DurraniN , LeeS , BarendsM , et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One2012;7(1):e28957. ">Kolaczinski 2012</a> (one of two arms); <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>; <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a> (three arms). </p> </li> <li> <p>Day 2: <a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a> (two arms). </p> </li> <li> <p>Day 3: <a href="./references#CD008152-bbs2-0014" title="LedermanER , MaguireJD , SumawinataIW , ChandK , ElyazarI , EstianaL , et al. Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia. Malaria Journal2006;5:108. ">Lederman 2006</a> (one of two arms); <a href="./references#CD008152-bbs2-0024" title="VásquezAM , SanínF , AlvarezLG , TobónA , RíosA , BlairS . Therapeutic efficacy of a regimen of artesunate‐mefloquine‐primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development [Estudio piloto de la eficacia y de los efectos sobre los gametocitos del esquema artesunato‐mefloquina‐primaquina para la malaria por Plasmodium falciparum]. Biomedica2009;29(2):307‐19. ">Vásquez 2009</a>; <a href="./references#CD008152-bbs2-0013" title="KolaczinskiK , LeslieT , AliI , DurraniN , LeeS , BarendsM , et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One2012;7(1):e28957. ">Kolaczinski 2012</a> (one of two arms); <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>; <a href="./references#CD008152-bbs2-0022" title="SutantoI , SuprijantoS , KosasihA , DahlanMS , SyafruddinD , KusriastutiR , et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin‐piperaquine in South Sumatra, Western Indonesia: an open‐label, randomized, controlled trial. Clinical Infectious Diseases2013;56(5):685–93. ">Sutanto 2013</a>; <a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> (two arms); <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> (two arms); <a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a> (three arms); <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>. </p> </li> <li> <p>Day 4: <a href="./references#CD008152-bbs2-0007" title="GogtayNJ , KamtekarKD , DalviSS , ChogleAR , AigalU , KshirsagarN . Preliminary report of the evaluation of the gametocytocidal action of bulaquine, in adult patients with acute, Plasmodium falciparum malaria. Annals of Tropical Medicine and Parasitology2004;98(5):525‐8. ">Gogtay 2004</a>; <a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a> (one of two arms); <a href="./references#CD008152-bbs2-0008" title="GogtayNJ , KamtekarKD , DalviSS , MehtaSS , ChogleAR , AigalU , et al. A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide‐responsive uncomplicated falciparum malaria [ISCRTN50134587]. BMC Infectious Diseases2006;6:16. ">Gogtay 2006</a>; <a href="./references#CD008152-bbs2-0005" title="El‐SayedB , El‐ZakiSE , BabikerH , GadallaN , AgeepT , MansourF , et al. A randomized open‐label trial of artesunate‐sulfadoxine‐pyrimethamine with or without primaquine for elimination of sub‐microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One2007;2(12):e1311. ">El‐Sayed 2007</a>; <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a>. </p> </li> <li> <p>Day 8: <a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a> (one of two arms). </p> </li> </ul> </p> <p>Three trials used a longer course of PQ.</p> <p> <ul id="CD008152-list-0014"> <li> <p>Three days: <a href="./references#CD008152-bbs2-0012" title="KhooKK . The treatment of malaria in glucose‐6‐phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology1981;75(6):591‐5. ">Khoo 1981</a>. </p> </li> <li> <p>Five days: <a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a>. </p> </li> <li> <p>Seven days: <a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a> (three arms). </p> </li> </ul> </p> </section> <section id="CD008152-sec-0085"> <h6 class="title">Length of follow‐up</h6> <p>The maximum time of follow‐up varied between trials. It was restricted here to eight days after treatment to enable maximum comparison between trials (some of which terminated at this point). Therefore, not all results from <a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a> could be included since PQ was given on day 8 in one arm. </p> </section> <section id="CD008152-sec-0086"> <h6 class="title">Prevalence of gametocytes at start of trial</h6> <p>The trials varied in inclusion criteria and hence in how representative they were of the gametocyte prevalence of the general or clinic population. Five trials included only people with microscopically detected gametocytes at onset (<a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a>; <a href="./references#CD008152-bbs2-0003" title="ChenPQ , LiGQ , GuoXB . The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin [Chinese]. Zhonghua Yi Xue Za Zhi1994;74(4):209‐10, 253‐4. ChenPQ , LiGQ , GuoXB , HeKR , FuYX , FuLC , et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal1994;107(9):709‐11. ">Chen 1994</a>; <a href="./references#CD008152-bbs2-0007" title="GogtayNJ , KamtekarKD , DalviSS , ChogleAR , AigalU , KshirsagarN . Preliminary report of the evaluation of the gametocytocidal action of bulaquine, in adult patients with acute, Plasmodium falciparum malaria. Annals of Tropical Medicine and Parasitology2004;98(5):525‐8. ">Gogtay 2004</a>; <a href="./references#CD008152-bbs2-0008" title="GogtayNJ , KamtekarKD , DalviSS , MehtaSS , ChogleAR , AigalU , et al. A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide‐responsive uncomplicated falciparum malaria [ISCRTN50134587]. BMC Infectious Diseases2006;6:16. ">Gogtay 2006</a>; <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>). In <a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a> over 90% of participants were gametocyte positive by microscopy, but this variable was reported as "within 3 days" rather than on day 1. The <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> trial had the next highest prevalence by microscopy, of 69%. The five arms of the <a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a> trial showed moderately high gametocyte prevalence (microscopy) between 29% and 38% depending on the arm. Trials with initial gametocyte prevalence between 15% and 27% by microscopy were: <a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a>; <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a>; <a href="./references#CD008152-bbs2-0024" title="VásquezAM , SanínF , AlvarezLG , TobónA , RíosA , BlairS . Therapeutic efficacy of a regimen of artesunate‐mefloquine‐primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development [Estudio piloto de la eficacia y de los efectos sobre los gametocitos del esquema artesunato‐mefloquina‐primaquina para la malaria por Plasmodium falciparum]. Biomedica2009;29(2):307‐19. ">Vásquez 2009</a>; <a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a>; <a href="./references#CD008152-bbs2-0013" title="KolaczinskiK , LeslieT , AliI , DurraniN , LeeS , BarendsM , et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One2012;7(1):e28957. ">Kolaczinski 2012</a>; <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>; <a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>; and <a href="./references#CD008152-bbs2-0022" title="SutantoI , SuprijantoS , KosasihA , DahlanMS , SyafruddinD , KusriastutiR , et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin‐piperaquine in South Sumatra, Western Indonesia: an open‐label, randomized, controlled trial. Clinical Infectious Diseases2013;56(5):685–93. ">Sutanto 2013</a>. The remaining three trials had low (&lt; 15%) gametocyte prevalence by microscopy at onset (<a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>; <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>; <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>). </p> <p>Two trials reported PCR prevalence only: <a href="./references#CD008152-bbs2-0005" title="El‐SayedB , El‐ZakiSE , BabikerH , GadallaN , AgeepT , MansourF , et al. A randomized open‐label trial of artesunate‐sulfadoxine‐pyrimethamine with or without primaquine for elimination of sub‐microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One2007;2(12):e1311. ">El‐Sayed 2007</a>, with 10.5% and <a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>, with 48%. Four trials did not report the prevalence of gametocytes at onset (<a href="./references#CD008152-bbs2-0012" title="KhooKK . The treatment of malaria in glucose‐6‐phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology1981;75(6):591‐5. ">Khoo 1981</a>; <a href="./references#CD008152-bbs2-0020" title="SinghasivanonV , ChongsuphajaisiddhiT , SabchareonA , AttanathP , WebsterHK , EdsteinMD , et al. Pharmacokinetic study of mefloquine in Thai children aged 5‐12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. European Journal of Drug Metabolism and Pharmacokinetics1994;19(1):27‐32. ">Singhasivanon 1994</a>; <a href="./references#CD008152-bbs2-0014" title="LedermanER , MaguireJD , SumawinataIW , ChandK , ElyazarI , EstianaL , et al. Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia. Malaria Journal2006;5:108. ">Lederman 2006</a>; <a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a>). </p> <p>The details of the trial locations, malaria treatments, gametocyte prevalence at onset, 8‐AQ doses, and schedules are in <a href="#CD008152-tbl-0006">Table 1</a>. </p> </section> </section> <section id="CD008152-sec-0087"> <h5 class="title">Outcomes</h5> <section id="CD008152-sec-0088"> <h6 class="title">Transmission</h6> <p>For malaria transmission intensity (prevalence, incidence or EIR), we found no community cluster‐RCTs measuring these outcomes that met inclusion criteria. </p> </section> <section id="CD008152-sec-0089"> <h6 class="title">Infectiousness</h6> <p>Infectiousness includes two components: proportion of participants infectious, and proportion of mosquitoes infected. Six trials intended to measure infectiousness with artemisinin partner drugs (DHAP, ASAQ, or AL) (<a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>; <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>; <a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>; <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>) and five (all except <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>) provided such data. Two trials measured infectiousness with non‐artemisinin drugs (in both cases MQ) with and without PQ (<a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a>; <a href="./references#CD008152-bbs2-0003" title="ChenPQ , LiGQ , GuoXB . The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin [Chinese]. Zhonghua Yi Xue Za Zhi1994;74(4):209‐10, 253‐4. ChenPQ , LiGQ , GuoXB , HeKR , FuYX , FuLC , et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal1994;107(9):709‐11. ">Chen 1994</a>). Results are reported here for two time points after commencement of treatment. The first day of treatment is day 1. The goal was reporting at day 4 and 8, but day 4 was varied to day 3 or 5 for some trials. </p> </section> <section id="CD008152-sec-0090"> <h6 class="title">Potential infectiousness</h6> <p>All other trials (except <a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a> and <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>) reported potential infectiousness: that is, the effects of PQ on gametocyte prevalence, density, or clearance time, or all three outcomes using either microscopy or PCR. The same time points are reported as for infectiousness (day 3, 4, or 5, and day 8). </p> <p>Nine trials reported gametocyte clearance time (<a href="./references#CD008152-bbs2-0020" title="SinghasivanonV , ChongsuphajaisiddhiT , SabchareonA , AttanathP , WebsterHK , EdsteinMD , et al. Pharmacokinetic study of mefloquine in Thai children aged 5‐12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. European Journal of Drug Metabolism and Pharmacokinetics1994;19(1):27‐32. ">Singhasivanon 1994</a>; <a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a>; <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a>; <a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a>; <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>; <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>; <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>; <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>). Four of these also reported a summary measure of potential infectiousness using area under the curve (AUC) of gametocyte density over time (<a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a>; <a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>; <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>). </p> <p><a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a> and <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a> reported only asexual stage outcomes and <a href="./references#CD008152-bbs2-0012" title="KhooKK . The treatment of malaria in glucose‐6‐phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology1981;75(6):591‐5. ">Khoo 1981</a> reported data that could not be used as the length of PQ course for each participant was not clear. </p> </section> </section> </section> <section id="CD008152-sec-0091"> <h4 class="title">Excluded studies</h4> <p>We have listed the reasons for exclusion of 48 trials in the ‘<a href="./references#CD008152-sec-0179" title="">Characteristics of excluded studies</a>' section. Some additional details of these trials and reasons for exclusion are expanded in a previous edition of this review (<a href="./references#CD008152-bbs2-0145" title="GravesPM , GelbandH , GarnerP . Primaquine or other 8‐aminoquinoline for reducing P. falciparum transmission. Cochrane Database of Systematic Reviews2014, Issue 6. [DOI: 10.1002/14651858.CD008152.pub3] ">Graves 2014</a>). </p> <p>We sought publications for Chinese trials cited in <a href="./references#CD008152-bbs2-0133" title="WhiteNJ , QiaoLG , QiG , LuzzattoL . Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malaria Journal2012;11:418. ">White 2012</a> and <a href="./references#CD008152-bbs2-0134" title="WhiteNJ . Primaquine to prevent transmission of falciparum malaria. Lancet. Infectious Diseases2013;13(2):175‐81. ">White 2013</a> and by personal communication from Professor Li Guo Qiao. We were unable to locate two (<a href="./references#CD008152-bbs2-0074" title="ChenL . Efficacy of artemether/primaquine against drug resistant P. falciparum [Chinese]. Journal of Applied Medicine1993;1(1):31‐3. ">Chen 1993b</a>; <a href="./references#CD008152-bbs2-0076" title="LiJ , et al. Artemether combined with primaquine for treatment of 50 Pf cases [Chinese]. Journal of Applied Medicine2006;22(19):2299‐300. ">Li 2006</a>); the others were translated where required. We excluded the following studies on the basis of no appropriate comparison (either all groups got PQ or there was no comparator group with same dose of malaria treatment drug but no PQ): (<a href="./references#CD008152-bbs2-0034" title="CheLG , HuangKG , YangHL , YuL , LinZL , HuangR . Combined use of pyronaridine, sulfadoxine and primaquine in areas with chloroquine‐resistant falciparum malaria. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi [Chinese Journal of Parasitology and Parasitic Diseases]1987;5(3):194‐6. ">Che 1987</a>; <a href="./references#CD008152-bbs2-0071" title="YangH , CheL , HuangK , YangP , DongY , LinZ , et al. The effect of combinations of pyronaridine, sufadoxine and primaquine on chloroquine‐resistant P. falciparum. Chinese Journal of Parasitic Disease Control1989;2(1):7‐10. ">Yang 1989</a>; <a href="./references#CD008152-bbs2-0035" title="CheL , HuangK , DongY , YangH , YangP . Efficacy of two combined therapies for treatment of chloroquine‐resistant P. falciparum. Chinese Journal of Parasitic Disease Control1990;3(1):24‐6. ">Che 1990</a>; <a href="./references#CD008152-bbs2-0048" title="HuangZ , MengF , FuS . Comparative studies on the treatment of drug‐resistant P. falciparum with pyronaridine/SP and primaquine. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi [Chinese Journal Parasitology and Parasitic Diseases]1996;14(4):314‐7. ">Huang 1996</a>; <a href="./references#CD008152-bbs2-0059" title="LinL , WangD‐L , LiuB , HuG . Artemether combined with primaquine for treatment of malaria cases from UN peace force. Chinese Journal of Parasitic Disease Control2004;17(5):5‐6. ">Lin 2004</a>; <a href="./references#CD008152-bbs2-0068" title="SunW‐H , TraoreA . Artesunate combined with primaquine in treatment study on delay or relapse of malaria. Chinese Journal of Clinical Pharmacology and Therapeutics2011;1:98‐100. ">Sun 2011</a>) or lack of randomization (<a href="./references#CD008152-bbs2-0032" title="CaiXZ , YangXP , HeXZ , ZhanWC , ZhanX , YeBS . The combined use of artemether, sulfadoxine, pyrimethamine and primaquine in the treatment of chloroquine‐resistant falciparum malaria. Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi [Chinese Journal of Parasitology and Parasitic Diseases]1985;3(2):81‐4. ">Cai 1985</a>; <a href="./references#CD008152-bbs2-0047" title="HuangZS , FuSG , CaiXZh . Combined use of pyronaridine/SP with primaquine for P. falciparum treatment. Journal of Hainan Medicine1993;4(1):10‐2. ">Huang 1993</a>). Three other trials of artemether with and without PQ in Africa were stated to be randomized (<a href="./references#CD008152-bbs2-0049" title="HuangJR , GaoYQ , ElieN . A study of artemether combined with primaquine in the treatment of falciparum malaria. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi [Chinese Journal of Parasitology and Parasitic Diseases]2001;19(5):308‐9. ">Huang 2001</a>; <a href="./references#CD008152-bbs2-0057" title="LiJ , XiaoH , WangW , MaW , RaoB . Artemether combined with primaquine for P. falciparum cases treatment. Clinical Medical Journal of China2007;14(5):736‐7. ">Li 2007</a>; <a href="./references#CD008152-bbs2-0058" title="LiWJ , LiXL . Observation of curative effect of falciparum malaria treatment with artemether/lumefantrine and primaquine. Journal of Modern Preventive Medicine2010;37(5):973‐5. ">Li 2010</a>), but we excluded them due to the late administration of PQ (after five to seven days of artemether) and lack of gametocyte outcomes. </p> </section> </section> <section id="CD008152-sec-0092"> <h3 class="title">Risk of bias in included studies</h3> <p>The ‘Risk of bias' assessment for each of the 25 included trials is shown in <a href="#CD008152-fig-0002">Figure 2</a> with a summary by component in <a href="#CD008152-fig-0003">Figure 3</a>. There was low risk of bias in 50% or more of trials for random sequence generation, allocation concealment, incomplete outcome data, selective reporting, and other bias. High risk of bias was present in less than 20% of the trials for these components. The trials were weakest on blinding, with low risk of bias in less than 25% for blinding of participants and personnel, and less than 50% of trials for blinding of outcome assessment. The highest risk of bias (30% of trials) was for blinding of participants and personnel. A relatively high proportion of trials (particularly older trials) did not report sufficient information to clarify the risk of bias, especially for blinding and allocation concealment (≥ 30% of trials). </p> <p><a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a> excluded G6PD‐deficient people from the PQ group post‐randomization. We had no reason to suppose it biased the primary outcomes but it could have affected assessment of adverse effects. </p> </section> <section id="CD008152-sec-0093"> <h3 class="title" id="CD008152-sec-0093">Effects of interventions</h3> <p>See: <a href="./full#CD008152-tbl-0001"><b>Summary of findings for the main comparison</b> Single dose primaquine at 0.2 to 0.25 mg/kg compared to no primaquine, with artemisinin partner, for reducing <i>P. falciparum</i> transmission</a>; <a href="./full#CD008152-tbl-0002"><b>Summary of findings 2</b> Single dose primaquine at 0.4 to 0.5 mg/kg compared to no primaquine, with artemisinin partner, for reducing <i>P. falciparum</i> transmission</a>; <a href="./full#CD008152-tbl-0003"><b>Summary of findings 3</b> Single dose primaquine at 0.75 mg/kg compared to no primaquine, with artemisinin partner, for reducing <i>P. falciparum</i> transmission</a>; <a href="./full#CD008152-tbl-0004"><b>Summary of findings 4</b> Single dose primaquine at 0.4 to 0.5 mg/kg compared to no primaquine, with non‐artemisinin partner, for reducing <i>P. falciparum</i> transmission</a>; <a href="./full#CD008152-tbl-0005"><b>Summary of findings 5</b> Single dose primaquine at 0.75 mg/kg compared to no primaquine, with non‐artemisinin partner, for reducing <i>P. falciparum</i> transmission</a> </p> <p>We subgrouped the data by whether or not the malaria treatment was artemisinin‐based, and by the gametocyte detection method. We included only one measure of gametocyte prevalence by PCR data if two different methods of PCR were reported, to avoid duplicate reporting of the same participants (<a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>). </p> <p>Results were stratified by two time points of follow‐up, with the exact day depending on what was reported. The goal was reporting at day 4 and 8, but this was varied to day 3 or 5 and day 8 in some trials. Results at these time points were included only if they were after the administration of PQ. For day 3 outcomes, we excluded <a href="./references#CD008152-bbs2-0022" title="SutantoI , SuprijantoS , KosasihA , DahlanMS , SyafruddinD , KusriastutiR , et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin‐piperaquine in South Sumatra, Western Indonesia: an open‐label, randomized, controlled trial. Clinical Infectious Diseases2013;56(5):685–93. ">Sutanto 2013</a> since PQ was given on that day. We excluded the QN comparison of <a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a> because PQ was not given until day 8, but included all other trials with gametocyte outcomes at day 8 (all trials except <a href="./references#CD008152-bbs2-0012" title="KhooKK . The treatment of malaria in glucose‐6‐phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology1981;75(6):591‐5. ">Khoo 1981</a>, <a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a>, and <a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a>). </p> <p>Where reported, summary estimates of effects on gametocyte clearance time over the whole period of follow‐up are reported. </p> <p>The day on which PQ was given varied, and is presented for each trial in <a href="#CD008152-tbl-0006">Table 1</a> and in the footnotes to each analysis. </p> <p>Results on infections acquired by mosquitoes are reported in tables only because we were not able to account for the bias due to varying numbers of mosquitoes dissected per individual. </p> <section id="CD008152-sec-0094"> <h4 class="title">1. PQ as part of artemisinin‐based treatment regimens</h4> </section> <section id="CD008152-sec-0095"> <h4 class="title">Follow‐up at day 3 or 4</h4> <section id="CD008152-sec-0096"> <h5 class="title">Infectiousness of people to mosquitoes</h5> <p>Four trials assessed proportion of participants infectious to mosquitoes on day 3 or 4 after first treatment on day 1. Results were stratified by dose. Only one trial out of three in the low dose (0.2 to 0.25 mg/kg) group had any events (infectious people) at day 3‐4 (<a href="./references#CD008152-fig-0005" title="">Analysis 1.1</a>). The proportion of people infectious to mosquitoes was reduced by 88% (95% CI 12% to 98%, 105 participants). In the moderate dose group, again only one trial had any events. The proportion of people infectious was reduced by 87% (95% CI 6% to 98%, 129 participants). At the high dose of 0.75 mg/kg (one trial), the reduction in one trial was 80% but the 95% CI was very wide and overlapped 100% (2% to 168%, 51 participants). </p> </section> <section id="CD008152-sec-0097"> <h5 class="title">Infections acquired by mosquitoes</h5> <p>Results were also expressed as the proportion of mosquitoes infected. At baseline, before treatment with the low dose, the groups were not well matched in one trial (<a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>), with 29% more mosquitoes infected in the PQ group (<a href="#CD008152-tbl-0007">Table 2</a>). With the low dose and the moderate dose, on day 3 or 4, there was a slight decrease in the proportion of mosquitoes infected (<a href="#CD008152-tbl-0008">Table 3</a>) with data available for only one trial out of three in each of the low‐ and moderate‐dose groups. In the 0.75 mg/kg dose group, the one trial showed a slight increase in percentage of mosquitoes infected in the group without PQ. </p> <div class="table" id="CD008152-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Infectivity to mosquitoes baseline</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>With PQ</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Without PQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Absolute difference (reduction or increase) in % of mosquitoes infected in PQ group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Average number of mosquitoes dissected per participant (both arms combined)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number<br/> of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of infectious<br/> people</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average % of mosquitoes infected</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of<br/> participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of infectious<br/> people</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average %<br/> of mosquitoes<br/> infected</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+28.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−10.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+4.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−5.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: PQ: primaquine.</p> </div> </div> <div class="table" id="CD008152-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Infectivity to mosquitoes day 3‐4</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>With PQ</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Without PQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Absolute difference (reduction or increase) in % of mosquitoes infected in PQ group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Average number of mosquitoes<br/> dissected per participant<br/> (both arms combined)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number<br/> of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of infectious<br/> people</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average % of<br/> mosquitoes infected</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of<br/> participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of infectious<br/> people</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average %<br/> of mosquitoes<br/> infected</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−7.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−7.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: PQ: primaquine.</p> </div> </div> </section> <section id="CD008152-sec-0098"> <h5 class="title">Gametocyte prevalence by PCR</h5> <p>At day 3 or 4 after treatment, there was no effect at any dose on the proportion of persons with gametocytes detected by PCR (<a href="./references#CD008152-fig-0006" title="">Analysis 1.2</a>). The risk ratios (RRs) (fixed effect) were 1.02 (95% CI 0.87 to 1.21; 3 trials, 414 participants) for low dose; 1.09 (95% CI 0.93 to 1.28; 3 trials, 418 participants) for moderate dose, and 0.92 (95% CI 0.75 to 1.13; 3 trials, 394 participants) for high dose. </p> </section> <section id="CD008152-sec-0099"> <h5 class="title">Gametocyte prevalence by microscopy</h5> <p>At day 3 or 4 after treatment, there was no reduction in proportion of persons with gametocytes detected by microscopy for the low and moderate doses (<a href="./references#CD008152-fig-0007" title="">Analysis 1.3</a>). The RRs were 0.73 (95% CI 0.21 to 2.50; 3 trials, 490 participants) for low dose, and 0.86 (95% CI 0.33 to 2.25; 2 trials, 225 participants) for moderate dose. Due to heterogeneity, a random effects RR was estimated. At the high dose, reduction of 58% was observed (RR 0.42, 95% CI 0.20 to 0.85; 3 trials, 248 participants). </p> </section> </section> <section id="CD008152-sec-0100"> <h4 class="title">Follow‐up at day 8</h4> <section id="CD008152-sec-0101"> <h5 class="title">Infectiousness of people to mosquitoes</h5> <p>Four trials assessed proportion of participants infectious on day 8 after first treatment on day 1. Results were stratified by dose. Three trials out of four using a low dose had events (infectious people) at day 8 (<a href="./references#CD008152-fig-0008" title="">Analysis 1.4</a>). The proportion of people infectious to mosquitoes was not significantly reduced at this time point (RR 0.34, 95% CI 0.07 to 1.58; 4 trials, 243 participants). In the moderate dose group, three of the four trials had any events. The reduction in proportion of people infectious was similar to the low dose group (RR 0.33, 0.07 to 1.57; 4 trials, 246 participants). At the high 0.75 mg/kg dose there were two trials, both with infectious events in the non‐PQ group (RR 0.18, 95% CI 0.02 to 1.41; 2 trials, 181 participants). Thus the reduction in infectiousness was large but the 95% CI was very wide and overlapped one. </p> </section> <section id="CD008152-sec-0102"> <h5 class="title">Infections acquired by mosquitoes</h5> <p>With the low and moderate dose, data on the proportion of mosquitoes infected were available for three out of four trials in each dose group (<a href="#CD008152-tbl-0009">Table 4</a>). One trial of the four in the low dose group had 29% more mosquitoes infected in the PQ than the non‐PQ group (arising from one infectious individual). Otherwise, there was very little difference between PQ and no‐PQ groups in the proportion of mosquitoes infected at day 8 in either the moderate dose group (four trials) or the high dose group (two trials). </p> <div class="table" id="CD008152-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Infectivity to mosquitoes day 8</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>With PQ</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Without PQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Absolute difference (reduction or increase) in % of mosquitoes infected in PQ group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Average number of mosquitoes dissected per participant (both arms combined)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of<br/> participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of infectious<br/> people</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average %<br/> of mosquitoes<br/> infected</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of<br/> participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of infectious people</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average %<br/> of mosquitoes<br/> infected</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>¹ </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+27.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−6.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>¹ </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>¹<a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a> reported the median number of mosquitoes per person. </p> <p>Abbreviations: PQ: primaquine.</p> </div> </div> </section> <section id="CD008152-sec-0103"> <h5 class="title">Gametocyte prevalence by PCR</h5> <p>At day 8 after first treatment, reductions were observed in the proportion of persons with gametocytes detected by PCR (<a href="./references#CD008152-fig-0009" title="">Analysis 1.5</a>). The RRs (fixed effects) were 0.52 (95% CI 0.41 to 0.65; 4 trials, 532 participants) for low dose; 0.37 (95% CI 0.28 to 0.48; 4 trials, 758 participants) for moderate dose, and 0.31 (0.23 to 0.43; 5 trials, 793 participants) for high dose. </p> </section> <section id="CD008152-sec-0104"> <h5 class="title">Gametocyte prevalence by microscopy</h5> <p>At day 8 after treatment, there was also a reduction in the proportion of people with gametocytes detected by microscopy for all dose groups (<a href="./references#CD008152-fig-0010" title="">Analysis 1.6</a>). The RRs (fixed effects) were 0.35 (95% CI 0.16 to 0.78; 3 trials, 491 participants) for low dose; 0.25 (95% CI 0.08 to 0.75; 2 trials, 225 participants for moderate dose, and 0.27 (95% CI 0.19 to 0.37; 6 trials (10 arms), 1433 participants) for high dose. There was moderate heterogeneity at the high dose, but not at low and moderate doses. </p> </section> </section> <section id="CD008152-sec-0105"> <h4 class="title">Additional summary measures of gametocyte persistence</h4> <section id="CD008152-sec-0106"> <h5 class="title">Gametocyte clearance time or duration of gametocyte carriage (the length of time each person has gametocytes) </h5> <p>Seven trial authors presented gametocyte clearance time (the number of hours or days until gametocytes disappear, sometimes described as "duration of gametocyte carriage"). <a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a> makes a distinction between these two parameters, with gametocyte carriage adjusting for intermittent periods of time without gametocytes. </p> <p>Using microscopy, at low dose, <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a> reported that duration of gametocyte carriage was reduced from average of 1.08 days in the ACT only group to 0.29 days in the ACT plus PQ group. In <a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a> (high dose), median time to clearance was reduced from 12 days in non PQ group to 1 day in the PQ group. </p> <p>At low and moderate doses, <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> showed that mean gametocyte clearance time (by PCR) was reduced on average by 12 days (95% CI −12.83 to −11.17) in the low dose group and by 11.5 days (−12.33 to ‐10.67) in the moderate dose group (<a href="./references#CD008152-fig-0011" title="">Analysis 1.7</a>). </p> <p>In <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>, also by PCR, the gametocyte clearance time was not significantly longer in the 0.4 mg/kg group (6.3 days, 95% CI 5.1 to 7.5) than the 0.75 mg/kg group (6.6 days, 95% CI 5.3 to 7.8). However the 0.75 mg/kg group had significantly shorter gametocyte clearance time than the placebo group (12.4 days, 95% CI 9.9 to 15.0). </p> <p>Two other trials reported results for the 0.75 mg/kg dose. Gametocyte clearance time in days was presented in <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a> and was significantly shorter (by PCR) in the PQ group (6.3 days, 95% CI 4.7 to 8.5) than in the non‐PQ group (28.6 days, 95% CI 17.0 to 48.0, P &lt; 0.001). <a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a>, using microscopy, also reported significantly shorter gametocyte clearance time in the PQ groups, reported as person‐gametocytaemia‐weeks standardized per 1000 person‐weeks of follow‐up. This was 5.5 weeks in the ACT+PQ groups versus 65.5 weeks in the non‐PQ groups (RR 11.9, 95% CI 7.4 to 20.5, P &lt; 0.001) and the difference was very large for each individual malaria treatment regimen (five different ACTs or formulations were tested). Although the duration of gametocyte carriage (without PQ) was significantly longer for AS+AQ, AL and DHAP than for AS+MQ, there was no difference in length of gametocyte carriage between the ACT groups when PQ was added (<a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a>). </p> <p><a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a> reported reduction in median gametocyte clearance time from 138 (range 12 to 264) hours with artesunate alone to 73 (range 6 to 145) hours with artesunate and 7 days of PQ (0.5 mg/kg). </p> </section> <section id="CD008152-sec-0107"> <h5 class="title">Gametocyte circulation time</h5> <p>Another outcome related to gametocytes estimated by PCR in <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a> and <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a> was the mean life (circulation time) of gametocytes (this is reported per gametocyte rather than per person as for gametocyte clearance time above). In <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a> the circulation time per gametocyte was significantly longer in the placebo group (1.97 days, 95% CI 1.64 to 2.31). than in the other two groups (0.95 and 0.98 days in the 0.4 and 0.75 mg/kg groups respectively). In <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a>, the mean gametocyte circulation time was reduced from 4.6 days (95% CI 2.9 to 7.3) after AS+SP alone to 0.5 days (95% CI 0.2 to 1.2) after AS+SP plus 0.75 mg/kg PQ (P &lt; 0.001). </p> </section> <section id="CD008152-sec-0108"> <h5 class="title">Area under curve of gametocyte density over time</h5> <p>Area under curve combines measures of density over time. Trials varied in the follow‐up time completed. Using microscopy, <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a> observed reduction of AUC (follow‐up to day 29) from 106.7 in the ACT+PQ group to 29.5 in the ACT only group. </p> <p>Gametocyte density by PCR over time was reported in four trials. For low and moderate dose, <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> reported a reduction of the mean AUC (up to day 15) of −9.20 (−10.79 to −7.61) for low dose and −9.10 (−10.50 to −7.70) for moderate dose (<a href="./references#CD008152-fig-0012" title="">Analysis 1.8</a>). <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a> also used a duration of 15 days to estimate AUC using PCR and found that the log(10)AUC in each intervention group was not significantly different from placebo. It was 3.8 (95% CI 1.7 to 8.2) gametocytes per μL per day in the placebo group, 2.1 (1.0 to 4.5) in the 0.4 mg/kg group, and 2.0 (0.9 to 4.3) in the 0.75 mg/kg group. </p> <p>Using PCR‐detected gametocyte density estimates, <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a> provided geometric mean and interquartile range (IQR) values on days 1, 4, 8, 15, 29, and 43. Mean density was consistently lower in the 0.75 mg/kg PQ than the non‐PQ group, for days when gametocytes were detected (with PQ: 5.8, IQR 0.8 to 55.1; without PQ: 15.8, IQR 4.1 to 85.8). <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a> also presented a statistical comparison of AUC of gametocyte density (by PCR) over a 43‐day period, with a 95% CI derived from generalized estimation equations. There was a significant reduction in AUC in the 0.75 mg/kg PQ groups over 43 days after treatment, reported as mean of 1.5 (IQR 0.3 to 8.8) in the PQ group versus 11.1 (IQR 2.2 to 53.8) in the non‐PQ group (P &lt; 0.001). </p> </section> </section> <section id="CD008152-sec-0109"> <h4 class="title">Haemolytic adverse effects</h4> <section id="CD008152-sec-0110"> <h5 class="title">Severe haemolysis</h5> <p>At the low dose, four trials evaluated severe haemolysis defined as drop of ≥ 25% (<a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>), or ≥ 2 g in haemoglobin (<a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>; <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>) over the course of follow‐up; only three of these trials had such events (<a href="./references#CD008152-fig-0013" title="">Analysis 1.9</a>). The results given for <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> included combined data from <a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> as they were not reported separately. <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> and <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> excluded G6PD deficient individuals identified by fluorescent spot test (FST) or the rapid test; <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a> and <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a> screened participants but did not exclude those with G6PD deficiency. Severe haemolysis as defined above was no different in frequency between the PQ group (12.3% of 381 participants) than the control group (13.2% of 371 participants). </p> <p><a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a> (low dose) also reported an outcome of "acute haemolytic anaemia", experienced by 2.8% of participants in both PQ and control groups (109 participants and 108 participants respectively). </p> <p>Severe haemolysis was reported for the moderate dose for two trials (<a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>), of which only the latter had any events (<a href="./references#CD008152-fig-0013" title="">Analysis 1.9</a>) . No difference was observed in the proportion of participants with this outcome between the PQ group (3.7% of 136 participants) and the control group (2.4% of 124 participants). </p> <p>At high dose, <a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a> stated that there were no cases of severe anaemia (&lt; 5 g/dL) or blackwater fever in any ACT or control group. <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a> stated that eight of 52 children in the PQ group had a 20% reduction in haemoglobin by day 8, compared to 0 of 53 children in the control group. However, <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a> also stated that no child developed clinical symptoms related to anaemia or a haemoglobin below 5 g/dL. </p> </section> <section id="CD008152-sec-0111"> <h5 class="title">Other measures of anaemia or haemoglobin</h5> <section id="CD008152-sec-0112"> <h6 class="title">Measures of haemoglobin or PCV at day 8</h6> <p>No trials at low or moderate dose reported these outcomes. At high dose <a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a> and <a href="./references#CD008152-bbs2-0022" title="SutantoI , SuprijantoS , KosasihA , DahlanMS , SyafruddinD , KusriastutiR , et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin‐piperaquine in South Sumatra, Western Indonesia: an open‐label, randomized, controlled trial. Clinical Infectious Diseases2013;56(5):685–93. ">Sutanto 2013</a> found no difference between groups in mean haemoglobin at day 8. Also using high dose, <a href="./references#CD008152-bbs2-0005" title="El‐SayedB , El‐ZakiSE , BabikerH , GadallaN , AgeepT , MansourF , et al. A randomized open‐label trial of artesunate‐sulfadoxine‐pyrimethamine with or without primaquine for elimination of sub‐microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One2007;2(12):e1311. ">El‐Sayed 2007</a> showed that there was no difference in PCV between groups at day 8: 34.2% (15% to 44%) versus 36.2% (26% to 42%). </p> </section> <section id="CD008152-sec-0113"> <h6 class="title">Maximum change in haemoglobin concentration</h6> <p>The maximum change in haemoglobin concentration (over all days of follow‐up) was measured in three trials, two of which reported results separately by G6PD status (<a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>; <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>), while the other did not (<a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>). In general, change in haemoglobin was less in the control than PQ groups (<a href="./references#CD008152-fig-0014" title="">Analysis 1.10</a>), but results were heterogenous especially at the low dose where the mean difference was 0.13 (−0.07 to 0.33) g of haemoglobin (random‐effects model). The change in haemoglobin by day 8 (rather than any day) was reported in <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a> and is included in <a href="./references#CD008152-fig-0014" title="">Analysis 1.10</a>. In the moderate and high dose groups, the mean difference was 0.18 (−0.08 to 0.44) and 0.05 (−0.04 to 0.14), respectively. </p> </section> <section id="CD008152-sec-0114"> <h6 class="title">Percentage change in haemoglobin by day 8</h6> <p>Using percentage change by day 8 (rather than absolute haemoglobin concentration at that time), the low, moderate, and high dose PQ groups were not different from the control groups (<a href="./references#CD008152-fig-0015" title="">Analysis 1.11</a>), but heterogeneity was high, especially at low dose. Some trials reported this outcome separately by G6PD status, and if so, the results were presented separately (see footnotes). </p> </section> <section id="CD008152-sec-0115"> <h6 class="title">Maximum percent change in haemoglobin</h6> <p>The maximum percent decrease in haemoglobin (by any day of follow‐up) was also reported in three trials, one in each dose category (<a href="./references#CD008152-fig-0016" title="">Analysis 1.12</a>). In low and moderate dose, the maximum percent decrease was larger in the PQ group than control, but the opposite was seen for high dose. </p> </section> <section id="CD008152-sec-0116"> <h6 class="title">Haemoglobinuria or dark urine</h6> <p>The presence of haemoglobinuria/dark urine was reported by <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> (low and moderate dose, but with no events in the latter), <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a> (low dose), and <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a> (low dose) and is shown in <a href="./references#CD008152-fig-0017" title="">Analysis 1.13</a>. These adverse effects were more than three times more likely in the PQ group (RR 3.40, 95% CI 2.15 to 5.38; 3 trials (4 arms), 527 participants) than the control group. </p> </section> </section> </section> <section id="CD008152-sec-0117"> <h4 class="title">Other adverse effects</h4> <p>These outcomes were not classified by dose. Frequencies of headache, fatigue, nausea, vomiting, abdominal pain, diarrhoea, pruritis, paraesthesia, fever, cough, runny nose, muscle ache/pain, dizziness, upper respiratory infections, back pain, burning or pain with urination, bronchitis, rhinitis/rhino bronchitis, shortness of breath, whitlow, leg osteoarthritis, malaria, otitis, epistaxis, dental pain, high transaminase, palpebral inflammation, foot trauma or inflammation, skin infection or rash, pallor, pneumonia, meningitis, blurred vision, cold sore, weakness/asthenia, palpitations, cyanosis, insomnia, or unspecified other event were not increased in the PQ groups (<a href="./references#CD008152-fig-0018" title="">Analysis 1.14</a>; <a href="./references#CD008152-fig-0019" title="">Analysis 1.15</a>; <a href="./references#CD008152-fig-0020" title="">Analysis 1.16</a>; <a href="./references#CD008152-fig-0021" title="">Analysis 1.17</a>; <a href="./references#CD008152-fig-0022" title="">Analysis 1.18</a>) as reported in <a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a>; <a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a>; <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>; <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>; <a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>; and <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>, with one to 11 trial arms per event type reported. Small differences in frequencies between PQ and control groups are noted for anorexia (increased in PQ group) and wound/trauma (decreased in PQ group). </p> </section> <section id="CD008152-sec-0118"> <h4 class="title">2. Comparison of low and moderate doses (artemisinin partner only)</h4> <p>Given the importance of confirming effectiveness of the low dose, and that fact that four trials included groups randomized to low and moderate doses, we compared these two doses directly. </p> </section> <section id="CD008152-sec-0119"> <h4 class="title">Follow‐up at day 3 or 4</h4> <section id="CD008152-sec-0120"> <h5 class="title">Infectiousness of people to mosquitoes</h5> <p>Only one of three trials had any infectious events: one infectious person in each of the PQ and non‐PQ groups, total 116 participants (<a href="./references#CD008152-fig-0023" title="">Analysis 2.1</a>). The RR was 0.93 (95% CI 0.06 to 13.54; 3 trials, 116 participants). </p> </section> <section id="CD008152-sec-0121"> <h5 class="title">Gametocyte prevalence by PCR</h5> <p>Comparing the low and moderate groups, there was no difference in the proportion of participants with gametocytes by PCR (RR 0.93, 95% CI 0.80 to 1.09; 3 trials, 424 participants (<a href="./references#CD008152-fig-0024" title="">Analysis 2.2</a>). </p> </section> <section id="CD008152-sec-0122"> <h5 class="title">Gametocyte prevalence by microscopy</h5> <p>In two trials (both in same location) that reported this outcome, there was also no difference in the proportion of participants with gametocytes detected by microscopy (RR 1.23, 95% CI 0.68 to 2.20; 2 trials, 231 participants; <a href="./references#CD008152-fig-0025" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD008152-sec-0123"> <h4 class="title">Follow‐up at day 8</h4> <section id="CD008152-sec-0124"> <h5 class="title">Infectiousness of people to mosquitoes</h5> <p>In four trials, two of which had infectious events, there was no evidence of any difference in effect on proportion of participants infectious between low and moderate doses (RR 0.95, 95% CI 0.14 to 6.48; 4 trials, 237 participants; <a href="./references#CD008152-fig-0026" title="">Analysis 2.4</a>). </p> </section> <section id="CD008152-sec-0125"> <h5 class="title">Gametocyte prevalence by PCR</h5> <p>There were four trials reporting gametocyte prevalence by PCR at day 8. The evidence suggested the effect tended to be greater at moderate than low dose (RR 1.33, 95% CI 0.97 to 1.82; 4 trials, 559 participants; <a href="./references#CD008152-fig-0027" title="">Analysis 2.5</a>). </p> </section> <section id="CD008152-sec-0126"> <h5 class="title">Gametocyte prevalence by microscopy</h5> <p>Two trials, both in the same site, showed the same trend as for PCR but no greater effect of moderate dose at day 8 (RR 1.80, 95% CI 0.51 to 6.38; 2 trials, 235 participants; <a href="./references#CD008152-fig-0028" title="">Analysis 2.6</a>). </p> </section> </section> <section id="CD008152-sec-0127"> <h4 class="title">3. PQ as part of non‐artemisinin‐based treatment regimens</h4> <p>Eleven trials contributed comparisons to this analysis, of which one trial tested both low dose and moderate dose PQ regimens over seven days (<a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a>), and one trial (two comparisons) tested moderate dose PQ (<a href="./references#CD008152-bbs2-0013" title="KolaczinskiK , LeslieT , AliI , DurraniN , LeeS , BarendsM , et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One2012;7(1):e28957. ">Kolaczinski 2012</a>). The remainder were high dose. </p> <p>We could not use data from one trial with non‐artemisinin partner CQ because it did not distinguish between patients with <i>P. falciparum</i> and <i>P. vivax</i> and their respective treatments (<a href="./references#CD008152-bbs2-0012" title="KhooKK . The treatment of malaria in glucose‐6‐phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology1981;75(6):591‐5. ">Khoo 1981</a>). There was a much higher risk of adverse haemolytic events in those who received PQ in the <a href="./references#CD008152-bbs2-0012" title="KhooKK . The treatment of malaria in glucose‐6‐phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology1981;75(6):591‐5. ">Khoo 1981</a> trial (OR 22.27 for both haemolysis and need for blood transfusion), but we could not include the results because the groups combined participants receiving a short course (three days) of PQ with those receiving a 14‐day regimen. The most unusual aspect of the trial, however, is that it included only individuals with G6PD deficiency. </p> </section> <section id="CD008152-sec-0128"> <h4 class="title">Follow‐up at day 5</h4> <section id="CD008152-sec-0129"> <h5 class="title">Infectiousness of people to mosquitoes</h5> <p>No trials tested the low or moderate dose for effect on infectiousness with non‐artemisinin partners. </p> <p>Using high dose, two small trials in China (<a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a>; <a href="./references#CD008152-bbs2-0003" title="ChenPQ , LiGQ , GuoXB . The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin [Chinese]. Zhonghua Yi Xue Za Zhi1994;74(4):209‐10, 253‐4. ChenPQ , LiGQ , GuoXB , HeKR , FuYX , FuLC , et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal1994;107(9):709‐11. ">Chen 1994</a>), with only six and nine participants per group, respectively, directly tested the impact of PQ added to MQ on infectiousness to mosquitoes. The proportion of people infectious was reduced to 0% in the PQ group when measured on day 5, compared to 66.7% in the control group (RR 0.09 (95% CI 0.01 to 0.62; 2 trials, 30 participants; <a href="./references#CD008152-fig-0029" title="">Analysis 3.1</a>). </p> </section> <section id="CD008152-sec-0130"> <h5 class="title">Infections acquired by mosquitoes</h5> <p><a href="./references#CD008152-bbs2-0003" title="ChenPQ , LiGQ , GuoXB . The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin [Chinese]. Zhonghua Yi Xue Za Zhi1994;74(4):209‐10, 253‐4. ChenPQ , LiGQ , GuoXB , HeKR , FuYX , FuLC , et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal1994;107(9):709‐11. ">Chen 1994</a> reported the number of mosquitoes infected after feeding on trial participants. None of the mosquitoes feeding on people receiving PQ were infected, with over 64% infected at day 5 after feeding on the group not receiving PQ, </p> </section> <section id="CD008152-sec-0131"> <h5 class="title">Gametocyte prevalence by PCR</h5> <p>No trials with non‐artemisinin partners assessed gametocyte prevalence by PCR.</p> </section> <section id="CD008152-sec-0132"> <h5 class="title">Gametocyte prevalence by microscopy</h5> <p>Two trials each at the moderate and high doses showed no difference in the gametocyte prevalence at day 4‐5 (<a href="./references#CD008152-fig-0030" title="">Analysis 3.2</a>); RR 0.83 (95% CI 0.62 to 0.13; one trial (two arms), 221 participants) for moderate dose and RR 0.85 (95% CI 0.48 to 1.50; 2 trials, 52 participants) for the high dose. </p> </section> </section> <section id="CD008152-sec-0133"> <h4 class="title">Follow‐up at day 8</h4> <section id="CD008152-sec-0134"> <h5 class="title">Infectiousness of people to mosquitoes</h5> <p>The two Chinese trials with MQ partner using high dose showed a similar effect at day 8 as at day 5 above: the proportion of infectious people was 93% in control group and 0% in the PQ group. (<a href="./references#CD008152-fig-0031" title="">Analysis 3.3</a>). RR 0.07 (95% CI 0.01 to 0.45; 2 trials, 30 participants). </p> </section> <section id="CD008152-sec-0135"> <h5 class="title">Infections acquired by mosquitoes</h5> <p><a href="./references#CD008152-bbs2-0003" title="ChenPQ , LiGQ , GuoXB . The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin [Chinese]. Zhonghua Yi Xue Za Zhi1994;74(4):209‐10, 253‐4. ChenPQ , LiGQ , GuoXB , HeKR , FuYX , FuLC , et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal1994;107(9):709‐11. ">Chen 1994</a> reported the number of mosquitoes infected after feeding on trial participants. None of the mosquitoes feeding on people receiving PQ were infected, with 54% infected at day 8 after feeding on the group not receiving PQ. </p> </section> <section id="CD008152-sec-0136"> <h5 class="title">Gametocyte prevalence by PCR</h5> <p>No trials with non‐artemisinin partners assessed gametocyte prevalence by PCR.</p> </section> <section id="CD008152-sec-0137"> <h5 class="title">Gametocyte prevalence by microscopy</h5> <p>At day 8 one trial (two arms) reported gametocyte prevalence at moderate dose (reduction of 40%); RR 0.60 (95% CI 0.49 to 0.75; 216 participants) and four trials (five arms) at the high dose (reduction of 61%) (RR 0.39, 95% CI 0.25 to 0.62; 4 trials, 186 participants; <a href="./references#CD008152-fig-0032" title="">Analysis 3.4</a>). </p> </section> </section> <section id="CD008152-sec-0138"> <h4 class="title">Additional summary measures of gametocyte persistence</h4> <section id="CD008152-sec-0139"> <h5 class="title">Gametocyte clearance time or duration of gametocyte carriage (the average number of days each person has gametocytes) </h5> <p>The median gametocyte clearance time was reduced in <a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a> (two comparisons; partner QN) from 48 (range: six to 324) hours with low dose PQ, and from 216 (range: six to 624) hours with quinine only to 87 (range: five to 207 hours) hours with moderate dose PQ. There was no difference between the median clearance time in the two PQ arms (P = 0.45). </p> <p>Using high dose, gametocyte clearance time (in days) was significantly reduced in the PQ group in <a href="./references#CD008152-bbs2-0020" title="SinghasivanonV , ChongsuphajaisiddhiT , SabchareonA , AttanathP , WebsterHK , EdsteinMD , et al. Pharmacokinetic study of mefloquine in Thai children aged 5‐12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. European Journal of Drug Metabolism and Pharmacokinetics1994;19(1):27‐32. ">Singhasivanon 1994</a> (which had MQ+SP partner) with a mean difference of −14.90 days (95% CI −18.18 to −11.62; <a href="./references#CD008152-fig-0033" title="">Analysis 3.5</a>). </p> </section> </section> <section id="CD008152-sec-0140"> <h4 class="title">Adverse events</h4> <p>The trials with non‐artemisinin partner regimens did not report adverse effects well or consistently. None of these trials reported on haemolysis, other haematological measures, or severe adverse events. </p> <p><a href="./references#CD008152-bbs2-0020" title="SinghasivanonV , ChongsuphajaisiddhiT , SabchareonA , AttanathP , WebsterHK , EdsteinMD , et al. Pharmacokinetic study of mefloquine in Thai children aged 5‐12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. European Journal of Drug Metabolism and Pharmacokinetics1994;19(1):27‐32. ">Singhasivanon 1994</a> using high dose found no difference in frequency of reported adverse effects (nausea, vomiting or dizziness) over 28 days follow‐up (<a href="./references#CD008152-fig-0034" title="">Analysis 3.6</a>). </p> </section> <section id="CD008152-sec-0141"> <h4 class="title">4. Comparison of different 8AQ</h4> </section> <section id="CD008152-sec-0142"> <h4 class="title">Follow‐up at day 8</h4> <p>Two small trials compared the effect of bulaquine and PQ (0.75 mg/kg) on gametocyte prevalence at day 8 (<a href="./references#CD008152-bbs2-0007" title="GogtayNJ , KamtekarKD , DalviSS , ChogleAR , AigalU , KshirsagarN . Preliminary report of the evaluation of the gametocytocidal action of bulaquine, in adult patients with acute, Plasmodium falciparum malaria. Annals of Tropical Medicine and Parasitology2004;98(5):525‐8. ">Gogtay 2004</a>; <a href="./references#CD008152-bbs2-0008" title="GogtayNJ , KamtekarKD , DalviSS , MehtaSS , ChogleAR , AigalU , et al. A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide‐responsive uncomplicated falciparum malaria [ISCRTN50134587]. BMC Infectious Diseases2006;6:16. ">Gogtay 2006</a>). Both trials suggested a greater reduction of gametocytes by bulaquine (RR 0.41, 95% CI 0.26 to 0.66; 2 trials, 112 participants; <a href="./references#CD008152-fig-0035" title="">Analysis 4.1</a>). Neither trial concealed allocation. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008152-sec-0143" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008152-sec-0143"></div> <section id="CD008152-sec-0144"> <h3 class="title" id="CD008152-sec-0144">Summary of main results</h3> <p>We included 24 RCTs and one quasi‐RCT. Sixteen trials included study arms with artemisinin‐based treatments, 11 trials included study arms with non‐artemisinin‐based treatments, and two trials included both types of partner arms. Fifteen trials tested for G6PD status: ten then excluded participants with G6PD deficiency, one included only those with G6PD deficiency, and four included all irrespective of status. The remaining 10 trials either did not report on whether they tested (eight trials), or reported that they did not test (two trials). No trials evaluated community effects on malaria transmission. </p> <section id="CD008152-sec-0145"> <h4 class="title">With artemisinin combination treatment</h4> <p>See <a href="./full#CD008152-tbl-0001">summary of findings Table for the main comparison</a>, <a href="./full#CD008152-tbl-0002">summary of findings Table 2</a> and <a href="./full#CD008152-tbl-0003">summary of findings Table 3</a> for low, moderate, and high dose with artemisinin partner drugs, respectively. </p> <section id="CD008152-sec-0146"> <h5 class="title">Low‐dose PQ</h5> <p>Infectiousness to mosquitoes was reduced (<i>Iow certainty evidence</i> ). For gametocytes detected by PCR, there was little or no effect of PQ at day 3 or 4 (<i>moderate certainty evidence</i> ) with clear reduction at day 8 (<i>high certainty evidence</i> ). Low‐dose PQ probably has little or no effect on severe haemolysis (<i>moderate certainty evidence</i>). </p> </section> <section id="CD008152-sec-0147"> <h5 class="title">Moderate‐dose PQ</h5> <p>Infectiousness to mosquitoes was reduced (<i>low certainty evidence</i> ). The pattern and level of certainty of evidence with gametocytes detected by PCR was the same as low dose (moderate and high at days 3 or 4 and 8 respectively, and severe haemolysis was infrequent in both groups (<i>low certainty evidence</i>). </p> </section> <section id="CD008152-sec-0148"> <h5 class="title">High dose PQ</h5> <p>Infectiousness to mosquitoes was reduced (<i>low certainty evidence</i>). The effects on gametocyte prevalence showed a similar pattern to moderate and low dose PQ (low and high certainty at days 3 or 4 and 8 respectively). Evidence of haemolysis was not systematically sought in this dose group. </p> </section> <section id="CD008152-sec-0149"> <h5 class="title">With non‐artemisinin treatment</h5> <p>See <a href="./full#CD008152-tbl-0004">summary of findings Table 4</a> and <a href="./full#CD008152-tbl-0005">summary of findings Table 5</a> for moderate and high dose with non‐artemisinin partner drugs respectively. </p> <p>Trials have been conducted only in the moderate‐ and high‐dose PQ categories. Two small trials from the same laboratory in China evaluated infectiousness to mosquitoes with high dose PQ, reporting that infectiousness was reduced markedly on day 5 and on day 8 (<i>very low certainty evidence</i>). </p> <p>Reduction in gametocytes, detected in this case by microscopy, showed similar patterns to the artemisinin‐based treatments. For moderate dose, there was little or no effect at day 4 or 5 (<i>moderate certainty evidence</i> ), and larger effect by day 8 (<i>moderate certainty evidence</i>). At high dose, findings were similar but certainly of evidence was low at day 4 to 5. No trials with non‐artemisinin partners systematically sought evidence of severe haemolysis. </p> <p>Two small trials comparing bulaquine with PQ suggest bulaquine may have larger effects on gametocytes (by microscopy) on day 8. </p> </section> </section> </section> <section id="CD008152-sec-0150"> <h3 class="title" id="CD008152-sec-0150">Overall completeness and applicability of evidence</h3> <section id="CD008152-sec-0151"> <h4 class="title">What is known</h4> <p>This review update adds recently available evidence on infectiousness of people with falciparum malaria treated with low and moderate PQ doses in addition to primary treatment. It also includes additional evidence on the effect of PQ at different doses on gametocyte prevalence at two time points after treatment. Previously only indirect evidence was available (for example, <a href="./references#CD008152-bbs2-0030" title="BunnagD , HarinasutaT , PinichpongseS , SuntharasamaiP . Effect of primaquine on gametocytes of Plasmodium falciparum in Thailand. Lancet1980;2(8185):91. ">Bunnag 1980</a>, with no difference in gametocyte outcomes between 15 mg PQ for five days in children, and single doses of 30 mg or 45 mg PQ in adults), in narrative summaries and analyses that have proposed widespread programmatic implementation of PQ (<a href="./references#CD008152-bbs2-0133" title="WhiteNJ , QiaoLG , QiG , LuzzattoL . Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malaria Journal2012;11:418. ">White 2012</a>; <a href="./references#CD008152-bbs2-0134" title="WhiteNJ . Primaquine to prevent transmission of falciparum malaria. Lancet. Infectious Diseases2013;13(2):175‐81. ">White 2013</a>). </p> <p>Adding PQ at around 0.25 mg/kg to treatment using artemisinin‐based combination therapies reduces infectiousness to mosquitoes at day 3 to 5 and at day 8 after treatment. These data come from four trials conducted in Burkina Faso (with AL partner) (<a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>) Gambia (DHAP) (<a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>), and Mali (DHAP) (<a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>). One other trial using high dose also reported on infectiousness in Cambodia with DHAP partner (<a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>). Two of these trials included only gametocyte carriers at screening (<a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>). Due to relatively low proportion of infectious individuals among treated malaria patients (even those with gametocytes), the absolute reduction in proportion of people infectious is not large. The absolute reduction in proportion of mosquitoes infected was also low. </p> <p>The effect on infectiousness was more marked at day 3 or 4 than day 8, which reflects the declining infectiousness in the non‐PQ control groups by this time. Unlike the pattern seen in reducing infectiousness, there was little reduction by PQ with artemisinin partners in gametocyte prevalence at day 3 or 4 with the low or moderate dose. By day 8, large effects of PQ on gametocyte prevalence were seen. Reductions in gametocyte clearance time were also dramatic. The results come from trials in different epidemiological settings and with a variety of artemisinin‐based treatments (Burkina Faso: AL (<a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>); Cambodia: DHAP (<a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a>); Colombia: AS+MQ (<a href="./references#CD008152-bbs2-0024" title="VásquezAM , SanínF , AlvarezLG , TobónA , RíosA , BlairS . Therapeutic efficacy of a regimen of artesunate‐mefloquine‐primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development [Estudio piloto de la eficacia y de los efectos sobre los gametocitos del esquema artesunato‐mefloquina‐primaquina para la malaria por Plasmodium falciparum]. Biomedica2009;29(2):307‐19. ">Vásquez 2009</a>; <a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a>); Gambia: DHAP (<a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>); Senegal: DHAP, AL, and ASAQ (<a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>); Indonesia: DHAP (<a href="./references#CD008152-bbs2-0022" title="SutantoI , SuprijantoS , KosasihA , DahlanMS , SyafruddinD , KusriastutiR , et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin‐piperaquine in South Sumatra, Western Indonesia: an open‐label, randomized, controlled trial. Clinical Infectious Diseases2013;56(5):685–93. ">Sutanto 2013</a>); Mali: DHAP (<a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>); Myanmar: AS+MQ, DHAP, AL and ASAQ (<a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a>); Sudan: AS+SP (<a href="./references#CD008152-bbs2-0005" title="El‐SayedB , El‐ZakiSE , BabikerH , GadallaN , AgeepT , MansourF , et al. A randomized open‐label trial of artesunate‐sulfadoxine‐pyrimethamine with or without primaquine for elimination of sub‐microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One2007;2(12):e1311. ">El‐Sayed 2007</a>); Tanzania: AS+SP (<a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a>); Thailand: AS (<a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a>); and Uganda: AL (<a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a>)). </p> <p>In terms of safety, adverse effects of PQ in people with G6PD deficiency are less common with lower doses of PQ (<a href="./references#CD008152-bbs2-0121" title="OlalekanU , GravesPM , SaundersR , GelbandH , RichardsonM , GarnerP . Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies. Malaria Journal2017;16:346. [DOI: 10.1186/s12936‐017‐1989‐3] ">Olalekan 2017</a>), although direct comparisons are few and sample sizes small. Most trials included in this review excluded individuals with G6PD deficiency, but some included them, did not test for it or did not state whether they tested; thus some trials included some G6PD deficient participants. However, few severe haematological effects were reported (<a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a>; <a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>; <a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a>; <a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a>; <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>). </p> </section> <section id="CD008152-sec-0152"> <h4 class="title">What is unknown</h4> <p>While reducing infectiousness to mosquitoes and the duration and density of gametocytaemia can be assumed to reduce transmission to mosquitoes at the level of the individual, it remains unclear whether it will impact materially on community level transmission, as reliable trials have never evaluated this. We excluded from this review several older trials, which are often cited as proof of an effect on community transmission, because either: i) they lacked an adequate control group with partner drug but without PQ (<a href="./references#CD008152-bbs2-0037" title="ClydeDF . Mass administration of an antimalarial drug containing 4‐aminoquinoline and 8‐aminoquinoline in Tanganyika. Bulletin of the World Health Organization1962;27:203‐12. ">Clyde 1962</a>); ii) they did not apply the interventions equally in intervention and control groups or had no ‘before' data (<a href="./references#CD008152-bbs2-0042" title="DoiH , KanekoA , PanjaitanW , IshiiA . Chemotherapeutic malaria control operation by single dose of Fansidar plus primaquine in North Sumatra, Indonesia. Southeast Asian Journal of Tropical Medicine and Public Health1989;20(3):341‐9. ">Doi 1989</a>; <a href="./references#CD008152-bbs2-0053" title="KanekoA , KameiK , SuzukiT , IshiiA , SiagianR , PanjaitanW . Gametocytocidal effect of primaquine in a chemotherapeutic malaria control trial in North Sumatra, Indonesia. Southeast Asian Journal of Tropical Medicine and Public Health1989;20(3):351‐9. ">Kaneko 1989</a>); iii) they administered PQ alongside vector control co‐interventions, which may equally be responsible for any effect seen (<a href="./references#CD008152-bbs2-0046" title="HiiJL , VunYS , ChinKF , ChuaR , TambakauS , BinisolES , et al. The influence of permethrin‐impregnated bednets and mass drug administration on the incidence of Plasmodium falciparum malaria in children in Sabah, Malaysia. Medical and Veterinary Entomology1987;1(4):397‐407. ">Hii 1987</a>; <a href="./references#CD008152-bbs2-0113" title="KanekoA , TaleoG , KalkoaM , YamarS , KobayakawaT , BjörkmanA . Malaria eradication on islands. Lancet2000;356(9241):1560‐4. ">Kaneko 2000</a>); or iv) they administered PQ or 8AQ alone and not alongside treatment regimens (which is the policy currently recommended) (<a href="./references#CD008152-bbs2-0028" title="BarberMA , RiceJB , BrownJY . Malaria studies on the Firestone Rubber Plantation in Liberia, West Africa. American Journal of Hygiene1932;15(3):601‐33. ">Barber 1932</a>). </p> <p>Many gametocyte carriers are asymptomatic and unlikely to seek treatment, at least in areas of moderate to high transmission where most adults have a level of acquired immunity that reduces the probability that parasitaemia will cause clinical symptoms. Therefore, since a minority of infected persons seek treatment, it is unclear whether a policy of adding PQ to malaria treatment regimens will reduce malaria transmission at a community level. <a href="./references#CD008152-bbs2-0112" title="JohnstonGL , GethingPW , HaySI , SmithDL , FidockDA . Modeling within‐host effects of drugs on Plasmodium falciparum transmission and prospects for malaria elimination. PLoS Computational Biology2014;10(1):e1003434. ">Johnston 2014</a> modelled the effect of treatment, and concluded that the most important factor predicting success is the percentage of infected individuals treated with an ACT, and that adding PQ is of negligible benefit. Johnston and colleagues estimated that "it would require switching 180 people from ACTs to ACTs plus PQ to achieve the same transmission reduction as switching a single individual from untreated to treated with ACTs". </p> <p>The relative contribution of symptomatic and asymptomatic gametocyte carriers to the infectious reservoir in the population, as well of the relative infectiousness of gametocytes detected by microscopy and PCR, are areas of active research (<a href="./references#CD008152-bbs2-0128" title="StoneW , GoncalvesBP , BousemaT , DrakeleyC . Assessing the infectious reservoir of falciparum malaria, past and future. Trends in Parasitology2015;31(7):287‐296. ">Stone 2015</a>). The proportion of asymptomatic carriers varies according to the level of transmission, with low density infections comprising a large proportion of infections in low transmission areas (<a href="./references#CD008152-bbs2-0103" title="GeraridinJ , OuedraogoAL , McCarthyKA , EckhoffPA , WengerJA . Characterization of the infectious reservoir of malaria with an agent‐based model calibrated to age stratified parasite densities and infectiousness. Malaria Journal2015;14:231. ">Gerardin 2015a</a>). If most infectious individuals are not among the care‐seeking population, they can only be reached by proactive strategies such as ‘mass screen and treat' or mass treatment programmes. </p> <p>Mass treatment programmes (where everyone in the community is treated at specified intervals until transmission is stopped) are a potential strategy to reach asymptomatic gametocyte carriers (<a href="./references#CD008152-bbs2-0130" title="vonSeidleinL , GreenwoodBM . Mass administrations of antimalarial drugs. Trends in Parasitology2003;19(10):452‐60. ">von Seidlein 2003</a>; <a href="./references#CD008152-bbs2-0105" title="Roll Back MalariaPartnership . Global Malaria Action Plan. Geneva: RBM/WHO, 2008. ">GMAP 2008</a>; <a href="./references#CD008152-bbs2-0118" title="MendisK , RietveldA , WarsameM , BosmanA , GreenwoodB , WernsdorferW . From malaria control to eradication: the WHO perspective. Tropical Medicine &amp; International Health2009;14(7):802‐9. ">Mendis 2009</a>; <a href="./references#CD008152-bbs2-0129" title="SturrockHJW , HsiangMS , CohenJM , SmithDL , GreenhouseB , BousemaT , et al. Targeting asymptomatic malaria infections: active surveillance in control and elimination. PLoS Medicine2013;10(6):e1001467. ">Sturrock 2013</a>). However, in theory, mass treatment consisting only of primary treatment (an ACT alone) could interrupt transmission, and the additional effects of adding PQ (interrupting transmission more quickly, or at a lower coverage levels) have not been demonstrated (<a href="./references#CD008152-bbs2-0124" title="PoirotE , SkarbinskiJ , SinclairD , KachurSP , SlutskerL , HwangJ . Mass drug administration for malaria. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD008846.pub2] ">Poirot 2013</a>). <a href="./references#CD008152-bbs2-0104" title="GerardinJ , EckhoffP , WengerEA . Mass campaigns with antimalarial drugs: a modeling comparison of artemether‐lumefantrine and DHA‐piperaquine with and without primaquine as tools for malaria control and elimination. BMC Infectious Diseases2015;15:144. ">Gerardin 2015b</a> modelled the impact of adding PQ to either AL or DHAP in mass treatment programs. and concluded that it would be most effective in combination with a long acting partner such as DHAP and where most of the population is protected against reinfection; otherwise, if transmission is high, the effect of adding PQ would be ‘negligible'. A similar conclusion was reached by the WHO Malaria Policy Advisory Committee (MPAC) through consensus modelling (<a href="./references#CD008152-bbs2-0141" title="World Health Organization MPAC. Background document for Session 3 of the Malaria Policy Advisory Committee Meeting MPAC meeting, Sept 2015: Consensus modelling evidence to support the design of mass drug administration programs. www.who.int/malaria/mpac/mpac‐sept2015‐consensus‐modelling‐mda.pdf (accessed 16 January 2018). ">WHO 2015c</a>). </p> <p>Infectiousness of a population to mosquitoes comprises two elements: the proportion of people who are infectious, and the proportion of mosquitoes infected after feeding on an infectious person. The two factors can be multiplied together to arrive at a combined ‘mosquito infection probability' (<a href="./references#CD008152-bbs2-0107" title="GravesPM , BurkotTR , SaulAJ , HayesRJ , CarterR . Estimation of anopheline survival rate, vectorial capacity and mosquito infection probability from malaria infection rates in villages near Madang, Papua New Guinea. Journal of Applied Ecology1990;27:134‐47. ">Graves 1990</a>; <a href="./references#CD008152-bbs2-0128" title="StoneW , GoncalvesBP , BousemaT , DrakeleyC . Assessing the infectious reservoir of falciparum malaria, past and future. Trends in Parasitology2015;31(7):287‐296. ">Stone 2015</a>), representing the likelihood of a mosquito acquiring infection after feeding on a member of the population. Considering only reduction in the proportion of infectious individuals may underestimate the impact of PQ, although evidence from the trials included here does not suggest large reduction in the proportion of mosquitoes infected by persons remaining infectious after treatment (<a href="#CD008152-tbl-0007">Table 2</a>; <a href="#CD008152-tbl-0008">Table 3</a>; <a href="#CD008152-tbl-0009">Table 4</a>). Larger sample sizes of infectious people are required. </p> <p>The relative effect of PQ on infectiousness when added to different artemisinin drugs is not well understood and needs to be empirically studied further, since it known that there is variation between them in gametocytocidal activity (<a href="./references#CD008152-bbs2-0143" title="WWARN . Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and metaanalysis of individual patient data. BMC Medicine2016;14:79. ">WWARN 2016</a>). Two studies included here compared multiple ACTs (AL, AS+MQ, ASAQ, and DHAP) (<a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a>; <a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a>), but no infectiousness data were included. </p> <p>The ability to metabolize PQ to active ingredients (dependent on human cytochrome P‐450 enzyme (CYP2D6)) may also affect its impact, since alleles conferring low and intermediate metabolizer phenotypes are unable to reap the benefits of PQ (<a href="./references#CD008152-bbs2-0090" title="BennettJW , PybusBS , YadavaA , ToshD , SousaJC , McCarthyWF , et al. Primaquine failure and cytochrome P‐450 2D6 in Plasmodium vivax malaria. New England Journal of Medcine2013;369(14):1381‐2. ">Bennett 2013</a>; <a href="./references#CD008152-bbs2-0117" title="MeltzerE , SchwartzE . Low‐dose primaquine for falciparum malaria. Lancet. Infectious Diseases2014;14(6):449. ">Meltzer 2014</a>). In this review, <a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a> reported on the CYP2D6 phenotypes of participants. Since this may be a factor in heterogeneity of effects observed, further study of geographical distribution of these variant phenotypes affecting ability to utilize PQ is needed to determine their impact on the effectiveness of PQ on gametocytes and for reducing transmission. </p> <p>The trials included in this review do not mention PQ resistance as a potential threat. PQ clearly should be used where it is of clinical importance, especially for <i>P. vivax</i> and <i>P. ovale</i> . Its effectiveness against those parasites could be compromised by resistance if used at low doses in populations where <i>P. falciparum</i> , <i>P. vivax</i> , and <i>P. ovale</i> coexist. As for all antimalarial drugs, there is a global responsibility to maintain the effectiveness of PQ for as long as possible without withholding it when needed. In this case, that translates into using it to reduce transmission only if there is reasonable evidence that it actually has that effect. Otherwise, it will be used to little or no effect but its value for radical cure may be diminished by the development of resistant <i>Plasmodium</i> parasites. </p> </section> </section> <section id="CD008152-sec-0153"> <h3 class="title" id="CD008152-sec-0153">Quality of the evidence</h3> <p>In our hierarchy of study types, the strongest, most direct evidence for an effect of PQ on falciparum malaria transmission would come from trials that randomize entire communities to treatment with and without PQ and then monitor malaria prevalence over a period of years. No such trials—at any dose or with any partner drug—met the inclusion criteria. The evidence is, therefore, all indirect, requiring some untested assumptions in evaluating an effect of single dose PQ on malaria transmission. </p> <p>The evidence is also predominantly for higher PQ doses than the 0.25 mg/kg currently recommended by the WHO. Out of 40 total trial arms that met the inclusion criteria and reported gametocyte outcomes, only five used a low dose (0.20 to 0.25 mg/kg). The remaining arms provide evidence, but the exact dose‐response relationship that would apply to single dose PQ is not known, so again, some assumptions are needed to evaluate the relevance of this information. </p> <p>Second in our evidence hierarchy were trials of the infectiousness of treated individuals to mosquitoes, of which there were four at the low dose of PQ. However, all four trials did not report all key data. Summing up, the infectiousness results for the low dose are based mainly on the results from only one trial (<a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a>), which observed one versus seven infectious events at day 3, and 0 versus 3 events at day 8 in the PQ and non‐PQ groups respectively. Thus, despite the inclusion of several new trials with infectiousness data in this update, the evidence for reduction is inconsistent and based on a very small number of trials and events. The three infectiousness trials at higher PQ doses reported significant declines, but once again, the relevance to lower doses is uncertain. </p> <p>Most of the included trials were on the next rung of the hierarchy: the effect of PQ on circulating gametocytes in people treated with and without PQ (potential infectiousness). The included trial arms span decades of research, including many conducted before the artemisinin era. Out of 40 arms, 16 were with non‐artemisinin partners (which also used higher PQ doses). Artemisinin drugs themselves have some impact on gametocytes, so how well the earlier evidence reflects the impact of an artemisinin derivative plus PQ is also unknown. Nonetheless, results of these trials were generally consistent. Differences in gametocyte detection method (microscopy or PCR) made synthesis somewhat difficult, but potential infectiousness is the most convincing and robust evidence for a possible effect on transmission, under the right conditions. </p> <p>The included trials do not provide sufficient evidence to evaluate the safety of this intervention. Many trials did not test for G6PD deficiency, and of those that did, most excluded deficient individuals. The trials were, by and large, not designed for safety evaluations. </p> <p>Overall, the evidence of efficacy is limited in both quality and quantity, and it is all indirect, to varying degrees. </p> </section> <section id="CD008152-sec-0154"> <h3 class="title" id="CD008152-sec-0154">Potential biases in the review process</h3> <p>We have identified three potential biases or deficiencies in the search and review processes. </p> <p>First, three trials could not be located. Two were earlier trials (publication dates 1993 and 2006) in Chinese; one was a conference abstract from 2009. Second, we restricted follow‐up only to day 8 because most persons were non‐infectious by then. Third, we stratified by artemisinin/non‐artemisinin drugs, since the former are the recommended treatments in the majority of malaria‐endemic areas. We believe these decisions should have no material impact on the results, but could be challenged. </p> </section> <section id="CD008152-sec-0155"> <h3 class="title" id="CD008152-sec-0155">Agreements and disagreements with other studies or reviews</h3> <p>A historical review of patients treated at clinics in India with either AS+SP+PQ (single dose 0.75 mg/kg on the third treatment day, nine sites) or AS+SP alone (12 sites) observed that PQ reduced the gametocyte clearance time by 45% and the AUC of gametocyte density over time (up to 28 days) by about the same proportion (<a href="./references#CD008152-bbs2-0065" title="ShahNK , SchapiraA , JulianoJJ , SrivastavaB , MacDonaldPD , PooleC , et al. Nonrandomized controlled trial of artesunate plus sulfadoxine‐pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes. Antimicrobial Agents and Chemotherapy2013;57(7):2948‐54. ">Shah 2013</a>). They expressed the reduction as a hazard ratio with PQ increasing the rate of gametocyte clearance by 1.9 (95% CI 1.1 to 1.3). These results are consistent with our findings. A paper whose title implies it was a systematic review of the impact of artemisinin derivatives and PQ on infectiousness, <a href="./references#CD008152-bbs2-0085" title="AbaySM . Blocking malaria transmission to Anopheles mosquitoes using artemisinin derivatives and primaquine: a systematic review and meta‐analysis. Parasites and Vectors2013;6(1):278. ">Abay 2013</a>, included only two before‐and‐after trials using PQ with small numbers of patients. Neither of these studies met our inclusion criteria (<a href="./references#CD008152-bbs2-0062" title="RieckmannKH , McNamaraJV , FrischerH , StockertTA , CarsonPE , PowellRD . Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine‐resistant strain of Plasmodium falciparum. Bulletin of the World Health Organization1968;38(4):625–32. ">Rieckmann 1968</a>; <a href="./references#CD008152-bbs2-0039" title="ClydeDF , MillerRM , MusicSI , McCarthyVC . Prophylactic and sporontocidal treatment of chloroquine‐resistant Plasmodium falciparum from Vietnam. American Journal of Tropical Medicine and Hygiene1971;20(1):1‐5. ">Clyde 1971</a>). </p> <p>In a Cochrane Review of MDA (<a href="./references#CD008152-bbs2-0124" title="PoirotE , SkarbinskiJ , SinclairD , KachurSP , SlutskerL , HwangJ . Mass drug administration for malaria. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD008846.pub2] ">Poirot 2013</a>), the authors found no studies directly comparing MDA regimens that included 8AQs with regimens that did not. In a secondary analysis, the authors then subgrouped the included non‐RCTs by regimens with and without 8AQs. In high endemicity areas, two studies included PQ, and one study did not. During multiple MDA rounds, there were substantial drops in parasitaemia regardless of whether PQ was included. At one to three months, the studies without PQ showed larger impact than the one study that did, but this single observation from a non‐randomized comparison cannot be relied upon. In a second similar subgroup analysis of four before‐and‐after studies, the stratified analysis was uninformative. </p> <p>In an opinion piece in the <i>Lancet</i>, the possibility that doses lower than 0.5 to 0.75 mg/kg might still be very effective in blocking transmission is raised (<a href="./references#CD008152-bbs2-0134" title="WhiteNJ . Primaquine to prevent transmission of falciparum malaria. Lancet. Infectious Diseases2013;13(2):175‐81. ">White 2013</a>). Based on the current review, it appears that the effect on infectiousness and gametocytes is preserved at lower doses of 0.2 to 0.25 mg/kg. </p> <p>A review in the <i>Malaria Journal</i> provides an analysis of published and unpublished data on 158 subjects with different drug exposures spanning 80 years (<a href="./references#CD008152-bbs2-0133" title="WhiteNJ , QiaoLG , QiG , LuzzattoL . Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malaria Journal2012;11:418. ">White 2012</a>). The methods, sources of data and comparisons are not clearly specified, but the authors argue this provides evidence that PQ decreases infectivity much faster than the effect on gametocytes would suggest. The current review supports this view that the effect of PQ on infectiousness appears earlier (day 3‐5) than the effect on gametocyte presence, at least for artemisinin partners. However the effect on infectiousness wanes by day 8 due to declining infectiousness in both PQ and control groups. </p> <p>Also in the <i>Malaria Journal</i>, <a href="./references#CD008152-bbs2-0135" title="WhiteNJ , AshleyEA , RechtJ , DelvesMJ , RueckerA , SmithuisFM , et al. Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malaria Journal2014;13(483):1‐13. [DOI: 10.1186/1475‐2875‐13‐483] ">White 2014</a> urged stratification of trials by dose, which has now been further accomplished with the newly included trials at lower doses. The overall conclusion of <a href="./references#CD008152-bbs2-0135" title="WhiteNJ , AshleyEA , RechtJ , DelvesMJ , RueckerA , SmithuisFM , et al. Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malaria Journal2014;13(483):1‐13. [DOI: 10.1186/1475‐2875‐13‐483] ">White 2014</a> endorses the conclusions of all earlier editions of this Cochrane Review: there is a need for more mosquito‐feeding studies for "the assessment of transmission‐blocking, dose‐response relationships". This updated review now includes several trials that report reduction in infectiousness soon after treatment, and hence improve on earlier recommendations based only on indirect measures. However, although there were five new trials aiming to study infectiousness included here, all trials except two had no or very few infection events. Overall infectiousness of patients attending for malaria treatment is very low and wanes quickly, despite a large proportion having PCR detectable gametocytes. </p> <p>In relation to current WHO guidelines, evidence is available from this systematic review to support the currently recommended 0.25 mg/kg dose as 1) effective in potentially reducing transmission from individuals to mosquitoes and 2) probably safer than higher doses for those without G6PD deficiency and possibly for those with the deficiency. This review of all available evidence sheds minimal light on the question of whether PQ at any dose will materially affect transmission in communities (<a href="./references#CD008152-bbs2-0138" title="Global Malaria Programme, World Health Organization. Single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Updated WHO Policy Recommendation. Geneva: World Health Organization, 2012. ">WHO 2012b</a>; <a href="./references#CD008152-bbs2-0140" title="World Health Organization. Guidelines for the Treatment of Malaria. 3rd Edition. Geneva: World Health Organization, 2015. ">WHO 2015b</a>). The amount of evidence on infectiousness of treated malaria patients to mosquitoes remains low, and evidence of the impact of treating malaria patients on transmission at a community level completely absent. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008152-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Review logic framework: the potential points in the Plasmodium parasite life cycle that could be impacted by PQ and the outcomes used to measure impact. Abbreviations: AUC: area under the curve. EIR: entomological inoculation rate; PQ: primaquine." data-id="CD008152-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Review logic framework: the potential points in the <i>Plasmodium</i> parasite life cycle that could be impacted by PQ and the outcomes used to measure impact. Abbreviations: AUC: area under the curve. EIR: entomological inoculation rate; PQ: primaquine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="‘Risk of bias' summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD008152-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>‘Risk of bias' summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="‘Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD008152-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>‘Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD008152-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 1 Participants infectious, day 3 or 4, by dose." data-id="CD008152-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 1 Participants infectious, day 3 or 4, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 2 Participants with gametocytes (PCR), day 3 or 4, by dose." data-id="CD008152-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 2 Participants with gametocytes (PCR), day 3 or 4, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 3 Participants with gametocytes (microscopy), day 3 or 4, by dose." data-id="CD008152-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 3 Participants with gametocytes (microscopy), day 3 or 4, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 4 Participants infectious, day 8, by dose." data-id="CD008152-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 4 Participants infectious, day 8, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 5 Participants with gametocytes (PCR), day 8, by dose." data-id="CD008152-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 5 Participants with gametocytes (PCR), day 8, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 6 Participants with gametocytes (microscopy), day 8, by dose." data-id="CD008152-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 6 Participants with gametocytes (microscopy), day 8, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 7 Gametocyte clearance time (PCR), by dose." data-id="CD008152-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 7 Gametocyte clearance time (PCR), by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 8 Area under curve of gametocytes (PCR), days 1 to 15, by dose." data-id="CD008152-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 8 Area under curve of gametocytes (PCR), days 1 to 15, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 9 Participants with severe haemolysis, by dose." data-id="CD008152-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 9 Participants with severe haemolysis, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 10 Mean max change in haemoglobin concentration, by dose." data-id="CD008152-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 10 Mean max change in haemoglobin concentration, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 11 Percent change in haemoglobin, day 8, by dose." data-id="CD008152-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 11 Percent change in haemoglobin, day 8, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 12 Max percent change in haemoglobin, by dose." data-id="CD008152-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 12 Max percent change in haemoglobin, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 13 Haemoglobinuria/dark urine." data-id="CD008152-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 13 Haemoglobinuria/dark urine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 14 Other adverse effects (CNS symptoms)." data-id="CD008152-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 14 Other adverse effects (CNS symptoms). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 15 Other adverse effects (systemic)." data-id="CD008152-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 15 Other adverse effects (systemic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 16 Other adverse effects (respiratory symptoms)." data-id="CD008152-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 16 Other adverse effects (respiratory symptoms). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 17 Other adverse effects (gastrointestinal symptoms)." data-id="CD008152-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 17 Other adverse effects (gastrointestinal symptoms). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 18 Other adverse effects (Miscellaneous)." data-id="CD008152-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Artemisinin treatment regimen: PQ versus no PQ, Outcome 18 Other adverse effects (Miscellaneous). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg, Outcome 1 Participants infectious, day 3 to 4." data-id="CD008152-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg, Outcome 1 Participants infectious, day 3 to 4. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg, Outcome 2 Participants with gametocytes (PCR), day 3 to 4." data-id="CD008152-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg, Outcome 2 Participants with gametocytes (PCR), day 3 to 4. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg, Outcome 3 Participants with gametocytes (microscopy), day 3 to 4." data-id="CD008152-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg, Outcome 3 Participants with gametocytes (microscopy), day 3 to 4. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg, Outcome 4 Participants infectious, day 8." data-id="CD008152-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg, Outcome 4 Participants infectious, day 8. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg, Outcome 5 Participants with gametocytes (PCR), day 8." data-id="CD008152-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg, Outcome 5 Participants with gametocytes (PCR), day 8. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg, Outcome 6 Participants with gametocytes (microscopy), day 8." data-id="CD008152-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg, Outcome 6 Participants with gametocytes (microscopy), day 8. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Non‐artemisinin treatment regimen: PQ versus no PQ, Outcome 1 Participants infectious, day 5, by dose." data-id="CD008152-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Non‐artemisinin treatment regimen: PQ versus no PQ, Outcome 1 Participants infectious, day 5, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Non‐artemisinin treatment regimen: PQ versus no PQ, Outcome 2 Participants with gametocytes (microscopy), day 4 to 5, by dose." data-id="CD008152-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Non‐artemisinin treatment regimen: PQ versus no PQ, Outcome 2 Participants with gametocytes (microscopy), day 4 to 5, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Non‐artemisinin treatment regimen: PQ versus no PQ, Outcome 3 Participants infectious, day 8, by dose." data-id="CD008152-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Non‐artemisinin treatment regimen: PQ versus no PQ, Outcome 3 Participants infectious, day 8, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Non‐artemisinin treatment regimen: PQ versus no PQ, Outcome 4 Participants with gametocytes (microscopy), day 8, by dose." data-id="CD008152-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Non‐artemisinin treatment regimen: PQ versus no PQ, Outcome 4 Participants with gametocytes (microscopy), day 8, by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Non‐artemisinin treatment regimen: PQ versus no PQ, Outcome 5 Gametocyte clearance time." data-id="CD008152-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Non‐artemisinin treatment regimen: PQ versus no PQ, Outcome 5 Gametocyte clearance time. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Non‐artemisinin treatment regimen: PQ versus no PQ, Outcome 6 Adverse effects." data-id="CD008152-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Non‐artemisinin treatment regimen: PQ versus no PQ, Outcome 6 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008152-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/urn:x-wiley:14651858:media:CD008152:CD008152-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_t/tCD008152-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 PQ versus other 8AQ, Outcome 1 Participants with gametocytes (microscopy), day 8." data-id="CD008152-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 PQ versus other 8AQ, Outcome 1 Participants with gametocytes (microscopy), day 8. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/media/CDSR/CD008152/image_n/nCD008152-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008152-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Single dose primaquine at 0.2 to 0.25 mg/kg compared to no primaquine, with artemisinin partner, for reducing P. falciparum transmission</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low‐dose primaquine (PQ) given with artemisinin combination treatment</b> </p> <p><b>Participants or population:</b> adults and children with malaria being treated with artemisinin combination treatment </p> <p><b>Settings:</b> Mali, Burkina Faso, The Gambia, Tanzania, Senegal </p> <p><b>Intervention:</b> single dose PQ dose 0.2 to 0.25 mg/kg </p> <p><b>Comparison:</b> no PQ </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no PQ, with artemisinin partner</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single dose PQ at 0.2 to 0.25 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 3‐4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.12<br/> (0.02 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 100<br/> (0 to 13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose PQ may reduce infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>243<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.34<br/> (0.07 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 100<br/> (0 to 6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose PQ may reduce infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 3 to 4 by PCR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>414<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.02<br/> (0.87 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 per 100<br/> (45 to 63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>2</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose PQ probably has little or no effect on gametocytes detected by PCR at day 3 to 4 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 8 by PCR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>532<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.52<br/> (0.41 to 0.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 per 100<br/> (19 to 31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose PQ reduces gametocytes detected by PCR at day 8</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with severe haemolysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>752<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.98<br/> (0.69 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 per 100<br/> (9 to 18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>2</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose PQ probably has little or no effect on severe haemolysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>PCR</b> : polymerase chain reaction; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 2 for imprecision: the CIs are wide; in addition, there is a large effect combined with a low number of events, which creates further uncertainty around the point estimate.<br/> <sup>2</sup>Downgraded by 1 for imprecision: the CIs are wide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Single dose primaquine at 0.2 to 0.25 mg/kg compared to no primaquine, with artemisinin partner, for reducing P. falciparum transmission</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008152-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Single dose primaquine at 0.4 to 0.5 mg/kg compared to no primaquine, with artemisinin partner, for reducing P. falciparum transmission</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Moderate‐dose primaquine (PQ) given with artemisinin combination treatment</b> </p> <p><b>Participants or population:</b> adults and children with malaria being treated with artemisinin combination treatment </p> <p><b>Settings:</b> Mali, Burkina Faso, The Gambia, Uganda </p> <p><b>Intervention:</b> single dose PQ 0.4 to 0.5 mg/kg </p> <p><b>Comparison:</b> no PQ </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no PQ, with artemisinin partner,</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single dose PQ at 0.4 to 0.5 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 3‐4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.13<br/> (0.02 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 100<br/> (0 to 13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ may reduce infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>246<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.33<br/> (0.07 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 100</p> <p>(0 to 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ may reduce infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 3‐4, by PCR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>418<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.09<br/> (0.93 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 100</p> <p>(48 to 67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE<sup>2</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ probably has little or no effect on gametocytes detected by PCR on day 3 to 4 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 8, by PCR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>758<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.37<br/> (0.29 to 0.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 100</p> <p>(13 to 21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ reduces gametocytes detected by PCR on day 8</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with severe haemolysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.54<br/> (0.38 to 6.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> <p>(1 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>3</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ may increase severe haemolysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 2 for imprecision: the CIs are wide; in addition, there is a large effect combined with a low number of events, which creates further uncertainty around the point estimate.<br/> <sup>2</sup>Downgraded by 1 for imprecision: the CIs are wide.<br/> <sup>3</sup>Downgraded by 2 for imprecision: the CIs are very wide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Single dose primaquine at 0.4 to 0.5 mg/kg compared to no primaquine, with artemisinin partner, for reducing P. falciparum transmission</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008152-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Single dose primaquine at 0.75 mg/kg compared to no primaquine, with artemisinin partner, for reducing P. falciparum transmission</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High‐dose primaquine (PQ) given with artemisinin combination treatment</b> </p> <p><b>Participants or population:</b> adults and children with malaria being treated with artemisinin combination treatment </p> <p><b>Settings:</b> Cambodia, Mali, Burkina Faso, The Gambia, Tanzania, Sudan, Uganda </p> <p><b>Intervention:</b> single dose PQ 0.75 mg/kg </p> <p><b>Comparison:</b> no PQ </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no PQ, with artemisinin partner</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single dose PQ at 0.75mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 3‐4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.20</p> <p>(0.02 to 1.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 100</p> <p>(0 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,2</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if high dose PQ may reduce infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>181<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.18<br/> (0.02 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 100</p> <p>(0 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dose PQ may reduce infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 3‐4, by PCR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.92<br/> (0.75 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 100</p> <p>(29 to 43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>3,4</sup> </p> <p>Due to indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dose PQ may have little or no effect on gametocytes detected by PCR</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 8, by PCR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>793<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.31<br/> (0.23 to 0.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> <p>(8 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dose PQ reduces gametocytes detected by PCR</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with severe haemolysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No estimate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We don't know if high dose PQ impacts on haemolysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>PCR</b> : polymerase chain reaction; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 2 for imprecision: the CIs are wide; in addition, there is a large effect combined with a low number of events, which creates further uncertainty around the point estimate. In addition, in this one trial baseline.<br/> <sup>2</sup>Baseline values for this outcome were unbalanced, but the downgrading by 2 for imprecision takes this in to account, as it could be a chance finding.<br/> <sup>3</sup>Downgraded by 1 for indirectness: all the data for the results come from one trial.<br/> <sup>4</sup>Downgraded by 1 for imprecision: the CIs are wide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Single dose primaquine at 0.75 mg/kg compared to no primaquine, with artemisinin partner, for reducing P. falciparum transmission</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008152-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Single dose primaquine at 0.4 to 0.5 mg/kg compared to no primaquine, with non‐artemisinin partner, for reducing P. falciparum transmission</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Moderate‐dose primaquine (PQ) given with non‐artemisinin treatment</b> </p> <p><b>Participants or population:</b> adults and children with malaria being treated with non‐artemisinin treatment </p> <p><b>Settings:</b> Pakistan </p> <p><b>Intervention:</b> single dose PQ 0.4 to 0.5 mg/kg </p> <p><b>Comparison:</b> no PQ </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no PQ, with non‐artemisinin partner</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single dose PQ at 0.4 to 0.5 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 4‐5, by microscopy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>221<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/> (0.62 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 per 100</p> <p>(30 to 54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> <p>Due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ probably reduces gametocytes detected by microscopy</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 8, by microscopy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.60<br/> (0.49 to 0.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 per 100</p> <p>(40 to 61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> <p>Due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium dose PQ probably reduces gametocytes detected by microscopy</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 for indirectness: all the results are from one setting. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Single dose primaquine at 0.4 to 0.5 mg/kg compared to no primaquine, with non‐artemisinin partner, for reducing P. falciparum transmission</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008152-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Single dose primaquine at 0.75 mg/kg compared to no primaquine, with non‐artemisinin partner, for reducing P. falciparum transmission</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Medium‐dose primaquine (PQ) given with non‐artemisinin treatment</b> </p> <p><b>Participants or population:</b> adults and children with malaria being treated with non‐artemisinin treatment </p> <p><b>Settings:</b> China, Colombia, India, Indonesia </p> <p><b>Intervention:</b> single dose PQ 0.75 mg/kg </p> <p><b>Comparison:</b> no PQ </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no PQ, with non‐artemisinin partner</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single dose PQ at 0.75 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 5</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.09<br/> (0.01 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 100</p> <p>(1 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1,2</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether high dose PQ reduces infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants infectious at day 8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.07<br/> (0.01 to 0.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 100</p> <p>(1 to 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1,2</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether high dose PQ reduces infectiousness</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 5, by microscopy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.85<br/> (0.48 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 per 100</p> <p>(24 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW<sup>3,4</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dose PQ may reduce gametocytes detected by microscopy</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with gametocytes at day 8, by microscopy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>186<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.39<br/> (0.25 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 100</p> <p>(12 to 29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE<sup>5</sup> </p> <p>Due to risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dose PQ probably reduces gametocytes detected by microscopy</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 for risk of bias: unclear risk of bias in several domains from both studies.<br/> <sup>2</sup>Downgraded by 2 for imprecision: the CIs are wide; in addition, there is a large effect combined with a low number of events, which creates further uncertainty around the point estimate.<br/> <sup>3</sup>Downgraded by 1 for risk of bias: <a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a> had serious risk for selection bias and <a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a> had unclear risk of bias in several domains.<br/> <sup>4</sup>Downgraded by 1 for imprecision: the CIs are wide.<br/> <sup>5</sup>Downgraded by 1 for risk of bias: <a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a> had serious risk for selection bias and <a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a> had unclear risk of bias in several domains. <a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a> had serious risk of bias for several domains. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Single dose primaquine at 0.75 mg/kg compared to no primaquine, with non‐artemisinin partner, for reducing P. falciparum transmission</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008152-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Trial locations, partner drugs, gametocyte status at onset, G6PD status, and PQ dose and treatment schedule</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Place</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>G6PD status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parasite species</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Partner or alternative drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion with gametocytes at onset (control group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion with gametocytes at onset (experimental group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Day(s)* PQ given</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target PQ dose per day</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>Artemisinin‐based partner</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="31" valign="top"> <p>AS or ACT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colombia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+MQ</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.8% Mic</p> <p>(N = 23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.3% Mic</p> <p>(N = 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Mali</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Only non‐deficient included<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>DHAP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>100% Mic</p> <p>(N = 15)</p> <p>Table 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic (N = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0625 mg/kg**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic (N = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.125 mg/kg**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic (N = 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic (N = 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0005" title="El‐SayedB , El‐ZakiSE , BabikerH , GadallaN , AgeepT , MansourF , et al. A randomized open‐label trial of artesunate‐sulfadoxine‐pyrimethamine with or without primaquine for elimination of sub‐microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One2007;2(12):e1311. ">El‐Sayed 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sudan</p> <p>(east)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+SP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5% PCR</p> <p>(N = 52)</p> <p>Table 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5% PCR</p> <p>(N = 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008152-bbs2-0006" title="ChangHH , MeibalanE , ZelinJ , DanielsR , EziefulaAC , MeyerEC , et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Scientific Reports2016;6:26330. [DOI: 10.1038/srep26330] EziefulaAC , BousemaT , YeungS , KamyaM , OwaraganiseA , GabagayaG , et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double‐blind, dose‐ranging trial. Lancet. Infectious Diseases2013;14(2):130‐9. EziefulaAC , PettH , GrignardH , OpusS , KiggunduM , KamyaMR , et al. Glucose‐6‐phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum‐infected African children receiving single‐dose primaquine. Antimicrobial Agents and Chemotherapy2014;58(8):4971‐3. [DOI: 10.1128/aac.02889‐14] EziefulaAC , StaedkeSG , YeungS , WebbE , KamyaM , WhiteNJ , et al. Study protocol for a randomised controlled double‐blinded trial of the dose‐dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open2013;3(3):e002759. PettH , DrakeleyC , EziefulaC , NeuvonenM , LankeK , SauerweinR , et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single‐dose primaquine. Malaria Journal2014;13(Suppl 1):P69. ">Eziefula 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Uganda</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Only non‐deficient included<sup>2</sup> </p> <p>(PCR testing of those included after FST)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>AL</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>23.1% Mic</p> <p>(N = 117)</p> <p>79.8% PCR</p> <p>(N = 114)</p> <p>Table 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.3% MIc</p> <p>(N = 115)</p> <p>86.7% PCR</p> <p>(N = 113)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 mg/kg**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.4% Mic</p> <p>(N = 113)</p> <p>78.7% PCR</p> <p>(N = 108)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.4% Mic</p> <p>(N = 116)</p> <p>82.0% PCR</p> <p>(N = 111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Burkina Faso</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only non‐deficient included<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AL</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17.7% Mic</p> <p>(N = 62)</p> <p>Table 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32% Mic (N = 75)</p> <p>92.9% PCR (N = 70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.5% Mic</p> <p>(N = 73)</p> <p>85.5% PCR (N = 62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Burkina Faso</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only non‐deficient included<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AL</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69.4% Mic</p> <p>(N = 49)</p> <p>Table 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.3% Mic (N = 47)</p> <p>93.7% PCR (N = 48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3% Mic (N = 46)</p> <p>100.0% PCR (N = 46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cambodia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Screened and severely deficient excluded<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf or Pf+Pv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10% Mic</p> <p>44% PCR</p> <p>(N = 51)</p> <p>Table 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8% Mic</p> <p>49% PCR</p> <p>(N = 50)</p> <p>Table 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0016" title="MwaisweloR , NgasalaBE , JovelI , Aydin‐SchmidtB , GoslingR , PremjiZ , et al. Adding a single low‐dose of primaquine (0.25 mg/kg) to artemether‐lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single‐blinded clinical trial. Malaria Journal2016;15(1):435. MwaisweloR , NgasalaBE , JovelI , GoslingR , PremjiZ , PoirotE , et al. Safety of a single low‐dose of primaquine in addition to standard artemether‐lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malaria Journal2016;15:316. ">Mwaiswelo 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Screened and all included<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AL</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 patient had gametocytes at recruitment but treatment group not given</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5% Mic</p> <p>(N = 220)</p> <p>both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>The Gambia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Only non‐deficient included<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>DHAP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>47.7% PCR</p> <p>(N = 153)</p> <p>Table 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.4% PCR (N = 148)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.6% PCR</p> <p>(N = 152)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.4% PCR</p> <p>(N = 146)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only non‐deficient included<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS</p> <p>days 1 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.1% Mic</p> <p>(N = 23)</p> <p>Table 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.0% Mic</p> <p>(N = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>days 1 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0019" title="BousemaT , OkellL , ShekalagheS , GriffinJT , OmarS , SawaP , et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal2010;9:136. ShekalagheS , DrakeleyC , GoslingR , NdaroA , vanMeegerenM , EnevoldA , et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine‐pyrimethamine and artesunate. PLoS One2007;2(10):e1023. ">Shekalaghe 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> <p>(North east)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Screened and all included<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+SP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.4% Mic (N = 63)</p> <p>88.2% PCR</p> <p>(N = 51)</p> <p>Table 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9% Mic</p> <p>(N = 53)</p> <p>90.6% PCR</p> <p>(N = 53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD008152-bbs2-0021" title="SmithuisF , KyawMK , PheO , WinT , AungPP , OoAP , et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open‐label randomised trial. Lancet. Infectious Diseases2010;10(10):673‐81. ">Smithuis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Myanmar</p> <p>(3 states)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Not screened</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Pf or mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+AQ</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.1% Mic</p> <p>(N = 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.6% Mic</p> <p>(N = 71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AL</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.5% Mic</p> <p>(N = 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.1% Mic</p> <p>(N = 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+MQ</p> <p>fixed dose</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.3% Mic</p> <p>(N = 83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.9%% Mic</p> <p>(N = 86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS</p> <p>days 1 to 3 + MQ day 1 loose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.5% Mic</p> <p>(N = 82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6% Mic</p> <p>(N = 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>e</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.6% Mic</p> <p>(N = 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5% Mic</p> <p>(N = 83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0022" title="SutantoI , SuprijantoS , KosasihA , DahlanMS , SyafruddinD , KusriastutiR , et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin‐piperaquine in South Sumatra, Western Indonesia: an open‐label, randomized, controlled trial. Clinical Infectious Diseases2013;56(5):685–93. ">Sutanto 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Indonesia</p> <p>(south Sumatra)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only non‐deficient included<sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAP</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4% Mic</p> <p>(N = 178)</p> <p>Figure 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.0% Mic</p> <p>(on day 3)</p> <p>(N = 171)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008152-bbs2-0023" title="TineRC , SyllaK , FayeBT , PoirotE , FallFB , SowD , et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in Senegal, to reduce gametocyte carriage: a randomized controlled trial. Clinical Infectious Diseases2017;65(4):535‐43. ">Tine 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Senegal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Screened and all included<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AL</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6.7% Mic</p> <p>(N = 135)</p> <p>Table 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>7.9% Mic</p> <p>(N = 139)</p> <p>Table 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>0.25 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAP</p> <p>days 1 to 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+AQ</p> <p>days 1 to 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0024" title="VásquezAM , SanínF , AlvarezLG , TobónA , RíosA , BlairS . Therapeutic efficacy of a regimen of artesunate‐mefloquine‐primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development [Estudio piloto de la eficacia y de los efectos sobre los gametocitos del esquema artesunato‐mefloquina‐primaquina para la malaria por Plasmodium falciparum]. Biomedica2009;29(2):307‐19. ">Vásquez 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colombia (Antioquia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS+MQ</p> <p>days 1 to 3</p> <p>(MQ only on day 2 for children &lt; 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16% Mic</p> <p>(N = 25)</p> <p>Figure 1 estimated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.0% Mic</p> <p>(N = 25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0025" title="WangYS , BrownPP . Clinical study on artemether combined with Primaquine for Pf cases treatment [Chinese]. Tianjin Medical Journal2006;34(8):538. ">Wang 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gabon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AS i.m.</p> <p>days 1 to 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>(N = 106)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>(N = 108)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>days 1 to 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.5 mg</p> <p>(˜0.38 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>Non‐artemisinin partner</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>CQ or</p> <p>(CQ+SP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India (Mumbai)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not screened</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CQ</p> <p>days 1 to 3 or</p> <p>CQ</p> <p>days 1 to 3 + SP day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(within 3 days)</p> <p>(N = 45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0012" title="KhooKK . The treatment of malaria in glucose‐6‐phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology1981;75(6):591‐5. ">Khoo 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malaysia (Sabah)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only deficient included<sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf, Pv or mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CQ</p> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> <p>(˜0.42 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0013" title="KolaczinskiK , LeslieT , AliI , DurraniN , LeeS , BarendsM , et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One2012;7(1):e28957. ">Kolaczinski 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pakistan</p> <p>(3 Afghan refugee camps)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CQ days 1 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.6% Mic</p> <p>(N = 239)</p> <p>Table 2 (combined CQ, CQ+AS, SP, SP+AS groups)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.7% Mic</p> <p>(N = 76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> <p>mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008152-bbs2-0014" title="LedermanER , MaguireJD , SumawinataIW , ChandK , ElyazarI , EstianaL , et al. Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia. Malaria Journal2006;5:108. ">Lederman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Indonesia (Central Java)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only non‐deficient included<sup>9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>CQ</p> <p>days 1 to 3 + SP day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8.2% Mic</p> <p>(N = 61)</p> <p>Figure 3 est (combined CQ, CQ+SP groups)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25% Mic</p> <p>(N = 28)</p> <p>Figure 3 est</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.3%</p> <p>(N = 28)</p> <p>Figure 3 est</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0013" title="KolaczinskiK , LeslieT , AliI , DurraniN , LeeS , BarendsM , et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One2012;7(1):e28957. ">Kolaczinski 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pakistan (2 Afghan refugee camps)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SP day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above under Kolaczinski 2012 a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.1% Mic</p> <p>(N = 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AQ+SP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0001" title="ArangoEA , UpeguiUA , Carmona‐FonsecaJ . Efficacy of different primaquine‐based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Tropica2012;122(2):177‐82. ">Arango 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colombia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AQ</p> <p>days 1 to 3 + SP day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15% Mic</p> <p>(N = 20)</p> <p>Table 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30% Mic</p> <p>(N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>MQ or (MQ+SP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0002" title="ChenPQ , LiGQ , GuoXB , FuYX , HeKR , FuLC , et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine1993;10(1):1‐5. ">Chen 1993a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MQ day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg (˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0003" title="ChenPQ , LiGQ , GuoXB . The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin [Chinese]. Zhonghua Yi Xue Za Zhi1994;74(4):209‐10, 253‐4. ChenPQ , LiGQ , GuoXB , HeKR , FuYX , FuLC , et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal1994;107(9):709‐11. ">Chen 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China (Hainan province)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MQ</p> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 9)</p> <p>MQ group only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0020" title="SinghasivanonV , ChongsuphajaisiddhiT , SabchareonA , AttanathP , WebsterHK , EdsteinMD , et al. Pharmacokinetic study of mefloquine in Thai children aged 5‐12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. European Journal of Drug Metabolism and Pharmacokinetics1994;19(1):27‐32. ">Singhasivanon 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand (Bangkok)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MQ+SP fixed day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>(N = 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>(N = 7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>QN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0011" title="KamtekarKD , GogtayNJ , DalviSS , KarnadDR , ChogleAR , AigalU , et al. A prospective study evaluating the efficacy of a single, 45‐mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology2004;98(5):453‐8. ">Kamtekar 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India (Mumbai)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not screened</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QN i.v.</p> <p>days 1 to 2 and orally days 1 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.6% Mic</p> <p>(N = 44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(within 3 days)</p> <p>(N = 45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008152-bbs2-0018" title="PukrittayakameeS , ChotivanichK , ChantraA , ClemensR , LooareesuwanS , WhiteNJ . Activities of artesunate and primaquine against asexual‐ and sexual‐stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy2004;48(4):1329‐34. ">Pukrittayakamee 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only non‐deficient included<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pf only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>QN</p> <p>days 1 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>23.3% Mic</p> <p>(N = 60)</p> <p>QN, QN+TC groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.6% Mic</p> <p>(N = 59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>days 1 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 mg base/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.4% Mic</p> <p>(N = 67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>days 1 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 mg base/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>Comparison of different 8AQ</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PQ versus Bulaquine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0007" title="GogtayNJ , KamtekarKD , DalviSS , ChogleAR , AigalU , KshirsagarN . Preliminary report of the evaluation of the gametocytocidal action of bulaquine, in adult patients with acute, Plasmodium falciparum malaria. Annals of Tropical Medicine and Parasitology2004;98(5):525‐8. ">Gogtay 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> <p>(Mumbai)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only non‐deficient included<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QN + doxycycline days 1 to 7</p> <p>+ BQ day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No control group without 8‐AQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0008" title="GogtayNJ , KamtekarKD , DalviSS , MehtaSS , ChogleAR , AigalU , et al. A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide‐responsive uncomplicated falciparum malaria [ISCRTN50134587]. BMC Infectious Diseases2006;6:16. ">Gogtay 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only non‐deficient</p> <p>included<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QN + doxycycline days 1 to 7</p> <p>+ BQ day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No control group without 8‐AQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% Mic</p> <p>(N = 93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>day 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 mg</p> <p>(˜0.75 mg/kg)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>*first day of any treatment = day 1</p> <p>**arm excluded as dose &lt; 0.2 mg/kg</p> <p><sup>1</sup>G6PD colorimetric method, R&amp;D diagnostics, Papagos, Greece.<br/> <sup>2</sup>G6PD by fluorescence spot test.<br/> <sup>3</sup>G6PD by Binax Now Alere rapid test.<br/> <sup>4</sup>G6PD by fluorescent spot test (R&amp;D diagnostics, Greece) and quantitative enzyme activity testing (Trinity Biotech, Ireland).<br/> <sup>5</sup>G6PD (phenotypic) by CareStart ™ Access Bio test; (genotypic) by PCR and RFLP digestion for the two most common Afrcian G6PD polymorphisms.<br/> <sup>6</sup>G6PD by detection of single nucleotide polymorphisms (G202A, A376G) by PCR and ELISA.<br/> <sup>7</sup>G6PD by qualitative test.<br/> <sup>8</sup>G6PD by Brewer's methaemoglobin reduction test.<br/> <sup>9</sup>G6PD by semi‐quantitative G6PD assay.<br/> <sup>10</sup>G6PD method not reported. </p> <p>Abbreviations: G6PD = glucose‐6‐phosphate dehydrogenase; FST = fluorescent spot test; PQ = primaquine; CQ = chloroquine; SP = sulfadoxine‐pyrimethamine; MQ = mefloquine; QN = quinine; AS = artesunate; ACT = artemisinin‐based combination therapy; 8AQ: 8‐aminoquinoline; AQ = amodiaquine; AL = artemether‐lumefantrine; DHAP = dihydroxyartemisinin‐piperaquine; BQ = bulaquine; i.v. = intravenous injection; i.m. = intramuscular injection; Mic = microscopy; Pf = <i>P. falciparum</i> ; Pv = <i>P. vivax</i>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Trial locations, partner drugs, gametocyte status at onset, G6PD status, and PQ dose and treatment schedule</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008152-tbl-0007"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Infectivity to mosquitoes baseline</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>With PQ</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Without PQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Absolute difference (reduction or increase) in % of mosquitoes infected in PQ group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Average number of mosquitoes dissected per participant (both arms combined)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number<br/> of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of infectious<br/> people</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average % of mosquitoes infected</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of<br/> participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of infectious<br/> people</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average %<br/> of mosquitoes<br/> infected</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+28.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−10.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+4.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−5.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: PQ: primaquine.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Infectivity to mosquitoes baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008152-tbl-0008"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Infectivity to mosquitoes day 3‐4</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>With PQ</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Without PQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Absolute difference (reduction or increase) in % of mosquitoes infected in PQ group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Average number of mosquitoes<br/> dissected per participant<br/> (both arms combined)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number<br/> of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of infectious<br/> people</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average % of<br/> mosquitoes infected</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of<br/> participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of infectious<br/> people</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average %<br/> of mosquitoes<br/> infected</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−7.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−7.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: PQ: primaquine.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Infectivity to mosquitoes day 3‐4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008152-tbl-0009"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Infectivity to mosquitoes day 8</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>With PQ</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Without PQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Absolute difference (reduction or increase) in % of mosquitoes infected in PQ group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Average number of mosquitoes dissected per participant (both arms combined)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of<br/> participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of infectious<br/> people</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average %<br/> of mosquitoes<br/> infected</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of<br/> participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of infectious people</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average %<br/> of mosquitoes<br/> infected</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>¹ </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+27.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0004" title="DickoA , BrownJM , DiawaraH , BaberI , MahamarA , SoumareHM , et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single‐blind, dose‐ranging, adaptive randomised phase 2 trial. Lancet. Infectious Diseases2016;16(6):674‐84. [DOI: 10.1016/s1473‐3099(15)00479‐x] ">Dicko 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0009" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0010" title="GonçalvesBP , TionoAB , OuédraogoA , GuelbéogoWM , BradleyJ , NebieI , et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether‐lumefantrine in children with asymptomatic infection: a randomised, double‐blind, placebo‐controlled trial. BMC Medicine2016;14:40. ">Gonçalves 2016b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0015" title="LinJT , LonC , SpringMD , SokS , ChannS , IttiverakulM , et al. Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open‐label randomized trial. PLoS One2017;12(6):e0168702. SpringM , LonC , ManningJ , VanachayangulP , ChaorattanakaweeS , GosiP , et al. Evaluation of dihydroartemisinin‐piperaquine with and without single dose primaquine: an open‐label randomized, controlled trial in Anlong Veng, Cambodia. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):276‐7. SpringMD , LinJT , ManningJE , VanachayangkulP , SomethyS , BunR , et al. Dihydroartemisinin‐piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet. Infect Diseases2015;15(6):686‐91. [DOI: 10.1016/S1473‐3099(15)70049‐6.] ">Lin 2017</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−6.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a>¹ </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>¹<a href="./references#CD008152-bbs2-0017" title="OkebeJ , BousemaT , AffaraM , DiTannaGL , DabiraE , GayeA , et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin‐piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial. EBioMedicine2016;13:348‐55. [DOI: 10.1016/j.ebiom.2016.10.032] OkebeJ , BousemaT , AffaraM , DiTanna , EziefulaAC , JawaraM , et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin‐piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial. Trials2015;16:70. [DOI: 10.1186/s13063‐015‐0597‐1] ">Okebe 2016</a> reported the median number of mosquitoes per person. </p> <p>Abbreviations: PQ: primaquine.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Infectivity to mosquitoes day 8</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/full#CD008152-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008152-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Artemisinin treatment regimen: PQ versus no PQ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants infectious, day 3 or 4, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants with gametocytes (PCR), day 3 or 4, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.87, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.93, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.75, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants with gametocytes (microscopy), day 3 or 4, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.21, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.33, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.20, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participants infectious, day 8, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.07, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.07, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.02, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Participants with gametocytes (PCR), day 8, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 0.2 to 0.25 mg/kg PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.41, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 0.4 to 0.5 mg/kg PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.29, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 0.75 mg/kg PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.23, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Participants with gametocytes (microscopy), day 8, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.16, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.08, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.19, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Gametocyte clearance time (PCR), by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Area under curve of gametocytes (PCR), days 1 to 15, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Participants with severe haemolysis, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.69, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.38, 6.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mean max change in haemoglobin concentration, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.07, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.08, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.04, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Percent change in haemoglobin, day 8, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐0.99, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [‐3.40, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [‐1.70, 4.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Max percent change in haemoglobin, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 0.2 to 0.25 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Haemoglobinuria/dark urine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.40 [2.15, 5.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Other adverse effects (CNS symptoms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.66, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Paresthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.13, 6.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.74, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Meningitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5 Blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.6 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.64, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Other adverse effects (systemic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.46, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Pruritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.65, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 Muscle ache/pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.12, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 Skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.46, 5.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6 Pallor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.59, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.7 Weakness/asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.43, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Other adverse effects (respiratory symptoms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.77, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Runny nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.07, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 URTI/respiratory infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.68, 9.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 Bronchitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.34 [0.50, 10.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 Rhinitis/rhinobronchitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.10, 5.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6 Shortness of breath</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 4.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7 Otitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [0.11, 50.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8 Epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.06, 35.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.9 Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.05, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10 Cold sores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.29, 6.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.11 Cyanosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Other adverse effects (gastrointestinal symptoms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.88, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.65, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.86, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 Diarrhoea/dysentery/stooling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.50, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 Anorexia/loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.45, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Other adverse effects (Miscellaneous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.04, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Burning with urination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.06, 29.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Pain with urination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.06, 29.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 Whitlow</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.06, 29.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5 Leg osteoarthritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 4.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.6 Uncomplicated malaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.12, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.7 Dental pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.8 High transaminase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.9 Palpebral inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.10 Wound/trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.12, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.11 Foot trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.06, 33.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.12 Foot inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.4 [0.06, 33.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.13 Skin infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.30, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.14 Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.80, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.15 Unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.46, 1.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Artemisinin treatment regimen: PQ versus no PQ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008152-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants infectious, day 3 to 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.06, 13.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants with gametocytes (PCR), day 3 to 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants with gametocytes (microscopy), day 3 to 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.68, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participants infectious, day 8 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.14, 6.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Participants with gametocytes (PCR), day 8 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.97, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Participants with gametocytes (microscopy), day 8 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.51, 6.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008152-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Non‐artemisinin treatment regimen: PQ versus no PQ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants infectious, day 5, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants with gametocytes (microscopy), day 4 to 5, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 0.4 to 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.62, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 0.75 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.48, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants infectious, day 8, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 0.75 mg/kg PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.01, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participants with gametocytes (microscopy), day 8, by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 0.4 to 0.5 mg/kg PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.49, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 0.75 mg/kg PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.25, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Gametocyte clearance time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Any adverse effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Non‐artemisinin treatment regimen: PQ versus no PQ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008152-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">PQ versus other 8AQ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants with gametocytes (microscopy), day 8 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.26, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">PQ versus other 8AQ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008152.pub5/references#CD008152-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008152.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008152-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008152-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD008152-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008152-note-0017">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008152\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008152\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008152\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008152\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008152\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008152.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008152.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008152.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008152.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008152.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726664173"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008152.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726664177"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008152.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e992a59f89368',t:'MTc0MDcyNjY2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 